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2. Vorwort 
In der vorliegenden kumulativen Habilitationsschrift werden neue Ansätze zur 
Risikostratifizierung und Therapie bei Patienten mit ischämischer Kardiomyopathie 
und struktureller Herzerkrankung zusammengefasst. Einleitend werden die aktuellen 
Strategien zur Risikostratifizierung nach Myokardinfarkt anhand der 
linksventrikulären Auswurffraktion dargestellt. Des Weiteren wird auf die Rolle des 
autonomen Nervensystems und neuer Methoden zur nicht-invasiven Testung der 
autonomen Funktion nach Myokardinfarkt, sowie bei struktureller Herzerkrankung 
eingegangen. Am Ende werden neue Ansätze zur Verbesserung der Therapie bei 
Patienten mit ischämischer Kardiomyopathie evaluiert und diskutiert. 
Auf Grundlage von 10 Originalarbeiten (5 Erst-, 2 Letzt-, und 3 Co-
Autorenschaften), 2 Übersichtsarbeiten (2 Erstautorenschaften) und eines 
Leitartikels (Erstautorenschaft) werden die Ergebnisse aus verschiedenen klinischen 
Studien im Hinblick auf die Risikostratifizierung und Therapie bei Patienten mit 
ischämischer Kardiomyopathie und struktureller Herzerkrankung dargestellt. 
Methodische Einzelheiten und Resultate sowie Abbildungen der jeweiligen Arbeiten 
finden sich detailliert in den jeweiligen Originalarbeiten (siehe Anhang). Eine 
Auswahl von Abbildungen im Text soll zentrale Aussagen den Originalarbeiten 
beispielhaft illustrieren und der Verdeutlichung wichtiger Diskussionspunkte dienen. 
Aus Gründen der Übersichtlichkeit wird die zitierte Literatur in numerischer 
Reihenfolge im Literaturverzeichnis aufgeführt. Die eigenen Veröffentlichungen 
(Erst-, Letzt- und Co-Autorenschaften) zum Thema „Neue Ansätze zur 
Risikostratifizierung und Therapie bei Patienten mit ischämischer Kardiomyopathie 
und struktureller Herzerkrankung“ sind in alphabetischer Indizierung (A-M) in einem 
separaten Verzeichnis aufgeführt.  
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3. Einleitung 
Die Prognose von Patienten nach Myokardinfarkt konnte in den letzten 
Jahrzehnten signifikant verbessert werden. Erreicht wurde dies durch eine 
Optimierung der Akutversorgung mit sofortiger Revaskularisation des akut 
verschlossenen Infarktgefäßes1,2 und durch die Weiterentwicklung der 
medikamentösen Begleittherapie3-5. Dennoch bleibt die Spätmortalität mit etwa 1,5% 
pro Jahr hoch6, auch wenn die Patienten optimal therapiert werden. Etwa jeder 
zweite Todesfall geschieht unter dem Bild des plötzlichen Herztodes, d.h. innerhalb 
von Sekunden bis Minuten aus scheinbar stabilen Verhältnissen heraus7. In über 
90% dieser Fälle ist der Herzkreislaufstillstand durch tachykarde 
Herzrhythmusstörungen, die in Kammerflimmern degenerieren, verursacht.  
Randomisierte Studien konnten belegen, dass Hochrisikopatienten nach 
Myokardinfarkt von einer primärprophylaktischen Implantation eines Defibrillators 
(„implantable cardioverter-defibrillator“, ICD) profitieren8,9. Die Identifizierung 
geeigneter Patienten erfolgt gegenwärtig durch Bestimmung der linksventrikulären 
Auswurffraktion (LVEF), welche derzeit als Goldstandard in der Risikoprädiktion 
gilt10. Nach den derzeit gültigen Richtlinien sind Patienten mit hochgradig 
eingeschränkter LVEF (≤35%) Kandidaten für eine primärprophylaktische ICD-
Implantation. Die Sensitivität und Spezifität der LVEF in der Risikoprädiktion nach 
Myokardinfarkt ist allerdings beschränkt. Etwa 70% der Todesfälle ereignen sich in 
der Patientengruppe mit erhaltener oder nur moderat eingeschränkter 
Pumpfunktion11. In der Patientengruppe mit hochgradig eingeschränkter LVEF, die 
mit ICD versorgt wird, erhält innerhalb von 5 Jahren nur jeder dritte Patient eine 
adäquate ICD-Therapie12. Die durch die ICD-Therapie reduzierte Rate des 
plötzlichen Herztodes ist allerdings mit einer Erhöhung der Rate des nicht plötzlichen 
Herztodes verbunden13.  
Aus diesen Gründen sind neue Verfahren zur Risikostratifizierung von großer 
klinischer Bedeutung. Experimentelle und klinische Studien belegen, dass die 
Qualität autonomer Regelungsprozesse des Herzens eine wesentliche und von der 
LVEF unabhängige prognostische Informationen trägt14. Es gibt Evidenz, dass ein 
Verlust vagaler Aktivität und ein Übermaß sympathischer Aktivität mit einer 
schlechten Prognose vergesellschaftet sind. Eine direkte Messung autonomer 
Aktivität am Herzen ist aufgrund der Invasivität als klinische Untersuchungsmethode 
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nicht möglich. Stattdessen können autonome Steuerungsprozesse indirekt durch 
Analyse von kardialen Biosignalen charakterisiert werden.  
Im Rahmen dieser Habilitationsarbeit sollen primär neue Ansätze zur 
Risikostratifizierung nach Myokardinfarkt mit Hauptaugenmerk auf Marker des 
autonomen Tonus untersucht werden. In einem weiteren Schritt sollen diese 
Methoden bei Patienten mit struktureller Herzerkrankung angewendet werden. Am 
Ende sollen neue Ansätze zur Verbesserung der Therapie bei Patienten mit 
ischämischer Kardiomyopathie evaluiert und diskutiert werden.  
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4. Klassische Analyse der Herzfrequenzvariabilität 
Ein seit langer Zeit bekannter diagnostischer Zugang zum autonomen 
Nervensystem des Herzens besteht in der Analyse der Herzfrequenzvariabilität 
(heart rate variability – HRV). In diesem Fall fungiert der, sowohl sympathisch, als 
auch parasympathisch innervierte, Sinusknoten als „Schreiber der autonomen 
Funktion“. Zur Bestimmung der HRV werden die aufeinanderfolgenden Schlag-zu-
Schlag-Abstände (RR-Intervalle) im Sinne einer Zeitreihenanalyse mit 
mathematischen Methoden analysiert. HRV gilt als Indikator für die Güte der 
autonomen Funktion. Kleiger und Mitarbeiter konnten erst in der MPIP (multicenter 
post-infarction project) Studie zeigen, dass eine eingeschränkte HRV mit erhöhter 
Gesamtmortalität nach akutem Myokardinfarkt vergesellschaftet ist. Dazu 
bestimmten die Autoren bei 808 Patienten die Standardabweichung aller Normal-zu-
Normal-Intervalle (SDNN) über 24-Stunden15. Die prognostische Bedeutung dieses 
vergleichsweise einfachen HRV-Parameters wurde in mehreren prospektiven 
Kohorten validiert16,17. Eine andere Methode um Rückschlüsse auf die anteilsmäßige 
Beteiligung zugrundeliegender autonomer Regelungsprozesse an der 
Gesamtvariabilität zu ziehen, bietet die Frequenzanalyse der HRV. Hierbei wird das 
Zeitsignal der RR-Intervalle in ein Frequenzspektrum umgewandelt und in 4 
Bereiche (Banden) aufgeteilt. Bigger und Mitarbeiter haben den prognostischen Wert 
spektraler HRV-Parameter an 715 Überlebenden eines akuten Myokardinfarktes 
untersucht. In der multivariablen Analyse war eine reduzierte Power im sogenannten 
very- (0.0033 – 0.4 Hz) und ultra-(<0.0033 Ηz) low Frequenzbereich hochsignifikant 
mit der Gesamtmortalität assoziiert18. Ein Nachteil der herkömmlichen Maßen der 
HRV-Bestimmung ist, dass es nicht zwischen vagalen und sympathischen 
Einflüssen unterschieden werden kann. Darüber hinaus ist ein 24-Stunden Langzeit-
EKG erforderlich. Angesichts des immer verkürzten Krankenhausaufenthalts stellt 
aber dieses Erfordernis ein wesentliches Haupthemmnis dar. Im Folgenden sollen 
neue nicht-invasive Ansätze zur selektiven Erkennung des vagalen Verlustes und 
der sympathischen Überaktivität aus Langzeit- und Kurzzeit-EKGs eingegangen 
werden. 
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5. Neue Ansätze zur Risikostratifizierung bei Postinfarktpatienten 
5.1. Herzfrequenzturbulenz  
 Die Herzfrequenzturbulenz quantifiziert die Baroreflex-vermittelte 
Kurzzeitoszillation der Herzfrequenz nach spontan einfallenden ventrikulären 
Extrasystolen (VES)19. Physiologisch kommt es nach einer VES zuerst zu einer 
Herzfrequenzbeschleunigung, gefolgt von einer progredienten 
Herzfrequenzverlangsamung. Der erste Teil dieser biphasichen Reaktion wird durch 
den Turbulence Onset (TO) quantifiziert. Der insuffiziente Auswurf der Extrasystole, 
sowie die nachfolgende kompensatorische Pause führen zu einer Aktivierung der 
Barorezeptoren, was einen abrupten Abfall des Vagotonus zur Folge hat. Dies ist die 
Ursache für die unmittelbare Beschleunigung der Herzfrequenz. Der zweite Teil der 
biphasischen Reaktion (Herfrequenzverlangsamung), der durch den Turbulence 
Slope (TS) quantifiziert wird entspricht der mit einer Latenzzeit Reaktion des 
sympathischen Nervensystems auf den Blutdruckabfall. Die HRT ist einer der 
bestuntersuchten Risikoparameter nach Myokardinfarkt und ist an mehreren 
prospektiven Kohorten validiert worden11.  In einer großen Metaanalyse, die 9 
prospektive Studien mit insgesamt 9.709 Patienten einbezog, konnte gezeigt 
werden, dass ein Abschwächen oder ein Fehlen der typischen HRT-Reaktion mit 
einem 6.2-fachen Mortalitätsrisko assoziiert war (Abb. 1) A. 
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Abb. 1: Metaanalyse des prognostischen Wertes der Herzfrequenzturbulenz für die Prädiktion der 
Gesamtmortalität. MPIP = Multicenter Post-infarction Program19, EMIAT = European Myocardial 
Infarction Amiodarone Trial19, ATRAMI = Autonomic Tone and Reflexes after Myocardial Infarction20, 
ISAR-HRT = Improved Stratification of Autonomic Regulation by means of Heart Rate Turbulence21, 
CAST = Cardiac Arrhythmia Suppression Trial22, FINGER = FINland and GERmany sudden cardiac 
death trial22, REFINE = Risk Estimation Following Infarction Non-invasive Evaluation23, ISAR-RISK = 
= Improved Stratification of Autonomic Regulation for Risk prediction after myocardial infarction24, 
CARISMA = Cardiac Arrhythmias and RIsk Stratification after AMI25 A. 
 
5.2. Dezelerationskapazität 
Die Dezelerationskapazität (deceleration capacity – DC) des Herzens ist ein 
neues Maß der HRV, das sich in wesentlichen Aspekten von herkömmlichen HRV-
Parametern unterscheidet26,27. Zur Bestimmung der DC wird die Serie der RR-
Intervalle mit Hilfe eines mathematischen Verfahrens (Phase Rectified Signal 
Averaging – PRSA) in ein neues wesentlich kürzeres Signal transformiert, welches 
sämtliche Schwingungen des Originalsignals enthält, dabei werden Rauschen und 
Nicht-Stationaritäten eliminiert26. Neben dem Vorteil des signifikant besseren Signal-
Rausch-Verhältnisses, besteht zudem eine weitere Besonderheit: Die DC ist ein 
integrales Maß sämtlicher an Verlangsamungen beteiligter Modulationen der 
Herzfrequenz und damit ein Maß der vagalen Innervierung des Herzens26,27. In einer 
großen Beobachtungsstudie an insgesamt 2.711 Postinfarktpatienten war DC nicht 
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nur Standardmaßen der HRV sondern auch der LVEF in der Mortalitätsprädiktion 
überlegen24. Die Bestimmung der DC erforderte bislang die Durchführung eines 24-
Stunden Langzeit-EKGs. Angesichts des immer verkürzten Krankenhausaufenthalts 
stellt dieses Erfordernis ein wesentliches Haupthemmnis dar. Die Berechnung der 
DC aus Kurzzeit-EKGs wäre deshalb von großem Vorteil und würde die 
Risikostratifizierung nach Myokardinfarkt im klinischen Alltag ermöglichen. Der 
prognostische Wert der DC aus Kurzzeit-EKGs nach Myokardinfarkt ist in zwei 
großen Kohorten mit insgesamt 1.286 Patienten untersucht worden (München-
Kohorte, ISAR-Risk,n = 908 und Tübingen-Kohorte, PRD-MI, n = 478) B. Der primäre 
Endpunkt beider Studien war die 3-Jahres-Gesamtmortalität. Der sekundäre 
Endpunkt war die 3-Jahres-kardiovaskuläre Mortalität. Abb. 2 zeigt repräsentative 
PRSA-Signale eines Patienten, der den Beobachtungszeitraum überlebt hat (A), 
sowie eines Patienten, der 9 Wochen nach dem Herzinfarkt verstorben ist (B). Die 
Amplituden der Periodizitäten sind bei dem verstorbenen Patienten deutlich niedriger 
als bei dem überlebenden Patienten.  
 
 
Abb. 2: Repräsentative PRSA-Signale zweier Postinfarkt-Patienten. (A) zeigt Dezelerations-
bezogene PRSA-Signale eines Patienten der den Beobachtungszeitraum überlebt hat. (B) zeigt die 
Dezelerations-bezogene PRSA-Signale eines Patienten der 9 Wochen nach dem Herzinfarkt 
verstorben ist. Die Amplituden der Periodizitäten sind bei dem verstorbenen Patienten deutlich 
niedriger als bei dem überlebenden Patienten B.  
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In beiden Kohorten war die eingeschränkte DC der stärkste Prädiktor der 3-
Jahres-Mortalität, sowie der 3-Jahres kardiovaskulären Mortalität (Abb. 3) B. 
Multivariable Analysen zeigten, dass der prädiktive Wert der DC unabhängig von 
anderen etablierten Risikoparametern, wie die LVEF und der GRACE (Global 
Registry of Acute Coronary Events) Score war (Tab. 1) B.  Hinzunahme der DC in 
das multivariable Modell führte zu einem signifikanten Anstieg des C-Indexes und 
des IDI (integrated discrimination improvenent) Maßes für die Prädiktion der 
Gesamtmortalität. 
 
Abb. 3: Kumulative Gesamt- und kardiovasuläre Mortalitätskurven von Postinfarktpatienten in zwei 
großen prospektiven Kohorten (A = ISAR-Risk, n = 908; B = PRD-MI, n = 455) stratifiziert nach der 
Dezelerationskapazität des Herzens B. 
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Tab. 1: Uni- und multivariable Cox-Regressionsanalyse für die Prädiktion der 3-Jahres 
Gesamtmortalität und der 3-Jahres-kardiovaskulären Mortalität bei 908 Postinfarkt-Patienten der 
ISAR-Risk Studie und bei 478 Patienten der PRD-MI Studie B. 
Munich cohort (ISAR-Risk): All-cause mortality 
Risk variable Univariable Cox Regression Multivariable Cox Regression 
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
GRACE score >140 4.35 (2.36 – 8.01) <0.001 1.91 (0.98 – 3.73) 0.059 
LVEF ≤35% 5.27 (2.89 – 9.61) <0.001 2.75 (1.43 – 5.27) 0.002 
DCst ≤2.5ms 7.18 (4.00 – 12.87) <0.001 5.04 (2.68 – 9,49) <0.001 
Munich cohort (ISAR-Risk): Cardiovascular mortality 
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
GRACE score >140 4.00 (1.75 – 9.14) 0.001 1.72 (0.69 – 4.27) 0.245 
LVEF ≤35% 6.13 (2.81 – 13.38) <0.001 3.47 (1.48 – 8.12) 0.004 
DCst ≤2.5ms 6.21 (2.88 – 13.37) <0.001 4.18 (1.81 – 9.68) <0.001 
Tuebingen cohort (PRD-MI): All-cause mortality 
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
GRACE score >140 3.48 (1.89 – 6.42) <0.001 2.29 (1.20 – 4.37) 0.012 
LVEF ≤35% 4.16 (2.35 – 7.37) <0.001 2.07 (1.11 – 3.86) 0.023 
DCst ≤2.5ms 4.57 (2.51 – 8.33) <0.001 3.19 (1.70 – 6.02) <0.001 
Tuebingen cohort (PRD-MI): Cardiovascular mortality 
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
GRACE score >140 3.79 (1.57 – 9.16) 0.003 2.49 (0.98 – 6.35) 0.056 
LVEF ≤35% 4.44 (1.99 – 9.93) <0.001 2.31 (0.95 – 5.60) 0.065 
DCst ≤2.5ms 3.79 (1.66 – 8.67) 0.002 2.51 (1.04 – 6.03) 0.040 
DCst = Dezelerationskapazität aus Kurzzeit EKGs, GRACE  = Global Registry Acute Coronary Events, 
LVEF = linksventrikuläre Auswurffraktion 
 
Des Weiteren evaluierten wir den prognostischen Wert der DC aus Kurzzeit-
EKGs als Risikoprädiktor in der Notaufnahme. DC war ein sehr starker Prädiktor der 
6-Monats-Mortalität bei unselektionierten Patienten (Abb. 4) C, sowie  bei Patienten 
mit Verdacht auf akutes Koronarsyndrom (Abb. 5) D.  
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Abb. 4: Kumulative Mortalitätskurven bei unselektionierten Patienten in der Notaufnahme stratifiziert 
nach der Dezelerationskapazität des Herzens C. 
 
Abb. 5: Kumulative Mortalitätskurven bei Patienten mit Verdacht auf akutes Koronarsyndrom 
stratifiziert nach der Dezelerationskapazität (DC) des Herzens D. 
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5.3. Periodic Repolarization Dynamics (PRD) 
5.3.1.  Berechnung der PRD 
 Aus direkten Nervenableitungen ist bekannt, dass sympathische Entladungen 
am Herzen in sogenannte niederfrequenten „Bursts“ organisiert sind (≤0,1 Hz; 
entsprechend Zykluslänge >10s)28. Mit Hilfe mathematischer Methoden konnte 
nachgewiesen werden, dass die kardiale Repolarisation in Ruhe niederfrequenten 
Modulationen unterliegt, welche mit bloßem Auge nicht sichtbar sind E. Dieses neue 
elektrokardiographische Phänomen, das zuerst 2014 erfunden worden ist E, wird 
“Periodic Repolarization Dynamics“ (PRD) genannt E,F,G. Um die PRD zu bestimmen, 
ist eine hochaufgelöste EKG-Aufzeichnung erforderlich. Die Untersuchung sollte in 
den orthogonalen, Frank-Ableitungen (X, Y und Z) über einen Zeitraum von 
mindestens 20-Minuten erfolgen. Da die Messung auf extrinsische oder intrinsische 
Störfaktoren empfindlich sein kann,  sollte sich der liegende Patient in einer ruhigen 
Umgebung befinden und spontan atmen. Schematisch erfolgt die PRD-Bestimmung 
in den folgenden Schritten: 
- Im ersten Schritt der Berechnung werden die kartesischen Koordinaten X, Y 
und Z in eine Zeitfolge von polaren Koordinaten umgewandelt. Der 
ursprüngliche Vektor wird dabei in zwei Winkel (Elevation und Azimut) und 
eine Länge zerlegt. 
- Als nächstes wird auf Basis der orthogonalen Koordinaten die gewichtete 
Richtung der Repolarisation definiert. Dafür werden Azimut und Elevation für 
jeden Zeitpunkt der T-Welle mit der Länge multipliziert. Die Summe aller 
Produkte wird anschließend mit der Summe aller Längen dividiert. Die dabei 
entstehenden polaren Winkel werden gewichteter Azimut (weight-averaged 
azimuth, WAA) und gewichtete Elevation (weight-averaged elevation, WAE) 
genannt. Gleichung 1 und Gleichung 2, sowie Abb. 6 und 7 zeigen die 
Berechnung von WAA und WAE. 
!"#$ℎ&	()"*+$",	(-#./&ℎ	 !(( = 	
((.23 ∗ 	(-#./&ℎ3)
36789:
367;<=><
((.23)
36789:
367;<=><
	(1) 
 
!"#$ℎ&	()"*+$",	@A")+&#BC	 !(@ = 	
(.23 ∗ 	@A")+&#BC3
36789:
367;<=><
(.23
36789:
367;<=><
	(2) 
 15 
 
Abb. 6: Berechnung des gewichteten Azimuts und der gewichteten Elevation. Die kartesischen 
Koordinaten X, Y und Z (A) werden zuerst in eine Zeitfolge von polaren Koordinaten umgewandelt 
(B). Für jeden Zeitpunkt (z.B. t1 = 50ms) werden Azimut und Elevation mit der Länge multipliziert und 
der gewichtete Mittelwert wird als die Summe aller Produkte durch die Summe der Längen berechnet 
(C und D) E. 
  
Abb. 7: Beispielrechnung eines gewichteten Azimuts (A), sowie einer gewichteten Elevation (B) E.   
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- In einem dritten Schritt wird jeweils der Winkel dT° zwischen zwei 
aufeinanderfolgenden T-Wellen-Vektoren berechnet (Gleichung 3 und Abb. 8) 
Dieser Winkel dient als Maß der momentanen Repolarisationsinstabilität.  
,E° = +GBH[sin !(@M ∗ cos !((M ∗ sin !(@P ∗ cos !((P +	
																																													cos !(@M ∗ cos !(@P +	
																									sin !(@M ∗ sin !((M ∗ sin !(@P ∗ sin !((P ]	(3)	
 
Abb. 8: (A) Projektion eines T-Wellen-Vektors auf zwei orthogonale Ebenen. (B) Berechnung des 
Winkels dT° zwischen zwei aufeinanderfolgenden T-Wellen-Vektoren (T1 und T2). (C) 
Beispielrechnung eines dT°-Winkels E.   
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- Meist betragen die Winkeländerungen dT° von T-Welle zu T-Welle nur wenige 
Grad. Trägt man die Winkel jedoch über die Zeit auf, so demaskieren sich 
periodische dT°-Anstiege etwa alle 15–30 s. Die periodischen Komponente 
des dT°-Signals werden anschließend durch eine kontinuierliche Wavelet-
Transformation quantifiziert. Die Koeffizienten der kontinuierlichen Wavelet-
Transformation werden mit bereits etablierten Algorithmen in eine 
Pseudofrequenz überführt. Die PRD erfasst schließlich den Bereich zwischen 
0 und 0,1 Hz der Pseudofrequenz und wird in deg2 angegeben (Abb. 9) E. 
 
 
Abb. 9: (A) Schematische Darstellung der Berechnung der „Periodic Repolarization Dynamics“: (A) 
EKG in orthogonalen Frank-Ableitungen. (B) Winkel zwischen zwei T-Wellen-Vektoren. (C und D) 
periodische dT°-Anstiege. (E), Wavelet- Transformation der periodischen dT°-Anstiege E.  
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5.3.2. Pathophysiologischen Mechanismen der PRD 
Die exakten pathophysiologischen Mechanismen, die PRD zugrunde liegen, 
sind noch nicht hinreichend erforscht. Experimentelle Befunde und theoretische 
Erkenntnisse sprechen jedoch dafür, dass PRD den Effekt niederfrequenter 
sympathischer Entladungen auf die kardiale Repolarisation des Ventrikelmyokards 
widerspiegelt E,F,G. Zuerst konnte in elektrophysiologischen Untersuchungen gezeigt 
werden, dass PRD unabhängig von der Herzfrequenzvariabilität ist (Abb. 10 und 
Abb. 12A) E. 
 
Abb. 10: Typisches RR-Intervall (A)  und dT°-Signal (B) bei einem gesunden Probanden in Ruhe.  
(C) Fast vollständige Elimination der Herzfrequenzvariabilität unter atrialer Stimulation (bei n=10, 
p=0.002 für die Änderung der Herzfrequenzvariabilität unter Stimulation). (D) dT°-Signal mit 
erhaltener Variabilität im niederfrequenten Spektrum unter atrialer Stimulation (p=0.230 bei n=10) E. 
 
In einem zweiten Schritt konnte in einem Tiermodell gezeigt werden, dass 
PRD unabhängig von der Atmung war (Abb. 11) E.   
 19 
 
Abb. 11: Testung der Interaktion zwischen der Atmung und der PRD im Tiermodell. 7 Schweine 
wurden intubiert und mit fixierter Atemfrequenz, sowie fixiertem Tidalvolumen beatmet. (A) Das 
Atemsignal, das nicht invasiv durch einen Atemgürtel abgeleitet ist, wird mit grüner Farbe 
gekennzeichnet.  Das dT°-Signal wird in Blau geplottet. (B) Spektralanalyse vom Atemsignal (grün) 
und dT°-Signal (blau). Es zeigen sich Peaks an unterschiedlichen Frequenzspektren (0.04 Hz für das 
dT°-Signal und 0.2 Hz für das Atemsignal), ohne signifikante Kreuzkorrelation in der 
Kreuzspektralanalyse (C) E. 
 
Der Effekt des sympathischen Nervensystems auf PRD ist mit 
physiologischen und pharmakologischen Provokationen untersucht worden.  Eine 
physiologische sympathische Aktivierung durch körperliche Belastung oder mittels 
eines Kipptischversuchs führte bei Gesunden zu einer deutlichen Zunahme der PRD 
(Abb. 12 B und C). Verabreichung eines Betablockers unter atrialer Stimulation 
supprimierte dagegen die PRD (Abb. 12 D) E. 
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Abb. 12: Effekte der atrialen Stimulation (A), der Kipptischuntersuchung (B), der Belastung (C) und 
der Verabreichung eines Betablockers (D) auf PRD E. 
 
Die niederfrequenten Oszillationen der kardialen Repolarisation29 und ihr 
Zusammenhang mit der sympathischen Innervierung des Herzens30 konnten auch 
von anderen Forschungsgruppen gezeigt werden. Hanson und Mitarbeiter konnten  
ein niederfrequentes oszillatorisches Verhalten der Aktionspotenzialdauer (APD) bei 
Patienten mit Herzinsuffizienz nachweisen29. Pueyo und Mitarbeiter konnten mit Hilfe 
einer Computermodellierung zeigen, dass eine phasische beta-adrenergische 
Stimulation zur Zunahme der niederfrequenten Oszillationen der Repolarisation 
führt30. 
Auf zellulärer Ebene verkürzt die sympathische Stimulation die APD der 
Kardiomyozyten. Unterschiedlich stark beeinflusst werden dabei die Zellen der 
einzelnen Schichten des Herzens31. So, verkürzt die sympathische Stimulation die 
APD der äußeren Myokardschichten stärker als die der mittleren Myokardschicht 
(transmurale Dispersion der Repolarisation)32. Die T- Welle des Oberflächen-EKGs 
ist die integrale Repräsentation der Phasen 2 und 3 der Aktionspotenziale aller 
Kardiomyozyten33,34. Die sympathische Aktivierung führt deswegen zu 
entsprechenden Mikrovoltänderungen der T-Welle, die mit bloßem Auge nicht 
sichtbar sind. Da efferente sympathische Aktivität am Herzen in niederfrequenten 
Clustern auftritt28,35-38, sind sympathisch induzierte T-Wellen-Modulationen auch in 
diesem Frequenzbereich zu erwarten. Eine besondere Situation findet sich bei 
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Patienten nach Myokardinfarkt statt. Bei diesen Patienten können sich myokardiale 
Bereiche finden, deren Zellen zwar vital, jedoch autonom denerviert sind. Diese 
Zellen können nicht auf sympathische Stimulation reagieren, wodurch sich die 
transmurale Dispersion und dementsprechend die PRD erhöhen.  
 
5.3.3. PRD bei Postinfarktpatienten mit erhaltener Pumpfunktion 
 Der prognostische Wert einer erhöhten PRD nach akutem Myokardinfarkt 
wurde in der ISAR-Risk-Studie an 908 Postinfarktpatienten getestet E. 
Einschlusskriterien waren das Vorhandensein eines Sinusrhythmus, ein Alter von 80 
Jahren oder weniger und ein Herzinfarkt innerhalb der letzten 30 Tage. Bei allen 
Patienten wurde eine 30-minütige EKG-Aufzeichnung in Frank-Ableitungen und 
unter standardisierten Bedingungen durchgeführt. Der primäre Endpunkt der Studie 
war die 5-Jahres-Gesamtmortalität, als sekundärer Endpunkt ist die 5-Jahres 
kardiovaskuläre Mortalität definiert worden. Während des Beobachtungszeitraums 
starben 69 Patienten, 36 davon waren als kardiovaskulär bedinge Todesfälle 
klassifiziert. Abb. 13 zeigt repräsentative dT°-Signale eines Patienten der den 
Beobachtungszeitraum überlebt hat (A), sowie eines Patienten der einige Monate 
nach dem Herzinfarkt plötzlich verstorben ist (B). In den Signalen beider Patienten 
waren niederfrequente Oszillationen erkennbar, die jedoch bei dem verstorbenen 
Patienten deutlich ausgeprägter waren E. Dieser Unterschied bestand hochsignifikant 
in der gesamten Kohorte. So betrug die mediane PRD bei Überlebenden 2,66 deg2 
(IQR 3,93 deg2), bei Verstorbenen hingegen 6,67 deg2 (IQR 8,53 deg2). Abb. 14 
zeigt die kumulativen Mortalitätskurven bei Postinfarktpatienten stratifiziert nach der 
PRD. Die 227 Patienten mit PRD ≥5.75 deg2 hatten eine 5-Jahresmortalität von 
18.2% im Vergleich zu einer 4.1% 5-Jahres-Mortalität bei Patienten mit PRD <5.75 
deg2. Multivariable Cox-Regressionsanalysen zeigten, dass der prädiktive Wert der 
PRD unabhängig von anderen etablierten Risikoparametern wie der LVEF, dem 
GRACE-Score und klinischen Markern war (Tab. 2) E. 
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Abb. 13: Repräsentative dT°-Signale eines Patienten der den Beobachtungszeitraum überlebt hat 
(A), sowie eines Patienten der einige Monate nach dem Herzinfarkt plötzlich verstorben ist (B). In den 
Signalen beider Patienten waren niederfrequente Oszillationen erkennbar, die jedoch bei dem 
verstorbenem Patienten deutlich ausgeprägter waren E. 
 
 
Abb. 14: Kumulative 5-Jahres-Mortalitätskurven stratifiziert nach PRD ≥5.75 deg2 E. 
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Tab. 2: Uni- und multivariable Cox-Regressionsanalyse für die Prädiktion der 5-Jahres 
Gesamtmortalität und der 5-Jahres-kardiovaskulären Mortalität bei 908 Postinfarkt-Patienten der 
ISAR-Risk Studie E.  
 
All-cause Mortality 
Risk variable Univariable Cox Regression Multivariable Cox Regression 
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
LVEF ≤ 35% 3.81 (2.23 – 6.51) < 0.001 2.13 (1.22 – 3.70) 0.008 
GRACE score ≥120 5.54 (3.24 – 9.46) < 0.001 3.61 (2.06 – 6.31) < 0.001 
Diabetes mellitus 2.61 (1.61 – 4.23) < 0.001 2.07 (1.25 – 3.41) 0.005 
Mean HR > 75 bpm 1.98 (1.11 – 3.55) 0.020 1.10 (0.56 – 2.17) 0.783 
SDNN ≤ 70 ms 2.01 (1.22– 3.33) 0.007 1.71 (0.96 – 3.07) 0.072 
QTVI > -0.47 2.54 (1.55 – 4.19) < 0.001 1.12 (0.65 – 1.93) 0.688 
PRD ≥ 5.75 deg2 4.75 (2.94 – 7.66) < 0.001 3.03 (1.79 – 5.11) < 0.001 
 
Cardiovascular Mortality 
Risk variable Univariable Cox Regression Multivariable Cox Regression 
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
LVEF ≤ 35% 4.69 (2.32 – 9.50) < 0.001 2.71 (1.30 – 5.67) 0.008 
GRACE score ≥120 5.82 (2.75 –12.33) < 0.001 3.80 (1.73 – 8.35) < 0.001 
Diabetes mellitus 2.72 (1.40 – 5.31) 0.003 2.16 (1.08 – 4.31) 0.029 
Mean HR > 75 bpm 2.22 (1.02 – 4.86) 0.046 1.36 (0.55 – 3.38) 0.510 
SDNN ≤ 70 ms 1.89 (0.93 – 3.82) 0.080 1.48 (0.65 – 3.36) 0.350 
QTVI > -0.47 1.99 (1.02 – 3.88) 0.044 0.81 (0.39 – 1.70) 0.586 
PRD ≥ 5.75 deg2 4.50 (2.33 – 8.69) < 0.001 2.99 (1.45 – 6.17) 0.003 
GRACE  = Global Registry Acute Coronary Events, LVEF = linksventrikuläre Auswurffraktion, QTVI = 
QT-Variabilitätsindex, PRD = Periodic Repolarization Dynamics 
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5.3.4. PRD bei Patienten mit Verdacht auf koronare Herzerkrankung 
Der prädiktive Wert der PRD bei Patienten mit Verdacht auf koronare 
Herzerkrankung ist in der FINCAVAS (FINnisch CArdioVAScular) Studie an 2.965 
Patienten evaluiert worden. Einschlusskriterien waren das Vorhandensein eines 
Sinusrhythmus, ein Alter zwischen 30 und 80 Jahren und die klinische Indikation zur 
Durchführung eines 12-Kanal-Belastungs-EKGs (GE CASE, 500 Hz). Patienten mit 
einer Vorbelastungsphase kürzer als 2.5 Minuten sind von der Studie 
ausgeschlossen worden. Der primäre Endpunkt der Studie war die Gesamtmortalität, 
der sekundäre Endpunkt war die kardiovaskuläre Mortalität. Zur Berechnung der 
PRD ist eine Konversion der Vorbelastungsphase mittels der inversen Dower’s 
Transformation in die orthogonalen X, Y und Z Ableitungen ausgeführt worden. PRD 
ist mit T-Wellen-Alternans (TWA), das ein starker Mortalitätsprädiktor in dieser 
Studienpopulation war, verglichen worden39. TWA ist ein seit mehr als 100 Jahren 
bekanntes elektrokardiographisches Phänomen, das mikroskopische T-Wellen-
Veränderungen im hochfrequenten Bereich (Schlag-zu-Schlag) erfasst40. Zur 
Berechnung des TWA in dieser Kohorte ist die MMA (modified moving average) 
Methode während der Belastungsphase ausgeführt worden39,40.  
Während eines mittleren Beobachtungszeitraums von 75 Monaten sind 309 
Patienten verstorben. In der multivariablen Cox-Regressionsanalyse war PRD der 
stärkste Mortalitätsprädiktor und einer der stärksten Prädiktoren der 
kardiovaskulären Mortalität. Der prädiktive Wert der PRD, die in Ruhe erfasst 
werden konnte, war unabhängig vom TWA, das eine ergometrische Untersuchung 
erforderte (Tab. 3) E. Die negative Interaktion zwischen PRD und TWA deutet darauf 
hin, das PRD Hochrisikopatienten mit niedrigem TWA erfassen kann. 
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Tab. 3: Multivariable Cox-Regressionsanalyse für die Prädiktion der Gesamtmortalität und der 
kardiovaskulären Mortalität in 2.965 Patienten der FINCAVAS Studie E. 
Multivariable Cox Regression Analysis 
Risk variable All-cause mortality Cardiovascular mortality 
 Beta (95% CI) p-value Beta (95% CI) p-value 
Age, continuous 0.055 (0.042 – 0.068) < 0.001 0.044 (0.027 – 0.063) < 0.001 
Sex (yes, no) -0.535 (-0.280 – -0.790) < 0.001 -0.960 (-0.531 – -1.386) < 0.001 
DM (yes, no)  -0.393 (-0.111 – -0.675) 0.006 -0.291 (-0.721 – 0.139) 0.184 
Previous MI (yes, no) 0.205 (-0.049 – 0.459) 0.115 0.288 (-0.080 – 0.656) 0.126 
Beta-blocker (yes, no) 0.350 (0.085 – 0.614) 0.010 0.582 (0.164 – 0.999) 0.006 
TWA, continuous 0.175 (0.007 – 0.284) 0.002 0.274 (0.133 – 0.414) < 0.001 
PRD, continuous 0.198 (0.103 – 0.292) < 0.001 0.269 (0.136 – 0.401) < 0.001 
TWA * PRD -0.091 (-0.022 – -0.160) 0.010 -0.136 (-0.048 – -0.244) 0.002 
DM = Diabetes mellitus, MI = Myokardinfarkt, TWA = T-Wellen-Alternans, PRD = Periodic 
Repolarization Dynamics 
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5.3.5. PRD bei Postinfarktpatienten mit eingeschränkter Pumpfunktion  
Die prognostische Bedeutung der PRD bei Patienten mit einem Herzinfarkt 
älter als 30-Tage und einer hochgradig eingeschränkten LVEF  ist in der 
Multicenter Automatic Defibillator Implantation Trial (MADIT-II) Studie untersucht 
worden H. In der MADIT-II Studie sind 1.232 Patienten mit einer LVEF ≤30% nach 
Myokardinfarkt ohne vorheriges Arrhythmieereignis 3:2 zu einer 
primärprophylaktischen ICD-Implantation oder einer medikamentösen Therapie 
randomisiert worden8. Der primäre Endpunkt der Studie war die Reduktion der 2-
Jahres Mortalität. Die Studie musste frühzeitig abgebrochen werden, nachdem die 
ICD-Therapie zu einer signifikanten Senkung der Gesamtmortalität führte8. Die 
MADIT-II Studie führte zur Änderung der Leitlinien und Etablierung der 
primärprophylaktischen ICD-Implantation bei Postinfarktpatienten mit hochgradig 
eingeschränkter LVEF als Grad-1-Empfehlung10. In einer Post-hoc Analyse der 
MADIT-II Studie ist der prognostische Wert der PRD als Prädiktor der 
Gesamtmortalität, der kardiovaskulären Mortalität, des plötzlichen und des nicht-
plötzlichen Herztodes bei Patienten mit hochgradig eingeschränkter LVEF 
untersucht worden H. Eingeschlossen sind Patienten mit Vorhandensein eines 
Sinusrhythmus, die vor der Randomisierung ein 10-minütiges Ruhe EKG in Masor-
Likar-Ableitungen bekommen haben (Abb. 15). In uni- und multivariablen Cox-
Regressionsanalysen war die erhöhte PRD einer der stärksten Prädiktoren der 
Gesamtmortalität (Abb. 16 und Tab. 4), der kardiovaskulären Mortalität (Tab. 4), des 
plötzlichen (Tab. 5), sowie auch des nicht-plötzlichen Herztodes (Tab. 5). Des 
Weiteren ist der Effekt der ICD-Therapie bei Postinfarktpatienten stratifiziert nach 
PRD-Quartilen evaluiert worden. Die ICD-Therapie führte zu einer signifikanten 
Reduktion des plötzlichen Herztodes in allen PRD-Quartilen (Abb. 17C und 17D). 
Allerdings  führte die ICD-Therapie zu einer Reduktion der Gesamtmortalität nur in 
den untersten drei PRD-Quartilen (Abb. 17A und 17B). Patienten mir sehr hohen 
PRD-Werten konnten von der primärprophylaktischen ICD-Implantation hinsichtlich 
der Gesamtmortalität nicht profitieren (17D), da die Reduktion des plötzlichen durch 
einen proportionalen Anstieg des nicht-plötzlichen Herztodes ausgeglichen worden 
ist H. 
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Abb. 15: Flussdiagramm der MADIT-II Studienpopulation H. 
 
 
Abb. 16: Kumulative Mortalitätskurven bei Patienten in der MADIT-II Studie stratifiziert nach PRD-
Quartilen H. 
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Abb. 17: Effekt der ICD-Therapie hinsichtlich der Gesamtmortalität (A und B) und des plötzlichen 
Herztodes bei Patienten mit unterschiedlichen PRD-Werten (A und C: PRD-Quartile 1-3, B und D: 
PRD-Quartil 4) H. 
 
Tab. 4: Multivariable Analyse für die Prädiktion der Gesamt- und kardiovaskulären Mortalität in der 
MADIT-II Studie H. 
Risk predictors Death Cardiac Death 
 HR (95% CI) X2 p-value HR (95% CI) X2 p-value 
Tx with ICD 0.66 (0.46 – 0.95) 5.0 0.026 0.57 (0.38 – 0.85) 7.7 0.006 
PRD (deg2), per SD 1.37 (1.19 – 1.59) 17.7 <0.001 1.39 (1.19 – 1.63) 16.8 <0.001 
LVEF (%), per SD 0.91 (0.76 – 1.09) 1.0 0.313 0.89 (0.73 – 1.08) 1.4 0.245 
NYHA class ≥II 1.08 (0.73 – 1.60) 0.2 0.694 1.16 (0.76 – 1.78) 0.5 0.500 
Diabetes mellitus 1.17 (0.80 – 1.72) 0.7 0.407 1.25 (0.83 – 1.89) 1.2 0.281 
BUN >25 mg/dl 2.26 (1.54 – 3.31) 17.2 <0.001 2.24 (1.48 – 3.39) 14.4 <0.001 
Beta-blockers 0.63 (0.44 – 0.92) 5.8 0.016 0.62 (0.42 – 0.93) 5.3 0.022 
QRS (s), per SD 1.42 (1.19 – 1.69) 15.2 <0.001 1.42 (1.17 – 1.71) 12.8 <0.001 
LVEF = linksventrikuläre Auswurffraktion, PRD = Periodic Repolarization Dynamics, Tx = Therapie   
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Tab. 5: Multivariable Analyse für die Prädiktion des plötzlichen und des nicht plötzlichen Herztodes in 
der MADIT-II Studie H. 
Risk predictors SCD N-SCD 
 HR (95% CI) X2 p-value HR (95% CI) X2 p-value 
Tx with ICD 0.33 (0.19 – 0.58) 14.5 <0.001 1.41 (0.68 – 2.91) 0.9 0.351 
PRD (deg2), per SD 1.40 (1.13 – 1.75) 9.1 0.003 1.41 (1.10 – 1.81) 7.4 0.006 
LVEF (%), per SD 0.79 (0.61 – 1.03) 3.0 0.082 1.22 (0.86 – 1.74) 1.2 0.266 
NYHA class ≥II 1.31 (0.72 – 2.41) 0.8 0.379 1.47 (0.68 – 3.17) 0.9 0.330 
Diabetes mellitus 1.25 (0.71 – 2.21) 0.6 0.407 1.16 (0.58 – 2.31) 0.2 0.684 
BUN >25 mg/dl 1.71 (0.96 – 3.06) 3.3 0.070 3.65 (1.79 – 7.41) 12.8 <0.001 
Beta-blockers 0.68 (0.39 – 1.18) 1.9 0.166 0.63 (0.32 – 1.25) 1.7 0.189 
QRS (s), per SD 1.25 (0.95 – 1.64) 2.6 0.106 1.61 (1.16 – 2.22) 8.3 0.004 
LVEF = linksventrikuläre Auswurffraktion, N-SCD = nicht-plötzlicher Herztod, PRD = Periodic 
Repolarization Dynamics, SCD = plötzlicher Herztod, Tx = Therapie 
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5.4. Kardiales Autonomes Versagen 
Die Kombination einer erhöhten PRD, als Marker der sympathischen 
Überfunktion und einer supprimierten DC als Marker des vagalen Verlustes 
identifiziert eine neue Hochrisikogruppe mit einer schweren autonomen Dysfunktion, 
die als kardiales autonomes Versagen (cardiac autonomic failure; CAF) definiert wird 
I.  Bei Patienten mit erhaltener LVEF >35% war die Kombination der abnormalen 
PRD und DC (CAF = 2) im Vergleich zur normalen PRD und DC (CAF 0) mit einem 
10-fachen 5-Jahres Mortalitätsrisiko assoziiert (Abb. 18 und Tab. 6 Tab. 6) I.         
Tab. 6: Univariable Cox-Regressionsanalyse für die Prädiktion der 5-Jahres Mortalität bei Patienten 
nach akutem Myokardinfarkt mit erhaltener linksventrikulärer Pumpfunktion I. 
Risk variables Hazard ratio (95% CI) p-value 
CAF 1 vs. CAF 0 3.4 (1.7 – 6.7) < 0.001 
CAF 2 vs. CAF 0 9.9 (5.0 – 19.6) < 0.001 
DC ≤ 2.5ms 4.9 (2.9 – 8.6) < 0.001 
PRD ≥ 5.75 deg2 4.1 (2.4 – 7.1) < 0.001 
LVEF ≤ 45% 1.6 (0.8– 3.0) 0.171 
CAF  = kardiales autonomes Versagen, DC = Dezelerationskapazität, PRD = periodic repolarization 
dynamics. CAF 0 = PRD <5.75 deg2 und DC >2.5ms, CAF 1 = PRD ≥5.75 deg2 oder DC ≤2.5ms, CAF 
2 = PRD ≥5.75 deg2 und DC >2.5ms  
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Abb. 18: Kumulative Mortalitätskurve bei Patienten nach Akutem Myokardinfarkt mit erhaltener 
Pumpfunktion stratifiziert nach kardialem autonomen Versagen I. 
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6. Neue Ansätze zur Risikostratifizierung bei struktureller Herzerkrankung 
 Der prognostische Wert der Kombination der abnormalen 
Dezelerationskapazität und der abnormalen Herzfrequenzturbulenz des Herzens, die 
als schwere autonome Dysfunktion (severe autonomic failure, SAF) bezeichnet wird,  
ist bei Patienten mit höhergradiger Aortenklappenstenose (AS) getestet worden J. 
Insgesamt sind 216 Patienten mit symptomatischer hochgradiger 
Aortenklappenstenose, die einem transfemoralen oder operativen 
Aortenklappenersatz unterzogen, untersucht worden. Der primäre Endpunkt der 
Studie war die 2-Jahres-Gesamtmortalität. Als sekundärer Endpunkt ist die 
Kombination aus kardiovaskulärer Mortalität und Herzinsuffizienz-assoziierte 
Hospitalisierung definiert worden. 29 und 37 haben den primären, beziehungsweise 
den sekundären Endpunkt erreicht. Die 32 Patienten mit schwerer autonomer 
Dysfunktion und hochgradiger symptomatischer AS zeigten eine 50.0% 
Gesamtmortalität verglichen mit einer 10.7% Gesamtmortalität bei den 184 SAF-
negativen Patienten (Abb. 19A). SAF war auch mit dem sekundären Endpunkt 
signifikant assoziiert (Abb. 19B). Multivariable Analysen zeigten, dass SAF der 
stärkste Mortalitätsprädiktor in dieser Kohorte war. Der prädiktive Wert der SAF war 
unabhängig von etablierten Mortalitätsprädiktoren bei AS, wie der logistische 
Euroscore, ein erhöhtes natriuretisches Peptid typ B, die Klappenöffnungsfläche und 
der mittlere Druckgradient über der Aortenklappe (Tab. 7) J.  
 Ein klinisches Merkmal der Spätphase der Aortenklappenstenose ist die 
ausgeprägte Aktivierung des sympathischen Nervensystems41. Dies könnte in einer 
Kohorte mit 139 Patienten mit höhergradiger AS gezeigt werden. Im Vergleich zu 
Alter und Geschlecht gematchte Postinfarktpatienten wiesen Patienten mit mittel- 
und hochgradiger AS deutlich erhöhte PRD Werte auf (6.04 ± 3.80 deg2  gegen 5.06 
± 4.24 deg2 bei Postinfarktpatienten; p = 0.019) K. Abb. 20 zeigt ein repräsentatives 
dT°-Signal bei einem Patienten mit hochgradiger AS. Eine erhöhte PRD konnte in 
dieser Arbeit zur Identifizierung von Hochrisikopatienten mit AS führen, die bei 
konventionellen klinischen, echokardiographischen und elektrokardiographischen 
Kriterien nicht erkennbar waren. 
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Abb. 19: Kaplan-Meier Analyse für die Prädiktion der Gesamtmortalität, sowie des kombinierten 
Endpunktes bestehend aus kardialer Mortalität und Herzinsuffizienz-assoziierter Hospitalisierung bei 
216 symptomatischen Patienten mit hochgradiger Aortenklappenstenose, die einem operativen oder 
interventionellen Aortenklappenersatz unterzogen J. 
 
Tab. 7 Univariable und multivariable Cox Regressionsanalyse für die Prädiktion der Gesamtmortalität 
bei 216 symptomatischen Patienten mit hochgradiger Aortenklappenstenose, die einem operativen 
oder interventionellen Aortenklappenersatz unterzogen J. 
Risk variable Univariable Cox Regression Multivariable Cox Regression 
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
Logistic EuroSCORE ≥11% 4.5 (1.4 – 14.8) 0.014 2.8 (0.8 – 9.8) 0.098 
BNP positive 2.1 (1.0 – 4.5) 0.041 2.7 (1.2 – 5.9) 0.013 
Mean Gradient ≥ 43mmHg 0.6 (0.3 – 1.2) 0.142 0.5 (0.2 – 1.2) 0.125 
AVA ≤ 0.7 cm2 1.2 (0.6 – 2.7) 0.590 1.5 (0.7 – 3.5) 0.322 
SAF 6.4 (3.1– 13.2) < 0.001 5.6 (2.6 – 12.0) < 0.001 
AVA = Aortenklappenöffnungsfläche, BNP = Natriuretisches Peptid typ B, SAF = schwere autonome 
Dysfunktion 
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Abb. 20: Repräsentatives dT°-Signal bei einem Patienten mit hochgradiger Aortenklappenstenose K.  
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7. Neue Therapieansätze bei Patienten mit ischämischer Kardiomyopathie 
7.1. SMART-MI Studie 
  SMART-MI (Implantable cardiac monitorS in high-risk post-infarction patients 
with cardiac autonoMic dysfunction And modeRaTely reduced left ventricular 
ejection fraction; clinicaltrials.gov NCT02594488) ist eine prospektive, randomisierte, 
kontrollierte Studie, die Postinfarktpatienten mit LVEF 35–50% auf eine kardiale 
autonome Dysfunktion testet. Patienten mit erhöhter PRD oder eingeschränkter DC 
sind als Risikopatienten betrachtet und werden 1:1 auf die Implantation eines 
Ereignisrekorders mit telemetrischer Überwachung oder eine konventionelle 
Therapie randomisiert (Abb. 21) L. Der primäre Endpunkt der Studie ist die 
Erkennung von vordefinierten Arrhythmien, beziehungsweise das Auftreten von 
Vorhofflimmern mit einer Dauer ≥6 Minuten, die Detektion einer höhergradigen AV-
Blockierung (AV-Block II° typ Mobitz, oder AV-Block III°) oder das Auftreten einer 
anhaltenden oder nicht-anhaltenden (≥12 Sek) Kammertachykardie. Zu den 
sekundären Endpunkten gehören die Gesamtmortalität, die kardiovaskuläre 
Mortalität, thromboembolische Ereignisse, ein Sinusarrest mit Dauer ≥6 Sekunden, 
nicht-anhaltende ventrikuläre Kammertachykardien mit einer Dauer von mindestens 
12 Komplexen,  sowie der kombinierte Endpunkt aus Gesamtmortalität, 
thromboembolischen Ereignissen und Hospitalisierung infolge einer akuten kardialen 
Dekompensation. Entdeckt man eine der vordefinierten Arrhythmien, so erfolgt 
innerhalb von 48h eine spezifische Intervention – entsprechend definierter 
Behandlungspfade im Sinne eines multifaktoriellen Ansatzes. Die mediane 
Nachbeobachtungszeit der Studie wird 18 Monate sein L. 
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Abb. 21: Flussdiagramm der SMART-MI Studie L.  
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7.2. Neue Therapieansätze in der Revaskularisationstherapie 
Die Wiederherstellung und die Bewahrung einer ausreichenden myokardialen 
Durchblutung sind die zentralen Zielsetzungen in der Therapie der koronaren 
Herzerkrankung. Die Stentimplantation hat sich gegenüber der alleinigen perkutanen 
transluminalen Koronarangioplastie (PTCA) aufgrund des besseren 
angiographischen Primärergebnisses und der geringeren Zahl von In-Stent-
Restenosen etabliert. Die Stents, die anfangs aus unbeschichtetem Metall (bare-
metal stents) bestanden, sind gegenwärtig mit einem Polymer beschichtet, der ein 
Zytostatikum oder Immunsuppressivum enthält und dieses allmählich freigibt (drug-
eluting Stents, DES). Dies hemmt die Bildung der Neointima, wodurch es zu weniger 
Restenosen kommt. Die Interaktion der Polymerbeschichtung mit der Gefäßwand 
kann jedoch zu einer Entzündungsreaktion und Neoatherosklerose führen42. Der 
Einsatz von biodegradierbaren Polymeren (BP) hat vielversprechende Resultate 
gezeigt, weil die Entzündungsreaktion geringer als bei den persistierenden 
Polymeren ausfällt42. In einer großen Metaanalyse, die 16 randomisierte kontrollierte 
Studien mit insgesamt 25.000 Patienten einbezog, konnte gezeigt werden, dass BP-
Stents den PP-Stents hinsichtlich der Einjarhres-Sicherheits- (Tod, Stentthrombose 
und Myokardinfarkt) und Wirksamkeits-Endpunkten (Revaskularisation der Target 
Läsion) nicht unterlegen waren (Abb. 22, 23, 24 und 25) M. Darüber hinaus waren die 
BP-Stents den PP-Stents in Bezug auf die sehr späte Spätthrombose-Rate 
überlegen (Abb. 26) M. 
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Abb. 22: Metaanalyse der Assoziation zwischen der Einjahres-Gesamtmortalität und der Therapie mit 
drug-eluting Stents (DES) mit biodegradierbaren Polymeren (BP-DES) gegen DES mit 
persistierenden Polymeren (PP-DES) M. BASKET-PROVE II trial = Safety and Efficacy Study 
Comparing 3 New Types of Coronary Stents43, BIOFLOW II trial = Study of the Orsiro Drug Eluting 
Stent System44,  BIOSCIENCE trial = Sirolimus-Eluting Stents With Biodegradable Polymer Versus an 
Everolimus-Eluting Stents45, CENTURY II trial = Clinical Evaluation of New Terumo Drug-Eluting 
Coronary Stent System in the Treatment of Patients with Coronary Artery Disease46, COMPARE II 
trial = Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent47, DESSOLVE II trial 
= Clinical Investigation of the MiStent DES in Coronary Artery Disease48, EVOLVE and EVOLVE II 
trials = Assess the Synergy Stent System for the Treatment of Atherosclerotic Lesion(s)49,50, ISAR-
TEST 3 trial =  Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis51,  
ISAR-TEST 4 trial = 3 Limus Agent Eluting Stents With Different Polymer Coating52, LEADERS trial, 
Limus Eluted From a Durable Versus Erodable Stent Coating53, NEXT trial, Nobori Biolimus-Eluting 
Versus Xience/Promus Everolimus-Eluting Stent Trial54, NOBORI Japan trial = Nobori Biolimus A9- 
Eluting Stent versus Sirolimus-Eluting Stent in Patients With Stenosis in Native Coronary Arteries55, 
SORT-OUT V trial  = Randomised Clinical Comparative Study of the Nobori and the Cypher Stent56, 
SORT OUT VI, Randomized Clinical Comparison of Biomatrix Flex and Resolute Integrity Stents57. 
TARGET I, Randomized MicroPort's Firehawk DES Versus Xience V58. 
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Abb. 23: Metaanalyse der Assoziation zwischen der Einjahres-Myokardinfarkt-Rate und der Therapie 
mit drug-eluting Stents (DES) mit biodegradierbaren Polymeren (BP-DES) gegen DES mit 
persistierenden Polymeren (PP-DES) M. BASKET-PROVE II trial = Safety and Efficacy Study 
Comparing 3 New Types of Coronary Stents43, BIOFLOW II trial = Study of the Orsiro Drug Eluting 
Stent System44,  BIOSCIENCE trial = Sirolimus-Eluting Stents With Biodegradable Polymer Versus an 
Everolimus-Eluting Stents45, CENTURY II trial = Clinical Evaluation of New Terumo Drug-Eluting 
Coronary Stent System in the Treatment of Patients with Coronary Artery Disease46, COMPARE II 
trial = Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent47, DESSOLVE II trial 
= Clinical Investigation of the MiStent DES in Coronary Artery Disease 8, EVOLVE and EVOLVE II 
trials = Assess the Synergy Stent System for the Treatment of Atherosclerotic Lesion(s)49,50, ISAR-
TEST 3 trial =  Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis51,  
ISAR-TEST 4 trial = 3 Limus Agent Eluting Stents With Different Polymer Coating52, LEADERS trial, 
Limus Eluted From a Durable Versus Erodable Stent Coating53, NEXT trial, Nobori Biolimus-Eluting 
Versus Xience/Promus Everolimus-Eluting Stent Trial54, NOBORI Japan trial = Nobori Biolimus A9- 
Eluting Stent versus Sirolimus-Eluting Stent in Patients With Stenosis in Native Coronary Arteries55, 
SORT-OUT V trial  = Randomised Clinical Comparative Study of the Nobori and the Cypher Stent56, 
SORT OUT VI, Randomized Clinical Comparison of Biomatrix Flex and Resolute Integrity Stents57. 
TARGET I, Randomized MicroPort's Firehawk DES Versus Xience V58. 
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Abb. 24: Metaanalyse der Assoziation zwischen der Einjahres-Stentthrombose-Rate und der 
Therapie mit drug-eluting Stents (DES) mit biodegradierbaren Polymeren (BP-DES) gegen DES mit 
persistierenden Polymeren (PP-DES) M. BASKET-PROVE II trial = Safety and Efficacy Study 
Comparing 3 New Types of Coronary Stents43, BIOFLOW II trial = Study of the Orsiro Drug Eluting 
Stent System44,  BIOSCIENCE trial = Sirolimus-Eluting Stents With Biodegradable Polymer Versus an 
Everolimus-Eluting Stents45, CENTURY II trial = Clinical Evaluation of New Terumo Drug-Eluting 
Coronary Stent System in the Treatment of Patients with Coronary Artery Disease46, COMPARE II 
trial = Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent47, DESSOLVE II trial 
= Clinical Investigation of the MiStent DES in Coronary Artery Disease48, EVOLVE and EVOLVE II 
trials = Assess the Synergy Stent System for the Treatment of Atherosclerotic Lesion(s)49,50, ISAR-
TEST 3 trial =  Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis51,  
ISAR-TEST 4 trial = 3 Limus Agent Eluting Stents With Different Polymer Coating52, LEADERS trial, 
Limus Eluted From a Durable Versus Erodable Stent Coating53, NEXT trial, Nobori Biolimus-Eluting 
Versus Xience/Promus Everolimus-Eluting Stent Trial54, NOBORI Japan trial = Nobori Biolimus A9- 
Eluting Stent versus Sirolimus-Eluting Stent in Patients With Stenosis in Native Coronary Arteries55, 
SORT-OUT V trial  = Randomised Clinical Comparative Study of the Nobori and the Cypher Stent56, 
SORT OUT VI, Randomized Clinical Comparison of Biomatrix Flex and Resolute Integrity Stents57. 
TARGET I, Randomized MicroPort's Firehawk DES Versus Xience V58. 
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Abb. 25: Metaanalyse der Assoziation zwischen der Einjahres-Revaskularisations-Rate und der 
Therapie mit drug-eluting Stents (DES) mit biodegradierbaren Polymeren (BP-DES) gegen DES mit 
persistierenden Polymeren (PP-DES) M. BASKET-PROVE II trial = Safety and Efficacy Study 
Comparing 3 New Types of Coronary Stents43, BIOFLOW II trial = Study of the Orsiro Drug Eluting 
Stent System44,  BIOSCIENCE trial = Sirolimus-Eluting Stents With Biodegradable Polymer Versus an 
Everolimus-Eluting Stents45, CENTURY II trial = Clinical Evaluation of New Terumo Drug-Eluting 
Coronary Stent System in the Treatment of Patients with Coronary Artery Disease46, COMPARE II 
trial = Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent47, DESSOLVE II trial 
= Clinical Investigation of the MiStent DES in Coronary Artery Disease48, EVOLVE and EVOLVE II 
trials = Assess the Synergy Stent System for the Treatment of Atherosclerotic Lesion(s)49,50, ISAR-
TEST 3 trial =  Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis51,  
ISAR-TEST 4 trial = 3 Limus Agent Eluting Stents With Different Polymer Coating52, LEADERS trial, 
Limus Eluted From a Durable Versus Erodable Stent Coating53, NEXT trial, Nobori Biolimus-Eluting 
Versus Xience/Promus Everolimus-Eluting Stent Trial54, NOBORI Japan trial = Nobori Biolimus A9- 
Eluting Stent versus Sirolimus-Eluting Stent in Patients With Stenosis in Native Coronary Arteries55, 
SORT-OUT V trial  = Randomised Clinical Comparative Study of the Nobori and the Cypher Stent56, 
SORT OUT VI, Randomized Clinical Comparison of Biomatrix Flex and Resolute Integrity Stents57. 
TARGET I, Randomized MicroPort's Firehawk DES Versus Xience V58. 
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Abb. 26: Metaanalyse der Assoziation zwischen der späten Stentthrombose-Rate und der Therapie 
mit drug-eluting Stents (DES) mit biodegradierbaren Polymeren (BP-DES) gegen DES mit 
persistierenden Polymeren (PP-DES) M. BASKET-PROVE II trial = Safety and Efficacy Study 
Comparing 3 New Types of Coronary Stents43, COMPARE II trial = Comparison of the Everolimus 
Eluting With the Biolimus A9 Eluting Stent59, DESSOLVE II trial = Clinical Investigation of the MiStent 
DES in Coronary Artery Disease60, ISAR-TEST 4 trial = 3 Limus Agent Eluting Stents With Different 
Polymer Coating61, LEADERS trial, Limus Eluted From a Durable Versus Erodable Stent Coating62, 
NEXT trial, Nobori Biolimus-Eluting Versus Xience/Promus Everolimus-Eluting Stent Trial63. 
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8. Diskussion und Zusammenfassung 
 Die Mortalität bei Patienten mit ischämischer Kardiomyopathie und 
struktureller Herzerkrankung bleibt trotz Weiterentwicklung der medikamentösen und 
interventionellen Therapie hoch. Die aktuellen Leitlinien empfehlen die 
primärprophylaktische Implantation eines Defibrillators bei Patienten mit reduzierter 
linksventrikulärer Auswurffraktion (LVEF ≤ 35%), welche derzeit als Goldstandard in 
der Risikoprädiktion gilt10. Die Sensitivität und Spezifität der LVEF in ist allerdings 
sehr beschränkt. Etwa 70% der Todesfälle nach einem Myokardinfarkt ereignen sich 
in der Patientengruppe mit erhaltener oder nur moderat eingeschränkter 
Pumpfunktion11. In der Patientengruppe mit hochgradig eingeschränkter LVEF, die 
mit ICD versorgt werden, erhält innerhalb von 5 Jahren nur jeder dritte Patient eine 
adäquate ICD-Therapie12. In einer vor kurzem veröffentlichten randomisierten Studie 
konnte an über 1.100 Patienten gezeigt werden, dass die ICD-Implantation das 
Sterberisiko bei Patienten mit nicht-ischämisch bedingter Kardiomyopathie und 
LVEF ≤35% nicht signifikant gesenkt hat64. Aus diesen Gründen sind neue 
Verfahren zur Risikostratifizierung von großer klinischer Bedeutung. Das 
Vorhandensein einer autonomen Dysfunktion des Herzens liefert prognostische 
Informationen, die von der LVEF unabhängig sind14. Darüber hinaus gibt es starke 
Evidenz, dass der Verlust vagaler Aktivität oder ein Übermaß sympathischer Aktivität 
mit einer schlechten Prognose vergesellschaftet sind. 
Die Dezelerationskapazität des Herzens ist ein neues Maß der 
Herzfrequenzvariabilität, das die vagale Innervierung des Herzens auf der Ebene 
des Sinusknotens quantifiziert. In dieser Arbeit konnte gezeigt werden, dass DC ein 
signifikanter Mortalitätsprädiktor bei Patienten mit ischämischer Kardiomyopathie B 
und struktureller Herzerkrankung war J. Der Einsatz der DC in der medizinischen 
Notaufnahme führte zur Identifizierung von Hochrisikopatienten, die bei aktuellen 
Methoden nicht erfasst werden konnten C,D. Diese Ergebnisse unterstreichen die 
Wichtigkeit der Testung der autonomen Funktion in der Notaufnahme, die zur 
Verbesserung der aktuell verfügbaren Triagesysteme beitragen kann. 
Periodic Repolarization Dynamics ist ein neues elektrokardiographisches  
Phänomen, das die sympathische Aktivität auf der Ebene des Ventrikelmyokards 
erfasst. In drei großen Kohorten war PRD ein starker Prädiktor der Gesamt-, sowie 
der kardiovaskulären Mortalität bei Patienten mit ischämischer Kardiomyopathie E,H. 
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In der MADIT-II Studie8, eine der wichtigsten Studien in der Kardiologie, die zur 
Etablierung der primärprophylaktischen ICD-Implantation bei Postinfarktpatienten mit 
hochgradig eingeschränkter LVEF als Grad-1-Empfehlung führte10, war PRD einer 
der stärksten Prädiktoren der Gesamtmortalität, der kardiovaskulären Mortalität, des 
plötzlichen, sowie des nicht-plötzlichen Herztodes. Anhand von PRD konnten in der 
MADIT-II Studie neue Gruppen definiert werden, die von der primärprophylaktischen 
ICD-Implantation besonders oder nicht profitieren H.  
Die Kombination aus der DC als Marker des Verlustes vagaler Aktivierung 
und der PRD als Übermaß der sympathischen Aktivierung kann Patienten mit einem 
kardialen autonomen Versagen identifizieren I.  In der Patientengruppe mit 
leichtgradig oder moderat eingeschränkter LV-Funktion (LVEF 35–50%) definieren 
die abnormale PRD oder DC eine neue Hochrisikogruppe, deren Prognose sich nicht 
von der von Patienten mit eingeschränkter LV-Funktion (LVEF ≤35%) unterscheidet. 
Diese Patientengruppe, die zahlenmäßig der Hochrisikogruppe mit LVEF ≤35% 
entspricht, bleibt in aktuellen Leitlinien jedoch unberücksichtigt. SMART-MI ist eine 
aktuell laufende prospektive, randomisierte, kontrollierte Studie, die Post-
Infarktpatienten mit LVEF 35–50% auf eine kardiale autonome Dysfunktion testet. 
Patienten mit erhöhter PRD oder eingeschränkter DC sind als Risikopatienten 
betrachtet und werden 1:1 auf die Implantation eines Ereignisrekorders mit 
telemetrischer Überwachung oder eine konventionelle Therapie randomisiert. 
Entdeckt man vordefinierte Arrhythmien, so erfolgt eine spezifische Intervention im 
Sinne eines multifaktoriellen Ansatzes L. Dies kann z.B. eine orale Antikoagulation 
im Fall von Vorhofflimmern oder eine Ischämiediagnostik im Fall von nicht- 
anhaltenden ventrikulären Tachykardien bedeuten. Bei höhergradigen AV-
Blockierungen kann eine Schrittmacherimplantation indiziert sein, bei anhaltenden 
ventrikulären Tachykardien eine Ablation oder eine ICD-Implantation. 
Zusammenfassend konnten in dieser Arbeit anhand der kardialen autonomen 
Dysfunktion neue Ansätze zur Risikostratifizierung bei Patienten mit ischämischer 
Kardiomyopathie und struktureller Herzerkrankung untersucht werden. Diese 
Ansätze führten zur Identifizierung von Hochrisikopatienten, die bei den 
gegenwärtigen Methoden nicht erfasst werden können. Eine Biomonitoring-
gesteuerte, personalisierte Therapie bei diesen Hochrisikopatienten mit autonomer 
Dysfunktion könnte ein vielversprechender neuer Therapieansatz sein. 
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This editorial refers to ‘Non-invasive risk stratification for
sudden cardiac death by heart rate turbulence and microvolt
T-wave alternans in patients after myocardial infarction’ by
V. Sulimov et al., doi:10.1093/europace/eus238
Despite significant advances in interventional and pharmacological
therapies, late mortality after acute myocardial infarction (MI) is
still high. Approximately 50% of cardiovascular deaths after MI
occur suddenly and are potentially preventable by prophylactic im-
plantation of a cardioverter-defibrillator (ICD). In recent decades,
substantial efforts have been made to identify high-risk patients
who may benefit from prophylactic therapy. While initial risk strati-
fication strategies guiding ICD therapy were based on the compre-
hensive electrophysiological testing in highly selected subgroups of
patients, a revolutionary concept was proposed in 2002, when
Moss et al.1 presented the results of MADIT-2 (Multicentre Auto-
matic Defibrillator Implantation Trial). In contrast with all previous
attempts, MADIT-2 used the finding of a reduced left ventricular
ejection fraction (LVEF) as the single selection criterion for
prophylactic ICD-implantation. In terms of efficacy and effective-
ness, the MADIT-2 criterion was a great success. Subsequent
trials confirmed the concept of prophylactic ICD-implantation in
patients with impaired LVEF, and later economic analyses verified
the cost-effectiveness of this approach.
However, when looking from an epidemiological point of view at
the global impact of ICD on the disease burden of sudden cardiac
death (SCD) after MI, there is a growing sense of disillusionment.
The vast majority of post-MI patients prone to SCD are not cap-
tured by the MADIT-2 criterion, and die despite exhibiting pre-
served or only moderately impaired LVEF.2 Identifying high-risk
individuals after MI by reduced LVEF is therefore like looking
at the tip of an iceberg with a telescope. Several studies have
documented that the sensitivity of impaired LVEF in predicting
death after MI is as poor as 30%; it is unlikely that a diagnostic
test with such a low sensitivity would be accepted in many other
fields of modern medicine.
But what are the alternatives? In the current issue of the Journal,
Sulimov et al.3 report on the usefulness of the combination of two
electrocardiogram (ECG)-based risk predictors, heart rate turbu-
lence (HRT), and microvolt T-wave alternans (TWA), for the pre-
diction of SCD after MI. Heart rate turbulence quantifies the
baroreflex-mediated short-term oscillation of cardiac cycle
lengths following spontaneous ventricular premature complexes.4
T-wave alternans refers to the beat-to-beat fluctuation in the
morphology and amplitude of the ST segment and/or T-wave
related to instabilities in membrane voltage and disruptions in
intracellular calcium cycling dynamics.5 The combination of both
markers makes sense from a pathophysiological point of view, as
they capture different pathologies involved in the genesis of
SCD. The main finding of the study was that both HRT and
TWA were strong and independent predictors of SCD, yielding
relative risks of 12.4 and 5.0, respectively. However, the study is
limited in several respects. First, the study is underpowered; a
sample size of 111 patients (out of whom 15 reached the
primary endpoint of SCD) is too small by orders of magnitude
to address the question of interest. Second, cumulative 1-year
event rates of SCD were surprisingly high (13.5%). For compari-
son, in the 14 609 participants in the VALLIANT (VALsartan In
Acute myocardial iNfarcTion) study, this figure was as low as
5.1%.6 Third, several technical and statistical issues remain, as the
authors used a non-standard ECG lead configuration and defined
new cut-off values for TWA that require prospective validation.
Nevertheless, the limitations of the study by Sulimov et al. do
not necessarily imply that the conclusions are wrong. There is a
huge body of evidence from retrospective and prospective
studies (together including more than 10 000 patients) that both
HRT and TWA are powerful predictors of risk after MI
(Figure 1). The combination of HRT and TWA was also tested in
the REFINE (Risk Estimation Following Infarction Noninvasive
Evaluation) study.7 Of particular importance, both predictors are
useful for the identification of high-risk patients otherwise classi-
fied as low-risk, making both markers suitable for combination
The opinions expressed in this article are not necessarily those of the Editors of Europace or of the European Society of Cardiology.
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with established criteria.4,5 The positive predictive values and spe-
cificities of both markers are in the range of that provided by
impaired LVEF, suggesting that ICD may be equally effective.8,9
As is the case with many other methods, HRT and TWA have
several shortcomings that are beyond the scope of this editorial
but do not affect the risk-predictive power of both methods.
Given this information, why have none of these markers been
tested in a randomized, interventional ICD trial?
Although several reasons could be cited here, the central ques-
tion remains: who is going to pay for such a trial? The costs of a
prospective, multicentre ICD trial are enormous, and probably
could only be covered by large ICD companies. However, these
companies need to follow the rules of economy, balancing the po-
tential benefits of widened ICD indications against the associated
costs and, importantly, the risks of a negative outcome. In this
respect, the DINAMIT (Defibrillation in Acute Myocardial Infarc-
tion Trial)10 and IRIS (Immediate Risk-Stratification Improves Sur-
vival)8 studies, which addressed questions different from those
proposed here, were painful experiences for St Jude Medical and
Medtronic. While discussing expansions of ICD indications to
fight SCD, it is important to note that ICD therapy is still signifi-
cantly underused in most, if not all, European countries according
to already approved criteria.9 Nonetheless, as scientists we should
promote the prospective validation of sound concepts. We strong-
ly believe that prophylactic ICD in high-risk post-MI patients char-
acterized by abnormal HRT and/or TWA belongs to this category
of concepts.
Conflicts of interest: none.
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Bedside autonomic risk stratification after
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Aims Twenty-four-hour deceleration capacity (DC24h) of heart rate is a strong predictor of mortality after myocardial in-
farction (MI). Assessment of DC from short-term recordings (DCst) would be of practical use in everyday clinical
practice but its predictive value is unknown. Here, we test the usefulness of DCst for autonomic bedside risk strati-
fication after MI.
...................................................................................................................................................................................................
Methods
and results
We included 908 patients after acute MI enrolled in Munich and 478 patients with acute (n = 232) and chronic MI
(n = 246) enrolled in Tuebingen, both in Germany. We assessed DCst from high-resolution resting electrocardio-
gram (ECG) recordings (<30 min) performed under standardized conditions in supine position. In the Munich co-
hort, we also assessed DC24h from 24-h Holter recordings. Deceleration capacity was dichotomized at the estab-
lished cut-off value of <_ 2.5 ms. Primary endpoint was 3-year mortality. Secondary endpoint was 3-year
cardiovascular mortality. In addition to DC, multivariable analyses included the Global Registry of Acute Coronary
Events score >140 and left ventricular ejection fraction <_ 35%. During follow-up, 48 (5.3%) and 48 (10.0%) patients
died in the Munich and Tuebingen cohorts, respectively. On multivariable analyses, DCst <_ 2.5 ms was the strongest
predictor of mortality, yielding hazard ratios of 5.04 (2.68–9.49; P < 0.001) and 3.19 (1.70–6.02; P < 0.001) in the
Munich and Tuebingen cohorts, respectively. Deceleration capacity assessed from short-term recordings <_ 2.5 ms
was also an independent predictor of cardiovascular mortality in both cohorts. Implementation of DCst <_ 2.5 ms
into the multivariable models led to a significant increase of C-statistics and integrated discrimination improvement
score.
...................................................................................................................................................................................................
Conclusion Deceleration capacity assessed from short-term recordings is a strong and independent predictor of mortality and
cardiovascular mortality after MI, which is complementary to existing risk stratification strategies.
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Keywords Deceleration capacity of heart rate • Heart rate variability • Myocardial infarction • Risk stratification
• Short-term electrocardiogram recordings
Introduction
Risk stratification after myocardial infarction (MI) is of crucial import-
ance to guide preventive strategies. Reduced left ventricular ejection
fraction (LVEF <_ 35%) remains the current gold standard risk pre-
dictor.1 However, it lacks both sensitivity and specificity.2 In fact, the
majority of patients who die after MI have an LVEF of 36% or
* Corresponding author. Tel: þ49 89 4400 52381; fax: þ49 89 4400 52258. E-mail address: axel.bauer@med.uni-muenchen.de
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greater,2–4 highlighting the need for refined risk stratification
strategies.
Deceleration capacity (DC) of heart rate is an advanced marker of
heart rate variability (HRV) that yields strong and independent prog-
nostic information in post-infarction patients.5 Deceleration capacity
is an integral measure of all deceleration-related oscillations of heart
rate over 24 h, including regulations in the ultra-low, very low, low,
and high frequency bands. In previous studies, the prognostic value of
impaired DC in predicting late mortality after MI exceeded that of ab-
normal standard measures of HRV and even reduced LVEF.5
However, in the light of increasingly shorter hospital stays the
need of a full 24-h Holter recording for DC assessment is considered
as a major drawback. For practical reasons, bedside autonomic risk
stratification that could be performed in a comparable time frame as
the echocardiographic assessment of left ventricular function would
be greatly appreciated and would help implementing autonomic risk
stratification in everyday clinical practice. In addition, compared to
24-h recordings, short-term ECGs can be performed under standar-
dized conditions eliminating noise, artifacts, and non-stationarities.
We therefore undertook this study to test the usefulness of DC
obtained from short-term ECG-recordings (DCst) in predicting death
after MI.
Methods
Study design and study populations
The prognostic value of DCst was evaluated in two post-infarction co-
horts, the Munich and Tuebingen cohort.
The study design of the Munich cohort has been described elsewhere6
and is illustrated in Figure 1A. The study included 908 survivors of acute
MI (left column of Table 1). Patients were enrolled between May 2000
and March 2005 at two university centres in Munich, Germany, the
German Heart Centre and the Klinikum Rechts der Isar. Eligible patients
had survived an acute MI (<_40 days), were aged <_80 years, had sinus
rhythm, and did not meet the criteria for prophylactic ICD implantation
prior hospital discharge.
Patients of the Tuebingen cohort were prospectively enrolled be-
tween September 2010 and February 2014 at the university hospital of
Tuebingen, Germany (Figure 1B). Inclusion criteria consisted of history of
previous MI, sinus rhythm and age <_80 years [n = 478, median age 66
(IQR 17), 109 females (22.8%); right column of Table 1]. Compared with
the Munich cohort, the study was not limited to patients with acute MI.
In 246 of the patients (51.5%), the index MI was older than 40 days. The
ethics committees of Munich and Tuebingen approved both studies.
Procedures
In both cohorts, high-resolution digital ECGs (Munich cohort: TMS, Porti
System version 1; 1600 Hz; 30 min; Tuebingen cohort: TMS, Porti System
version 2; 2048 Hz; 20 min) were performed in Frank leads configuration.
The recordings were done in the morning hours under standardized con-
ditions in supine and resting position. Patients were spontaneously
breathing. In the Munich cohort, the median time from the index MI to
the ECG recording was 7 (IQR 4) days. In Tuebingen cohort, which also
included patients with chronic MI, the median time from the index MI to
the ECG recording was 154 (IQR 3071) days.
In the Munich cohort, additionally, 24-h Holter recordings (Oxford
Excel Holter system, Oxford instruments; Pathfinder700, Reynolds
Medical; and Mortara Holter system, Mortara Instrument) were per-
formed in 861 patients within the second week after MI.
Assessment of deceleration capacity
Deceleration capacity assessed from short-term recordings and DC24h
were calculated using the same algorithms.5,7 The exact technology of
DC assessment has been described elsewhere. Very briefly, computation
of DC is based on the transformation of the sequence of RR intervals into
a new time series by phase-rectified signal averaging (PRSA). In a first
step, RR intervals that are longer than their respective preceding RR-
intervals are identified (so-called anchors). In a second step, segments
around anchors are averaged to obtain the so-called PRSA-signal. The
PRSA-signal can be considered as a condensed version of the original RR-
interval time series, including all periodic components of HRV related to
decelerations. The central part of the PRSA-signal is quantified by
wavelet-analysis to obtain the numerical measure of DC (Figure 2). Thus,
DC is an integral measure of all deceleration-related oscillations that take
place during the observational period. As previously described, patients
with DC <_ 2.5 ms were classified as high-risk patients.
Assessment of other risk predictors
Left ventricular ejection fraction was assessed by echocardiography or
angiography. The Global Registry of Acute Coronary Events (GRACE)
score was calculated as previously described8 and included following vari-
ables: age, heart rate, systolic blood pressure, creatinine level, Killip class,
cardiac arrest at admission, ST-segment deviation, and elevated cardiac
enzyme levels. The GRACE score was dichotomized at the established
cut-off value of >140. Estimated glomerular filtration rate (eGFR) was
estimated using the modified diet in renal disease formula and dichotom-
ized at the cut-off value of <60 mL/min/1.73 m2. To compare DCst with
standard measures of HRV,9 all measures in time and frequency domain
as well as non-linear indices were calculated according to the recommen-
dations provided by the task force.9 For each domain, we identified the
measure that showed the strongest association with the primary end-
point in the Munich cohort. As no established cut-off values for short-
term HRV measures exist, we used maximally selected rank statistics to
What’s new?
• Twenty-four-hour deceleration capacity (DC24h) of heart rate
is a strong predictor of mortality after myocardial infarction.
However, the need of 24-h recordings is considered as major
drawback. Here, we tested the usefulness of deceleration cap-
acity assessed from short-term recordings (DCst) in two large
cohorts.
• In both cohorts, DCst was the strongest predictor of 3-year
mortality.
• Deceleration capacity assessed from short-term recordings
was independent from established risk predictors including the
Global Registry of Acute Coronary Events score and left ven-
tricular ejection fraction (LVEF).
• The predictive value of DC assessed from short-term record-
ings was comparable to that of DC assessed from 24-h
recordings.
• Deceleration capacity assessed from short-term recordings is
a useful tool for bedside risk stratification that complements
LVEF and clinical factors.
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determine the optimum cut-off values for all markers, which were then
also used in the Tuebingen cohort.
Study endpoints and follow-up
In both cohorts, primary endpoint was 3-year all-cause mortality.
Secondary endpoint was 3-year cardiovascular mortality. Patients were
followed-up at regular intervals, either in the outpatient clinic or by tele-
phone calls, with median follow-up periods of 36 and 27 months,
respectively.
Statistical analysis
Continuous variables are presented as medians with IQRs and were com-
pared using the Wilcoxon rank-sum test. Categorical variables are ex-
pressed as percentages and were analysed using the v2 and Fisher’s exact
tests. We quantified receiver-operator characteristic (ROC) curves by
the integrals of the curves (AUC, area under the curve), plotting the de-
pendency of specificity on sensitivity. To test the difference between two
ROC curves, we used bootstrapping, based on the creation of pseudo-
replicate datasets by random resampling of the dataset N times for error
estimation (N = 2000 in this study). We estimated survival curves using
the Kaplan–Meier method and compared them by means of the log-rank
test. Sensitivities and specificities were extracted from the survival curves.
Multivariable analyses were implemented by the adaptation of Cox re-
gression models. Subgroup analyses were performed by means of the re-
gression technique. Results are presented as hazard ratios with 95%
confidence interval (CI). To test the incremental prognostic value of DCst
on top of the GRACE score and LVEF, we implemented C-statistics, inte-
grated discrimination improvement (IDI) score, and continuous net re-
classification improvement analysis (NRI). To test the difference between
C-statistics bootstrapping was employed. Agreement between DCst with
DC24h was assessed by the method described by Bland and Altman.
Differences were considered statistically significant when the two-sided
P-value was less than 0.05. All statistical analyses were performed using
CRAN R, version 3.2.3.
Results
Table 1 shows baseline, clinical, follow-up, and treatment characteris-
tics in the Munich (n = 908) and Tuebingen cohorts (n = 478). In the
Munich cohort, 48 patients died (27 cardiovascular deaths) during a
median follow-up time of 36.0 months. In the Tuebingen cohort, 48
patients died (24 cardiovascular deaths) over a median interval of
27.3 months. Supplementary material online, Table S1 shows associ-
ation of clinical parameters with DCst <_ 2.5 ms.
Figure 2 shows representative PRSA-signals from short-term
recordings in two post-MI patients of the Munich cohort. Panel A
shows a patient who survived the 3-year follow-up period. Panel B
shows a patient who suddenly died 9 weeks after the index MI. In the
surviving patient, the amplitude of the PRSA-signal is significantly
higher as compared to the non-surviving patient.
Table 2 shows the association of risk factors with 3-year all-cause
mortality. In both cohorts, non-surviving patients were older, had a
lower LVEF and had higher GRACE scores. Non-surviving patients in
the Munich cohort but not in the Tuebingen cohort had higher inci-
dence of diabetes mellitus. In both cohorts, non-surviving patients
had substantially lower DCst compared to surviving patients
(2.0 ± 3.6 vs. 4.8 ± 3.9 ms in the Munich cohort and 1.4 ± 3.5 vs.
4.1 ± 4.0 ms in the Tuebingen cohort, P < 0.001 for both).
Figure 3A and B depict cumulative mortality rates of patients strati-
fied by DCst <_ 2.5 ms in the Munich cohort and Tuebingen cohort, re-
spectively. In the Munich cohort, the 182 patients with DCst <_ 2.5 ms
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Figure 1 Consort flow-diagrams for the training and validation cohorts.
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had a 3-year mortality rate of 16.5% compared to 3-year mortality
rate of 2.5% in the 726 patients with DCst > 2.5 ms (Figure 3A), cor-
responding to a sensitivity of 63% and specificity of 82%. Also in the
Tuebingen cohort, risk stratification by DCst <_ 2.5 ms led to highly
significant separation of low and high-risk patients. The 152 patients
with DCst <_ 2.5 ms have a 3-year mortality rate of 27.5% compared
to a 3-year mortality rate of 6.3% in the 326 patients with
DCst > 2.5 ms (Figure 3B), corresponding to a sensitivity of 67% and
specificity of 73%.
In both cohorts, DCst was the strongest predictor of mortality in
uni- and multivariable Cox regression analyses (Table 3 and
Supplementary material online, Table S2). Its predictive value was in-
dependent from and incremental to that of the GRACE score and
LVEF, as well as that of HRV-index (HRVI) <_ 26 units, the normalized
power in the low frequency range (LFn) <_ 0.42, and the multiscale
sample entropy index <_ 4.47, which were the strongest HRV meas-
ures in the Munich cohort (Table 3 and Supplementary material on-
line, Table S2). Implementing DCst into the multivariable model of
GRACE score and LVEF led to a significant increase of C-statistics
from 68.23% (95% CI 61.16–75.71%) to 76.80% (69.11–83.86%;
P = 0.004 for difference) in the Munich cohort and from 70.16%
(62.16–77.55%) to 76.83% (69.98–82.98%; P = 0.017 for difference)
in the Tuebingen cohort. Integrated discrimination improvement
increased by 0.045 (0.018–0.092, P < 0.001) in the Munich cohort and
by 0.037 (0.006–0.110, P = 0.007) in the Tuebingen cohort, whereas
continuous NRI improved by 0.449 (0.314–0.577, P < 0.001) in the
Munich cohort and by 0.389 (0.214–0.558, P < 0.001) in the
Tuebingen cohort. Deceleration capacity assessed from short-term
recordings was also a strong and independent predictor of cardiovas-
cular mortality in both cohorts (Table 3). Adjusting for other param-
eters, including treatment with beta-blockers and statins did not have
a significant impact on the predictive power of DCst.
In the Munich cohort, we also compared DC from short-term and
24-h recordings. DC24h was slightly higher than DCst (mean differ-
ence 0.62 ± 5.97, P = 0.002, Supplementary material online, Figure S2).
The Pearson’s correlation coefficient between the two measure-
ments was 0.75 (0.72–0.78, P < 0.001). Univariable analysis revealed
that both measurements yielded comparable AUC (73.37%, [64.28–
81.67%] for DCst and 76.24%, [67.75–83.85%] for DC24h; P = 0.386
for the difference; Supplementary material online, Figure S1).
However, in multivariable analysis including both DCst and DC24h,
only DCst was significantly associated with prediction of 3-year mor-
tality (see Supplementary material online, Table S3).
Subgroup analyses revealed that DCst was stronger predictor of
mortality among younger patients (HR 10.89 [4.62–25.70], P < 0.001
for patients < 70 years and 2.78 [1.25–6.19], P = 0.012 among pa-
tients >_ 70 years; P = 0.023 for the difference between the two sub-
groups) in the Munich cohort but not in the Tuebingen cohort
(Figure 4). Although in the Tuebingen cohort there was a trend for
better predictive power of DCst among non-diabetics and patients
with eGFR >_ 60 mL/min/1.73 m2, this did not reach statistical signifi-
cance (Figure 4). Moreover, DCst <_ 2.5 ms was a strong predictor of
mortality in both acute and chronic MI [HR 5.36 (2.27–12.65),
P < 0.001 for acute MI vs. 4.06, (1.75–9.40), P = 0.001 for chronic MI;
P = 0.211 for the difference between the two subgroups].
Discussion
In the present study, we assessed DC from short-term ECG record-
ings under standardized conditions and tested its predictive value in
two large cohorts of post-MI patients. Our findings demonstrate that
DCst is a strong predictor of 3-year mortality, which is independent
from and incremental to that of established risk markers. The findings
of our study therefore indicate that DCst is a useful tool for bedside
risk stratification that complements LVEF and clinical factors.
Heart rate variability refers to the variation over time of consecu-
tive heart beat intervals and predominantly reflects the overall state of
the autonomic nervous system. Heart rate variability has been con-
ventionally analysed by means of time- and frequency- domain meth-
ods, as well as non-linear methods such as fractal scaling exponents.
...................................................................................................
Table 1 Patients’, clinical, and treatment characteris-
tics in the Munich and Tuebingen cohorts
Characteristic Munich
cohort
Tuebingen
cohort
Study characteristics
Number of patients, n 908 478
Median follow-up (IQR), months 36.0 (0) 27.3 (11.3)
Total deaths, n 48 48
Cardiovascular deaths, n 27 24
Patients’ and clinical characteristics
Age (IQR), years 61 (17) 66 (17)
Acute MI, n (%) 908 (100) 232 (48.6)
Acute MI localization (AW, LW, PW) (%) 42/11/47 46/19/35
Time from index MI, days (IQR) 7 (4) 154 (3071)
Females, n (%) 174 (19.2) 109 (22.8)
Diabetes mellitus, n (%) 179 (19.7) 210 (43.9)
LVEF, % (IQR) 53 (15) 50 (15)
GRACE, Score (IQR) 110 (32) 134 (43)
eGFR, mL/min/1.73 m2 (IQR) 69 (25) 79 (32)
SP on admission, mmHg (IQR) 130 (35) 130 (27)
Cardiogenic shock on admission, n (%) 10 (1.1) 11 (2.3)
Previous MI, n (%) 86 (9.5) 277 (58)
Multivessel CAD, n (%) 563 (62.0) 387 (81)
MHR, bpm (IQR) 62 (13) 65 (16)
DC24h, ms (IQR) 5.2 (3.5) n/a
DCst, ms (IQR) 4.7 (4.0) 3.9 (4.0)
Treatment
PCI, n (%) 848 (93.4) 439 (92)
CABG surgery, n (%) 32 (3.5) 48 (10)
Beta-blockers, n (%) 864 (95.1) 440 (92.1)
Statins, n (%) 843 (92.8) 432 (90.4)
ACE Inhibitor 850 (93.6) 366 (76.6)
ACE, angiotensin converting enzyme; AW, anterior wall; CAD, coronary artery
disease; DCst, deceleration capacity assessed from short-term recordings; DC24h,
deceleration capacity assessed from 24-h Holter electrocardiograms; CABG,
coronary artery bypass graft; eGFR, estimated glomerular filtration rate;
GRACE, Global Registry of Acute Coronary Events; IQR, interquartile range;
LVEF, left-ventricular ejection fraction; LW, lateral wall; MHR, mean heart
rate from short-term recordings; MI, myocardial infarction; PCI, percutaneous
coronary intervention; PW, posterior wall; SP, systolic pressure.
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Reduced HRV has been proven to be a strong and independent pre-
dictor of adverse outcome in the general population10 and in patients
with heart disease. The strong prognostic value of reduced HRV in
post-MI patients has been documented in many studies. The
multicenter post-infarction project (MPIP) showed that reduced HRV
quantified by means of 24-h standard deviation of normal-to-normal
RR intervals (SDNN) was a strong and independent predictor of 4-
year mortality after acute MI.11 These results have been validated in
several prospective cohorts.12,13 Other studies, including a reanalysis
of MPIP have shown that reduced spectral measures of HRV in the
very low- and low-frequency domain are also associated with
increased risk of death.14 More recently some new indices describing
non-linear heart rate dynamics, such as fractal scaling exponents15 and
DC5 of heart rate have been emerged. These markers are more ro-
bust to non-stationarities and artifacts and have been proven to yield
stronger prognostic information than the traditional measures of
HRV among post-MI patients. Heart rate turbulence is a method that
in comparison to other HRV measures quantifies the physiological
short-term oscillation of cardiac cycle length that follows spontaneous
ventricular premature complexes. Heart rate turbulence alone16 and
in combination with other HRV parameters, such as DC3 has been
shown to be a strong predictor of mortality and SCD after acute MI.
Besides MI, the prognostic meaning of HRV has been evaluated in vari-
ous other cardiovascular diseases, including patients with chronic
10A B
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Table 2 Statistical association of clinical and HRV-markers with 3-year mortality in the Munich and Tuebingen cohorts
Characteristic Munich cohort Tuebingen cohort
Survivors Non-survivors P-value Survivors Non-survivors P-value
Number of patients, n 860 48 430 48
Age, years (IQR) 60 (17) 70 (9) <0.001 65 (18) 72 (7) <0.001
Females, n (%) 164 (19.1) 10 (20.1) 0.910 98 (22.8) 11 (22.9) 0.999
Acute MI, n (%) 860 (100) 48 (100) n/a 209 (48.6) 23 (47.9) 0.999
Diabetes mellitus, n (%) 156 (18.1) 23 (47.9) <0.001 184 (42.8) 26 (54.2) 0.176
Median LVEF, % (IQR) 53 (16) 44 (23) <0.001 50 (15) 40 (20) <0.001
GRACE, Score (IQR) 109 (32) 132 (24) <0.001 132 (42) 163 (46) <0.001
MHR, bpm (IQR) 62 (13) 69 (19) 0.033 65 (15) 70 (18) 0.003
DC24h, ms (IQR) 5.3 (3.4) 2.8 (2.1) <0.001 n/a n/a n/a
DCst, ms (IQR) 4.8 (3.9) 2.0 (3.6) <0.001 4.1 (4.0) 1.4 (3.5) <0.001
DCst, deceleration capacity assessed from short-term recordings; DC24h, deceleration capacity assessed from 24-h Holter electrocardiograms; HRV, heart rate variability;
GRACE, Global Registry of Acute Coronary Events; IQR, interquartile range; LVEF, left-ventricular ejection fraction; MHR, mean heart rate from short-term recordings; MI,
myocardial infarction n/a, not available.
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heart failure,17 patients with severe aortic stenosis18 and patients pre-
senting to the emergency department.19
One major problem of current autonomic risk markers is that
their assessment is either too complicated or too time-consuming. In
most clinical studies HRV was assessed from 24-h Holter recordings.
Only very few studies have analysed the predictive value of HRV
measures assessed from short-term recordings. Fei et al.12 evaluated
the predictive power of both short- and long-term HRV in 700 post-
MI patients. Although the statistical association with cardiac mortality
could be demonstrated for both, short-term SDNN and long-term
HRVI, the predictive power of short-term SDNN was significantly
lower than that of the 24-h HRVI. One reason for the lower predict-
ive value of standard short-term HRV might be that spectral meas-
ures of short-term HRV are more prone to artifacts and noise,
leading to substantial variations of normal values.20 Assessment of
short-term HRV by means of DC provides significant advantages
over standard measures. Due to its underlying signal processing algo-
rithm, DC is more robust to artifacts, noise, and non-stationarities. In
addition, DC specifically captures deceleration-related oscillations of
heart rate,5,19 irrespective of their frequency, which are more closely
related to vagal modulations. In our study, predictive power of DCst
was superior to other short-term HRV measures, including other
non-linear indices of heart rate dynamics.
We also compared DC assessed from short-term and 24-h record-
ings. The two measurements were significantly correlated and their
predictive value as estimated by ROC analysis was comparable. In
multivariable analysis including both DCst and DC24h, DCst was a sig-
nificant and independent predictor of 3-year mortality, whereas
DC24h was not. One reason for the higher predictive value of DCst in
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Figure 3 Cumulative 3-year mortality rates in patients stratified
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Table 3 Univariable and multivariable cox regression analyses of the association of risk variables with 3-year total and
cardiovascular mortality in the Munich and Tuebingen cohorts
Munich cohort
All-cause mortality
Risk variable Univariable cox regression Multivariable cox regression
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
GRACE score > 140 4.35 (2.36–8.01) <0.001 1.91 (0.98–3.73) 0.059
LVEF <_ 35% 5.27 (2.89–9.61) <0.001 2.75 (1.43–5.27) 0.002
DCst <_ 2.5 ms 7.18 (4.00–12.87) <0.001 5.04 (2.68–9.49) <0.001
Cardiovascular mortality
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
GRACE score > 140 4.00 (1.75–9.14) 0.001 1.72 (0.69–4.27) 0.245
LVEF <_ 35% 6.13 (2.81–13.38) <0.001 3.47 (1.48–8.12) 0.004
DCst <_ 2.5 ms 6.21 (2.88–13.37) <0.001 4.18 (1.81–9.68) <0.001
Tuebingen cohort
All-cause mortality
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
GRACE score >140 3.48 (1.89–6.42) <0.001 2.29 (1.20–4.37) 0.012
LVEF <_ 35% 4.16 (2.35–7.37) <0.001 2.07 (1.11–3.86) 0.023
DCst <_ 2.5 ms 4.57 (2.51–8.33) <0.001 3.19 (1.70–6.02) <0.001
Cardiovascular mortality
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
GRACE score > 140 3.79 (1.57–9.16) 0.003 2.49 (0.98–6.35) 0.056
LVEF <_ 35% 4.44 (1.99–9.93) <0.001 2.31 (0.95–5.60) 0.065
DCst <_ 2.5 ms 3.79 (1.66–8.67) 0.002 2.51 (1.04–6.03) 0.040
DCst, deceleration capacity assessed from short-term recordings; GRACE, Global Registry of Acute Coronary Events; LVEF, left-ventricular ejection fraction.
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multivariable analysis might be that 30-min ECGs recordings are per-
formed in standardized conditions compared to 24-h Holter record-
ings, which also include phases of physical activity, ECG lead
displacement and non-stationarities created by variations in heart rate.
Clinical implications
An important finding of our study is that DCst provides information of
mortality risk on top of the information obtained by LVEF and GRACE
score. In particular, in both Munich and Tuebingen cohorts the addition
of DCst led to a significant increase of C-statistics, IDI, and NRI scores.
Assessment of DC from short-term recordings allows standardized,
bedside risk assessment of post-MI patients, which makes the technol-
ogy more suitable for clinical practice. Deceleration capacity-based risk
assessment from short-term recordings could also open new perspec-
tives in other fields of cardiac risk stratification, such as the integration
of this technology in implantable devices.
Limitations
Our study has several limitations: first, autonomic function by means
of DC can only be assessed in patients with sinus rhythm; second, in
both cohorts, age was restricted to 80 years. The results cannot,
therefore, be extrapolated to older patients; third, although we ad-
justed for various important risk predictors there are many other
markers, such as heart rate recovery and brain natriuretic peptide,
which were not routinely measured in this study; fourth, the use of
total mortality as the primary endpoint has both advantages and dis-
advantages. Although the definition of death is without any ambiguity,
the potential association with arrhythmic death might be lost.
However, the incidence of unambiguous arrhythmic death in both
cohorts was too low to power further statistical analyses.
Conclusion
In conclusion, DCst is a strong and independent predictor of mortal-
ity and cardiovascular mortality after MI. The prognostic value of
short-term DC is incremental to that of established risk markers,
including LVEF and GRACE Score.
Supplementary material
Supplementary material is available at Europace online.
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Objectives: To evaluate heart rate deceleration capacity, an elec-
trocardiogram-based marker of autonomic nervous system activity, 
as risk predictor in a medical emergency department and to test its 
incremental predictive value to the modified early warning score.
Design: Prospective cohort study.
Setting: Medical emergency department of a large university hospital.
Patients: Five thousand seven hundred thirty consecutive patients 
of either sex in sinus rhythm, who were admitted to the medical 
emergency department of the University of Tübingen, Germany, 
between November 2010 and March 2012.
Interventions: None.
Measurements and Main Results: Deceleration capacity of heart 
rate was calculated within the first minutes after emergency 
department admission. The modified early warning score was 
assessed from respiratory rate, heart rate, systolic blood pres-
sure, body temperature, and level of consciousness as previously 
described. Primary endpoint was intrahospital mortality; second-
ary endpoints included transfer to the ICU as well as 30-day 
and 180-day mortality. One hundred forty-two patients (2.5%) 
reached the primary endpoint. Deceleration capacity was highly 
significantly lower in nonsurvivors than survivors (2.9 ± 2.1 ms vs 
5.6 ± 2.9 ms; p < 0.001) and yielded an area under the receiver-
operator characteristic curve of 0.780 (95% CI, 0.745–0.813). 
The modified early warning score model yielded an area under the 
receiver-operator characteristic curve of 0.706 (0.667–0.750). 
Implementing deceleration capacity into the modified early warn-
ing score model led to a highly significant increase of the area 
under the receiver-operator characteristic curve to 0.804 (0.770–
0.835; p < 0.001 for difference). Deceleration capacity was also 
a highly significant predictor of 30-day and 180-day mortality as 
well as transfer to the ICU.
Conclusions: Deceleration capacity is a strong and independent 
predictor of short-term mortality among patients admitted to a medi-
cal emergency department. (Crit Care Med 2015; 43:1079–1086)
Key Words: cardiac autonomic function; electrocardiogram; 
emergency department; heart rate variability; risk stratification
In most healthcare systems around the world, emergency departments (EDs) are the frontline venue to provide acute medical treatment. However, deficits in ambulatory 
care, demographic changes, and the rising complexity of dis-
eases led to a dramatic increase in the number of admissions 
over the past years (1, 2). So-called ED overcrowding became 
a serious healthcare problem directly affecting the quality of 
patient care and mortality (3, 4). A recent population-based 
study showed an increase of intrahospital mortality by 79% 
when waiting times exceeded 6 hours (5).
Rapid risk stratification at first contact to define appropri-
ate treatment priorities is of key importance to overcome lim-
ited resources. Current concepts of initial risk stratification are 
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based on clinical judgment, vital signs, including respiratory 
rate, heart rate, arterial blood pressure (BP), and body tem-
perature, and neurological status. For clinical practice, these 
variables can be combined using a multivariable scoring sys-
tem such as the “modified early warning score” (MEWS) (6–8). 
The MEWS can be quickly assessed within minutes by nursing 
staff before completion of any laboratory or other diagnostic 
tests. However, although the MEWS has been shown to sig-
nificantly predict adverse events, it lacks both sensitivity and 
specificity for clinical decision making. Therefore, comple-
mentary approaches for risk stratification at first contact are 
of great clinical interest.
Essential information about the current condition of a 
patient can be derived from the functional status of the auto-
nomic nervous system (ANS). The ANS is an integrated neu-
ral network connecting all vital organ systems. Severe damage 
of any organ within the network leads to a global change in 
the functional status of the ANS. Analyzing autonomic mod-
ulations of the sinus node by means of heart rate variabil-
ity (HRV) has practical appeal as beat-to-beat intervals can 
be obtained noninvasively by a routine electrocardiogram 
(ECG) (9). Over the last decades, numerous measures have 
been proposed to assess HRV including standard measures in 
time and frequency domains (9) as well as complexity mea-
sures such as sample entropy (SampEN) or the multiscale 
sample entropy (MSE) index (10–13). Previous studies indi-
cated that a depressed HRV has prognostic implications in 
various diseases, including myocardial infarction (14), heart 
failure (15), sepsis (16, 17), pulmonary diseases (18), stroke 
(19), hemorrhagic shock (20), renal failure (21), and trauma 
patients (22).
However, automated and reliable assessment of HRV in 
the setting of an ED is limited by the huge amount of noise 
and nonstationarities in ECG signals obtained under routine 
clinical conditions. Phase-rectified signal averaging (PRSA) 
is a robust signal processing algorithm that is capable of 
extracting periodic components out of noisy ECG signals. In 
previous studies, PRSA-based deceleration capacity (DC) of 
heart rate has been shown to yield strong and independent 
prognostic information in survivors of acute myocardial 
infarction (23, 24). DC is an integral measure of all decel-
eration-related oscillations of heart rate and considered to 
be a measure of overall tonic autonomic activity. Recently, 
we presented a refinement of the technology, including opti-
mized R-peak detection and filtering techniques, allowing 
for a fully automated assessment of DC from unprocessed 
noisy ECG signals (25).
In the present study, we tested the prognostic power of 
DC in prediction of intrahospital mortality among patients 
admitted to a medical ED and compared it to standard and 
complexity measures of HRV. Furthermore, we aimed to assess 
the incremental value of DC to the MEWS model. We hypoth-
esized that impaired DC was a strong and independent predic-
tor of intrahospital mortality and that implementing DC into 
the MEWS model improved the predictive power of the MEWS 
model alone.
MATERIALS AND METHODS
Participants
Consecutive patients of either sex were prospectively enrolled 
between November 2010 and December 2012 if they were 
admitted to the medical ED of the University of Tübingen, 
Germany. Patients were included if they were 18 years old or 
older and presented in sinus rhythm, which is required for the 
assessment of cardiac autonomic function. Figure 1 shows the 
flowchart of the validation cohort. The study was approved by 
the local ethics committee.
Biosignal Recording
The ED was equipped with six monitoring devices (DASH 
4000/5000 and Teleguard, General Electrics, Fairfield, CT; 
sample frequency, 100 Hz). Nursing staff were advised to 
monitor patients directly after admission. Treating physicians 
were blinded to the study design. Management of patients 
in the ED was not influenced by monitoring. In particu-
lar, monitoring did not delay any diagnostic or therapeutic 
procedures.
Assessment of DC
Technical details of the methodology of automated assess-
ment of DC have been described elsewhere (25). To account 
for the substantial noise and artifacts in the absence of 
manual editing, extensive filtering techniques and trans-
formations were applied to the ECG raw signals to obtain 
the sequence of RR intervals. Briefly, a band-pass filter (4th 
order Chebyshev bandwidth filter 6–18 Hz) was applied to 
the signal followed by a 1st order forward differencing filter. 
Amplitudes were normalized and nonlinearly transformed 
using the Shannon energy envelope. Subsequently, a Hilbert 
Figure 1. Enrollment, follow-up, and analysis of the study.
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transformation and a moving average filter (250 samples) 
were applied followed by a Savitzky-Golay filter (frame 15, 
degree 0). Times of zero-crossing were identified and the 
R-peaks were searched.
The first 10 minutes of the recordings were used for DC 
computation. In case of low signal quality, the time frame was 
gradually extended to a maximum of 30 minutes until at least 
200 anchors suitable for DC computation (see below) were 
detected. This led to an average recording time of 14.3 ± 8.5 
minutes.
The RR time series were checked for the presence of atrial 
fibrillation using a validated automated algorithm (26). 
Recordings with atrial fibrillation were excluded from further 
analysis. The RR time series were transformed by PRSA (27) 
to obtain a modified, more robust version of DC (23). DC is 
an integral measure of the periodic power of all deceleration-
related oscillations of heart rate in the observation period. 
The exact methodologies of PRSA and DC assessment have 
been described elsewhere (27). Briefly, instances within the RR 
interval time series are identified where the heart rate deceler-
ates (so-called anchors). The central part of the PRSA signal is 
then quantified by Haar wavelet analysis to obtain an estimate 
of DC. The PRSA technology allows for several adjustments, 
which make the method more robust to artifacts and noise and 
improve agreement between automatically and manually pro-
cessed ECGs (25). Here, we used T = 4 (instead of 1; equation 
2a in [27]) and s = 5 (instead of 2; equation 8 in [27]). Figure 2 
exemplarily shows the phase-rectified signal of a patient who 
survived the hospital stay (Fig. 2A) and the phase-rectified sig-
nal of a patient who died within the hospital stay (Fig. 2B). In 
the nonsurviving patient (Fig. 2B), oscillations were blunted 
compared with the surviving patient (Fig. 2A).
In line with previous studies, patients were stratified accord-
ing to DC to following risk categories: DC category 0 = low risk 
(> 4.5 ms); DC category 1 = intermediate risk (2.5–4.5 ms); 
and DC category 2 = high risk (≤ 2.5 ms) (23).
Assessment of Standard and Complexity Measures 
of HRV
For assessment of standard and complexity measures of HRV, 
the first 30 minutes of the recordings were analyzed. In cases 
of lower recording time, the total length of the recording was 
used. Measures of HRV were calculated for segments of 256 
RR intervals and subsequently averaged. Segments with exces-
sive artifact burden (> 50%) were disregarded. We assessed fol-
lowing standard measures of HRV in the time and frequency 
domain in line with recommendations of the task force (9): 
the standard deviation of all normal-to-normal intervals 
(SDNNs), the HRV index, the root mean square of the succes-
sive difference, the power in the low frequency (LF; 0.04–0.15 
Hz) and high frequency (HF) ranges (0.15–0.4 Hz), and the 
ratio between LF and HF. We also assessed two complexity 
measures of HRV, SampEn and the MSE index. For calculation 
of SampEn, we used m = 2 and r = 6 ms in line with previous 
reports (12). MSE index was defined as the summation of the 
SampEn values for scales 1–4 (12).
Assessment of the MEWS
The MEWS was calculated from physiological variables, 
including respiratory rate, heart rate, systolic BP, and body 
temperature and level of consciousness at ED admission, as 
previously described (7). The MEWS can range from 0 (lowest 
risk) to 14 (highest risk).
Study Endpoints
The primary endpoint was intrahospital mortality. Secondary 
endpoints were total mortality at 30 and 180 days as well trans-
fer to the ICU during the hospital stay.
Follow-Up
Intrahospital deaths were monitored via the electronic hospi-
tal information system. Patients were followed up at intervals 
of 30 and 180 days after admission to the ED. Information 
about the patient’s status after 
ED discharge was also derived 
from the hospital information 
system in patients who were 
readmitted to the hospital. The 
status at 30 days after admis-
sion to the ED was available in 
all patients. The status at 180 
days after admission to the ED 
was available in 97.5% of the 
patients. Patients who were lost 
to follow-up were censored at 
the date of latest contact.
Statistical Analyses
Continuous variables are 
presented as the mean and 
sd and were compared using 
the Mann-Whitney U test. 
Qualitative data are expressed 
Figure 2. Representative phase-rectified signals from 10-min recordings of heartbeat intervals in one patient 
who survived the hospital stay (A) and one patient who died during the hospital stay (B). In the surviving patient, 
the amplitude of the phase-rectified signal is significantly greater compared with the nonsurviving patient. 
Bolded points = values of phase-rectified signal used for computation of deceleration capacity (DC), i = index 
of phase-rectified signal X(i).
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as percentages and were analyzed using the chi-square test. 
Receiver-operator characteristic (ROC) curves were con-
structed for all tested predictors by plotting 1 – specificity 
versus sensitivity. ROC curves were quantified by the area 
under the curve (AUC). To test the difference between ROC 
curves, we used bootstrapping based on the creation of 
pseudo-replicate datasets by random resampling of the data-
set n times for error estimation (n = 1,000 in this study) (28). 
The association of risk variables with the primary endpoint 
was tested by univariable and multivariable logistic regres-
sion analyses. Multivariable analyses were adjusted for age 
and gender. In logistic regression analyses, coefficients were 
standardized by the procedure suggested by Menrad (29). To 
test the incremental prognostic value of DC on top of the 
MEWS model, we implemented C-statistic and integrated 
discrimination improvement (IDI) score (30). Mortality 
rates were estimated by the Kaplan-Meier method (31). Odds 
ratios are presented with 95% CIs. Differences were consid-
ered statistically significant when p value is less than 0.05. 
Statistical analyses were performed using CRAN R 2.15.2 and 
SPSS 20.0 (SPSS: IBM, Armonk, NY).
Sample Size Calculation
The sample size was defined by the number of endpoints with 
a maximum of 10,000 patients to be screened. Based on pre-
vious work, we postulated that 10 endpoints per risk predic-
tor should be on hand (32). We aimed to include a sample 
size with at least 100 patients reaching the primary endpoint, 
which allows for multivariable analysis with more than 10 vari-
ables to be included.
RESULTS
Table 1 shows the patients’ characteristics. Main causes for 
admission to the ED were cardiovascular and gastrointestinal 
diseases followed by oncologic, hematologic, and pulmonary 
diseases. During the hospital stay, 142 patients died (2.5%). 
After 30 and 180 days, these figures were 196 (3.4%) and 436 
patients (7.6%), respectively. As shown in Table 2, nonsurviv-
ing patients were older and had higher heart rates and respi-
ratory rates but lower systolic, mean, and diastolic arterial 
blood pressures and low levels of consciousness. Correspond-
ingly, the MEWS score was substantially higher in nonsurviv-
ing than surviving patients (3.5 ± 1.7 vs 2.3 ± 1.4; p < 0.001).
Table 3 shows the statistical association of markers of 
HRV with intrahospital mortality. DC was significantly lower 
in nonsurvivors than survivors (2.9 ± 2.1 ms vs 5.6 ± 2.9 ms; 
p < 0.001). Also standard and complexity measures of HRV 
were highly significantly associated with the primary end-
point. Nonsurviving patients had lower levels of time and fre-
quency domain measures of HRV (p < 0.001 for all) as well as 
lower levels of SampEn and MSE-index (p < 0.001 for both). 
Table 3 also shows the areas under the ROC curves for pre-
diction of intrahospital mortality. Among all HRV measures 
tested, DC yielded the greatest area under the curve followed 
by the HRV index and the MSE index.
Table 4 shows the univariable and multivariable logistic 
regression analyses for prediction of intrahospital mortality. 
On univariable analysis, the MEWS and all measures of HRV 
were significantly associated with intrahospital mortality. 
On multivariable analysis, however, only the MEWS and DC 
provided independent prognostic information (standardized 
coefficients of 1.14 and 0.85, respectively; p < 0.001 for both). 
All other markers of HRV were not independently associated 
with intrahospital mortality.
Figure 3 shows the ROC curve analyses for prediction of 
intrahospital mortality by DC, the MEWS, and the combi-
nation of DC and the MEWS. DC yielded an AUC of 0.780 
(95% CI, 0.745–0.813; p < 0.001) (Fig. 3A). The MEWS model 
yielded an AUC of 0.706 (0.667–0.750; p < 0.001) (Fig. 3B). 
Implementing DC into the MEWS model led to a highly sig-
nificant increase of the AUC to 0.804 (0.770–0.835; p < 0.001 
for difference) (Fig. 3B). The relative IDI was 60% (p < 0.001).
Using the established risk categories, DC classified 3,595 
(62.7%), 1,157 (20.2%), and 901 (15.7%) patients as low-risk 
(DC category 0), intermediate-risk (DC category 1), and high-
risk patients (DC category 2), respectively. Of these, 26 (0.7%), 
39 (3.4%), and 77 patients (7.9%) died during the hospital 
stay (p < 0.001). We also assessed whether DC was a predic-
tor of long-term mortality. Figure 4 shows cumulative 180-day 
mortality rates of patients stratified by DC categories. At 30 
days, cumulative mortality rates were 0.9%, 5.5%, and 10.1% 
in the low-, intermediate-, and high-risk groups, respectively 
(p < 0.001). At 180 days, these figures were 2.7%, 12.0%, and 
21.0%, respectively (p < 0.001).
TABLE 1. Patients’ Characteristics and 
Outcomes of the Study Population 
No. of patients 5,730
Age 61.2 ± 17.7
Female (%) 2,605 (45.5)
Main causes for emergency department admission, n (%)
  Cardiovascular 3,427 (59.8)
  Gastrointestinal 565 (9.9)
  Oncological and hematologic 214 (3.7)
  Pulmonary 412 (7.2)
  Endocrinologic 128 (2.2)
  Infectiologic 178 (3.1)
  Renal 49 (0.9)
  Other 757 (13.2)
Admission to ICU (%) 366 (6.4)
Duration of hospital stay (d) 6.1 ± 8.9
Intrahospital deaths (%) 142 (2.5)
Deaths at 30 days (%) 196 (3.4)
Deaths at 180 days (%) 436 (7.6)
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Cause of admission had no significant influence on the pre-
dictive value of DC. DC was a significant predictor of mortality 
in the 3,427 patients admitted for cardiovascular causes (AUC, 
0.767 [0.707–0.827]; p < 0.001) as well as in the 2,303 patients 
admitted for noncardiovascular causes (AUC, 0.768 [0.725–
0.811]; p < 0.001). Furthermore, DC was significantly lower 
in the 366 patients who were transferred to the ICU during 
their hospital stay than in patients who were not transferred 
(3.8 ± 2.7 ms vs 5.7 ± 2.9 ms; p < 0.001).
DISCUSSION
The main findings of our study indicate that DC is a strong 
predictor of intrahospital mortality in patients admitted to a 
medical ED. Its prognostic value was independent of estab-
lished measures of HRV and significantly improved the MEWS 
model, which is an established scoring system for early risk 
stratification in the ED. The predictive power of DC was com-
parable for patients admitted for cardiovascular and noncar-
diovascular diseases. DC was also a strong predictor of 30-day 
and 180-day mortality.
Previous studies have shown that reduced HRV is associ-
ated with poor outcome in various cardiac and noncardiac dis-
eases (14–16, 18–21). However, only very few studies tested the 
clinical usefulness of HRV as clinical tool for risk prediction in 
a medical ED (33). DC differs from standard measures of HRV 
in several aspects. First, due to its underlying signal processing 
algorithm, DC is robust to artifacts, noise, and nonstationari-
ties. This is of particular advantage when analyzing biological 
signals that are recorded under uncontrolled conditions in the 
setting of an ED (25). Second, DC is an integral measure of all 
deceleration-related periodic components of HRV, irrespective 
of their frequency. Thus, DC is not driven by any specific phys-
iological mechanism but rather influenced by alterations of the 
vagal, sympathetic, vascular, and humoral systems. Thereby, 
DC differs from traditional spectral measures of HRV, which 
assess the spectral power in distinct frequency bands. Global 
measures of HRV, such as SDNN or HRV index, also include 
nonperiodic patterns of HRV, which might not be directly 
related to autonomic mechanisms.
In contrast to previous studies (23), DC was assessed from 
short-term ECG recordings, which raises both methodologi-
cal and physiological questions. First, the number of segments 
entering the PRSA-averaging process is much smaller com-
pared to a full 24-hour Holter recording that might limit the 
capability of eliminating noise and artifacts. Second, short-
term DC does not reflect ultra and very low-frequency oscilla-
tions. DC as assessed in the present study should therefore be 
interpreted as measure of short-term cardiovascular control.
In our study, the prognostic performance of DC was statis-
tically superior to that of other measures of HRV. However, it 
needs to be emphasized that direct comparisons between DC 
and other metrics might be difficult. Several requirements for 
assessment of traditional measures of HRV, particularly in the 
frequency domain, were not met, including stationarity of the 
signal and manual preprocessing of the raw data (9). Notably, 
the complexity measures SampEN and MSE index that quan-
tify the amount predictability of the signal were strong predic-
tors of mortality in our population. As previous studies have 
TABLE 2. Statistical Association of Clinical and Physiological Markers With Intrahospital 
Mortality
Variable Survivors Nonsurvivors p
Demographics
  Patient age (yr) 60.9 ± 17.8 70.5 ± 12.9 < 0.001
  Female, % 45.5 43.0 0.386
Physiologic markers
  Heart rate (beats/min) 83.5 ± 24.9 95.6 ± 23.7 < 0.001
  Mean blood pressure (mm Hg) 96 ± 18 84 ± 18 < 0.001
  Systolic blood pressure (mm Hg) 144 ± 26 125 ± 28 < 0.001
  Diastolic blood pressure (mm Hg) 79 ± 19 68 ± 15 < 0.001
  Respiratory rate (breaths/min) 16.5 ± 1.8 17.5 ± 1.9 < 0.001
  Body temperature (°C) 36.2 ± 0.7 36.2 ± 0.8 0.783
Level of consciousness (according to the alert, voice, pain, unresponsive scale) (%)
  Alert 5,454 (97.6) 135 (95.1) < 0.001
  Reaction to voice 37 (0.6) 6 (4.2)
  Reaction to pain 96 (1.7) 1 (0.7)
  Unresponsive 1 (< 0.1) 0 (0)
Modified early warning score (score points) 2.3 ± 1.4 3.5 ± 1.7 < 0.001
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shown that SampEN and MSE index are highly sensitive to 
their respective input variables m, r, and scale (12), future stud-
ies are needed to test whether the prognostic ability of these 
complexity measures might be optimized by refined settings.
We assessed the predictive value of DC and the MEWS 
model by ROC curve analysis, which is independent from 
selection of specific cutoff values. The largest separation of 
ROC curves between DC and the MEWS model occurred 
at high sensitivity levels of 80%. At this level of sensitiv-
ity, the corresponding specificity of DC was substantially 
higher than that of the MEWS model. Hence, DC-based risk 
assessment is particularly useful for a better identification 
TABLE 3. Statistical Association of Markers of Heart Rate Variability With Intrahospital 
Mortality
Variable Survivors Nonsurvivors p
Area Under the  
Receiver-Operator  
Characteristic Curve  
(95% CI) p
Deceleration capacity 5.6 ± 2.9 2.9 ± 2.1 < 0.001 0.780 (0.745–0.813) < 0.001
Standard deviation of all 
normal to-normal intervals
42.7 ± 29.6 29.3 ± 21.4 < 0.001 0.658 (0.608–0.708) < 0.001
Root mean square of 
successive differences 
of all normal-to-normal 
intervals
22.6 ± 12.6 19.8 ± 12.3 < 0.001 0.598 (0.542–0.654) < 0.001
Heart rate variability 
triangular index
6.0 ± 2.9 3.8 ± 2.3 < 0.001 0.744 (0.699–0.789) < 0.001
LF 614.1 ± 1229.3 348.8 ± 783.3 < 0.001 0.662 (0.611–0.712) < 0.001
HF 187.0 ± 270.5 128.0 ± 182.0 < 0.001 0.602 (0.548–0.656) < 0.001
LF/HF 3.8 ± 4.2 2.5 ± 3.2 < 0.001 0.654 (0.606–0.701) < 0.001
Sample entropy 1.8 ± 0.5 1.4 ± 0.5 < 0.001 0.677 (0.625–0.729) < 0.001
Multiscale entropy index 5.0 ± 2.1 3.2 ± 2.0 < 0.001 0.736 (0.689–0.783) < 0.001
LF = power in the low-frequency range, HF = power in the high-frequency range.
TABLE 4. Univariable and Multivariable Binary Logistic Regression Analysis for Prediction 
of Intrahospital Mortality
Variable
Univariable Analysis Multivariable Analysis
OR (95% CI) z p OR (95% CI) z p
Modified early warning score 1.28 (1.22–1.35) 9.7 < 0.001 1.14 (1.09–1.19) 5.8 < 0.001
deceleration capacity 0.75 (0.71–0.79) 10.0 < 0.001 0.81 (0.74–0.89) 4.3 < 0.001
Standard deviation of all 
normal to-normal intervals
0.83 (0.79–0.89) 5.5 < 0.001 1.01 (0.92–1.11) 0.2 0.835
Root mean square of 
successive differences of all 
normal-to-normal intervals
0.93 (0.87–0.98) 2.5 0.012 1.05 (0.97–1.13) 1.2 0.213
Heart rate variability triangular 
index
0.76 (0.72–0.81) 8.3 < 0.001 0.91 (0.75–1.11) 0.9 0.358
LF 0.90 (0.84–0.97) 2.9 0.003 1.01 (0.92–1.10) 0.2 0.879
HF 0.92 (0.86.0.98) 2.5 0.011 0.98 (0.90–1.07) 0.4 0.687
LF/HF 0.88 (0.82–0.94) 3.9 < 0.001 0.99 (0.93–1.07) 0.1 0.886
Sample entropy 0.83 (0.78–0.88) 6.3 < 0.001 0.99 (0.89–1.09) 0.3 0.778
Multiscale entropy index 0.77 (0.72–0.82) 8.6 < 0.001 1.01 (0.83–1.23) 0.1 0.913
OR = odds ratio, LF = power in the low-frequency range, HF = power in the high-frequency range.
Multivariable analysis adjusted for age and gender; standardized coefficients presented.
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of low-risk patients who could be treated with less priority. 
This was also confirmed when using DC risk categories. DC 
greater than 4.5 ms classified almost two thirds of patients 
as low-risk patients. These patients were at very low risk of 
death (0.7%; 26 deaths in 3,595 patients). By contrast, DC 
less than or equal to 2.5 ms identified a smaller high-risk 
group of 978 patients (17% of admitted patients) who were 
at an almost 12-fold risk of death compared with the low-
risk group. Our findings therefore suggest that these patients 
should be treated with high priority. In this context of note, 
impaired DC at admission also predicted later transfer to the 
ICU. Extended follow-up to 6 months revealed that impaired 
DC was also a strong predictor of late mortality. Patients with 
DC less than or equal to 2.5 ms at admission had a cumulative 
6-month mortality rate of 21%, indicating that these patients 
should be closely monitored after discharge. Importantly, risk 
predictive power of DC was equally strong in both cardio-
vascular and noncardiovascular patients. It needs to be men-
tioned that the used cutoff values have been derived from 
24-hour Holter recordings in postinfarction patients. Post 
hoc analyses revealed an optimum cutoff value of 3.2 ms for 
DC in the study population, which needs to be validated in 
further studies.
The limitations of our study need to be recognized. First, 
autonomic function by means of HRV can only be assessed in 
patients with sinus rhythm. Second, our study was performed 
in a medical ED. Further investigations are necessary to deter-
mine whether DC provides prognostic value in different set-
tings. Furthermore, we did not compare the predictive value of 
DC to biochemical markers such as the sensitive troponins or 
C-reactive protein. We also cannot rule out that assessment of 
other markers might have influenced triage in our ED. Finally, 
as our study was purely observational, it needs to be shown 
whether clinical decision making based on DC and other pre-
dictors leads to a better outcome.
Figure 3. Receiver-operator characteristic curves for prediction of intrahospital mortality. A, Deceleration capacity (DC). B, The modified early warning 
score (MEWS) as well as the combination of the MEWS and DC. The difference between the area under the receiver-operator characteristic curve (AUC) 
of the MEWS and the combination of the MEWS and DC was highly significant (p < 0.001).
Figure 4. Cumulative 180-day mortality rates in patients stratified by 
deceleration capacity (DC) risk categories. The numbers of patients in the 
individual groups involved in the analysis at 0, 45, 90, 135, and 180 days 
are shown under the graph.
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CONCLUSIONS
In conclusion, assessment of the ANS activity by DC provides 
strong and independent prognostic information in patients 
admitted to a medical ED. DC can be obtained fully automati-
cally within minutes at first contact and significantly improves 
established risk stratification models. The technology is inexpen-
sive, readily available, and can be implemented in existing moni-
toring devices. Further technical developments might realize the 
integration of the technology into cheaper mobile devices, which 
could be used in waiting halls of ED or in ambulatory settings.
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endpoints, respectively. DC was a highly significant predic-
tor of both endpoints, yielding areas under the curve (AUC) 
of 0.784 (95% CI 0.714–0.854) and 0.781 (0.727–0.832) 
(p < 0.001 for both), respectively. Implementing DC into 
the GRACE-risk model leads to a significant increase of 
the C-statistics from 0.788 (0.703–0.874) to 0.825 (0.750–
0.900; p < 0.01 for difference) and from 0.814 (0.759–
0.864) to 0.851 (0.808–0.889; p < 0.01 for difference) for 
the primary and secondary endpoints, respectively. Strati-
fication by dichotomized DC was especially powerful in 
patients with GRACE score <140.
Conclusions In patients with suspected ACS, point-of-
care testing of cardiac autonomic function by means of DC 
is feasible and improves risk assessment by the GRACE 
score.
Clinical Trial Registration Clinicaltrials.gov 
NCT01486589.
Abstract 
Background Impaired cardiac autonomic function has 
been linked to adverse outcomes in patients with acute cor-
onary syndromes (ACS) but is not included in clinical risk 
models. This is the first study to investigate whether point-
of-care testing of cardiac autonomic function by means 
of short-term deceleration capacity (DC) of heart rate 
improves risk assessment in patients with suspected ACS.
Methods 1821 patients with suspected ACS were pro-
spectively enrolled if they were older than 17 years and in 
sinus rhythm. Short-term DC was automatically assessed 
from monitor recordings at hospital admission. The Global 
Registry of Acute Coronary Events (GRACE) score was 
used as gold standard risk predictor. Primary endpoint was 
the composite of intrahospital and 30-day mortality. Sec-
ondary endpoint was 180-day mortality.
Results Of the 1,821 patients with suspected ACS, 28 
(1.5%) and 60 (3.3%) reached the primary and secondary 
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Introduction
Patients with acute coronary syndrome (ACS) represent a 
highly heterogeneous population with respect to their risk 
for developing adverse events. Therefore, early risk strati-
fication is essential to guide optimum tailored treatment. 
The Global Registry of Acute Coronary Events (GRACE) 
score is currently believed to provide the most accurate risk 
stratification in ACS patients [1, 2]. Although the strong 
prognostic value of the GRACE score has been validated 
by many studies [3–5], risk stratification particularly in 
low-risk patients with ACS still needs to be improved.
Experimental and clinical studies indicated that in car-
diac patients, important prognostic information could be 
derived from the functional status of the cardiac autonomic 
nervous system [6–10]. In the setting of acute myocardial 
ischemia, impaired cardiac autonomic function has been 
linked to increased mortality risk [11]. Deceleration capac-
ity (DC) of heart rate is an ECG-based risk marker that cap-
tures autonomic activity-related modulations of heart rate 
[9]. In post-infarction patients, decreased DC was shown to 
be a strong and independent predictor of late mortality that 
was superior to standard measures of heart rate variability 
and established risk predictors [7, 9]. We have developed a 
computer-based technology that allows automated point-of-
care assessment of DC from short-term monitor recordings 
[12, 13].
In the present study, we, therefore, hypothesized that 
short-term DC yields important prognostic information in 
patients with suspected ACS and significantly improves 
risk prediction by the GRACE score.
Methods
The study included 1,821 consecutive patients who pre-
sented with symptoms suspected of ACS in the chest-pain 
unit of the university of Tuebingen, Germany, between 
November 2010 and December 2012. Patients were 
excluded if they were younger than 18 years or not in sinus 
rhythm (Fig. 1). The present study is a substudy of a larger 
study (NCT01486589 [13]) which evaluated the predictive 
value of cardiac autonomic function for risk assessment in 
5,730 all-comers to a large medical emergency university 
department. The present study was designed to assess the 
prognostic value of DC in patients with suspected acute 
coronary syndromes.
Nursing staff was advised to monitor patients directly 
after admission (DASH 4000/5000 and Teleguard, General 
Electrics, Fairfield, CT; sample frequency, 100 Hz). Treat-
ing physicians were blinded to the study design. Monitor-
ing did not influence management of the patients. Assess-
ment of DC was performed before any invasive treatment.
Technical details of automated assessment of DC have 
been described elsewhere [8, 9, 12]. To account for the sub-
stantial noise and artifacts in the absence of manual edit-
ing, extensive filtering techniques and transformations were 
applied to the ECG raw signals to obtain the sequence of 
RR intervals. Briefly, a band-pass filter (fourth-order Che-
byshev bandwidth filter 6–18 Hz) was applied to the signal 
followed by a first-order forward differencing filter. Ampli-
tudes were normalized and non-linearly transformed using 
the Shannon energy envelope. Subsequently, a Hilbert 
transformation and a moving average filter (250 samples) 
were applied followed by a Savitzky–Golay filter (frame 
15, degree 0). Times of zero-crossing were identified, and 
the R-peaks were searched.
The first 10  min of the recordings were used for DC 
computation. In case of low signal quality, the time frame 
was gradually extended to a maximum of 30  min until 
at least 200 anchors suitable for DC computation were 
detected. The mean record times was 12.6 ± 5.0 min. The 
determination of DC can be computerized, within seconds.
The RR time series was checked for the presence of 
atrial fibrillation using a validated automated algorithm 
[14]. Recordings with atrial fibrillation were excluded from 
further analysis. The RR time series were transformed by 
phase-rectified signal averaging [15] to obtain a modified, 
more robust version of DC [9]. DC is an integral meas-
ure of the periodic power of all deceleration-related oscil-
lations of heart rate in the observation period. The exact 
Fig. 1  Flow chart of the study population
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methodologies of phase-rectified signal averaging and DC 
assessment have been described elsewhere [15]. Briefly, 
instances within the RR interval time series are identified, 
where the heart rate decelerates (so-called anchors). The 
central part of the phase-rectified signal averaging signal is 
then quantified by Haar wavelet analysis to obtain an esti-
mate of DC. The phase-rectified signal averaging technol-
ogy allows for several adjustments, which make the method 
more robust to artifacts and noise and improve agreement 
between automatically and manually processed ECGs [16]. 
Here, we used T = 4 (instead of 1; Eq. 2a in [15]) and s = 5 
(instead of 2; Eq. 8 in [15]).
The GRACE score for prediction of the intrahospital 
mortality was calculated as previously described [2] and 
included following variables: age, systolic blood pressure, 
heart rate, Killip classification, creatinine, cardiac arrest at 
admission, ST-segment deviation, and cardiac biomarkers. 
In the present study, sensitive troponine I was used as car-
diac biomarker.
Left ventricular ejection fraction was not routinely 
assessed at hospital admission.
The primary endpoint was the composite of intrahospi-
tal mortality and 30-day mortality. The secondary endpoint 
was 180-day mortality. Intrahospital deaths were moni-
tored via the electronic hospital information system and 
classified by independent physicians who received pseu-
donymized patient data. To obtain information about out-
come after hospital discharge, patients were contacted by 
phone call 180 days thereafter. 180-day follow-up informa-
tion was available in all patients.
Continuous variables are presented as mean ± standard 
deviation and were compared using the Mann–Whitney 
U test. Qualitative data are expressed as percentages and 
were analyzed using the Chi-square test. Receiver–opera-
tor characteristic (ROC) curves were constructed for risk 
predictors by plotting 1—specificity vs. sensitivity. ROC 
curves were quantified by the area under the curve (AUC). 
To test the difference between ROC curves, bootstrapping 
was employed based on the creation of pseudo-replicate 
data sets by random resampling of the data set n times for 
error estimation (n = 1000 in this study). The association of 
risk variables with the endpoints was tested by univariable 
and multivariable Cox-regression analyses. Multivariable 
analyses included DC as well as the single components of 
the GRACE score: age, systolic blood pressure, heart rate, 
Killip classification, creatinine, cardiac arrest at admission, 
ST-segment deviation, and cardiac biomarkers. To test the 
incremental prognostic value of DC on top of the GRACE-
risk model, we implemented C-statistic and continuous net 
reclassification improvement (NRI). Mortality rates were 
estimated by the Kaplan–Meier method. Hazard ratios were 
presented with 95% CIs. When used as categorical vari-
able, DC was dichotomized at the established cut-off values 
of 2.5 and 4.5 ms, respectively [9]. Two-tailed Fisher exact 
test was used to compare sensitivities (proportion between 
true positive and false negative) and positive predictive 
accuracies (proportion between true positive and false posi-
tive) in different selections of high-risk groups. Differences 
were considered statistically significant when p value was 
less than 0.05. Statistical analyses were performed using 
CRAN R 3.0.1 and SPSS 21.0 (SPSS: IBM, Armonk, NY).
Results
Table 1 shows the patients’ characteristics. Mean age was 
60.7 years, and 38% of the patients were female. 21.9% of 
the patients had elevated cardiac troponins, 10.1% of the 
patients showed ST-deviations on the ECG. 931 (51%) 
of the patients underwent invasive diagnostic testing, 
and out of whom 838 (90%) were treated by PCI. Of the 
1,821 patients with suspected ACS, the final diagnosis of 
ACS was made in 910 patients (50.0%). Among them, 99 
patients (5.4%) had ST-elevation myocardial infarction 
(STEMI), 312 (17.1%) had non-ST-elevation myocardial 
Table 1  Patients’ characteristics and outcomes of the study popula-
tion
CVD cardiovascular disease, MI myocardial infarction, NSTEMI non-
ST-elevation myocardial infarction, PCI percutaneous coronary inter-
vention, STEMI ST-elevation myocardial infarction
Variable
Number of patients 1821
Age (years) 60.7 ± 16.3
Females 695 (38.2%)
History of previous MI 338 (18.6%)
Known congestive heart failure 252 (13.8%)
Cardiovascular risk factors
 Hypertension 1110 (61.0%)
 Diabetes mellitus 340 (18.6%)
 Hyperlipidemia 615 (33.8%)
 Smoking 378 (20.8%)
 Family history of CVD 359 (19.7%)
 History of PCI 566 (31.1%)
Invasive diagnostic and treatment
 Coronary angiography 931 (51.0%)
 PCI 838 (46.0%)
Diagnosis at hospital discharge
 STEMI 99 (5.4%)
 NSTEMI 312 (17.1%)
 Unstable angina pectoris 499 (27.4%)
 Chest pain 911 (50.0%)
Outcomes
 Intrahospital and 30-day mortality 28 (1.5%)
 180-day mortality 60 (3.3%)
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infarction (NSTEMI), and 499 (27.4%) had unstable angina 
pectoris (UAP).
Twenty-eight patients (1.5%) died within 30 days after 
hospital admission. 60 patients (3.3%) died within 180 days 
after hospital admission. Table 2 shows patients’ character-
istics of patients reaching and not reaching the primary and 
secondary endpoints.
DC was substantially lower in patients reaching the pri-
mary and secondary endpoints than in those who did not 
(3.9 ± 2.0 vs. 6.6 ± 2.9 and 3.8 ± 2.5 vs. 6.7 ± 3.8 ms for the 
primary and secondary endpoints, respectively, p < 0.001 
for both). Highly significant differences were also noted 
for the GRACE score (146.4 ± 47.0 vs. 99.7 ± 32.7 and 
143.6 ± 39.7 vs. 98.9.5 ± 32.2 for the primary and sec-
ondary endpoints, respectively, p < 0.001 for both). DC 
yielded AUCs of 0.784 (95% CI 0.714–0.854) and 0.781 
(0.727–0.832) for the primary and secondary endpoints, 
respectively (p < 0.001 for both) (Fig. 2a, c). The GRACE 
score yielded AUCs of 0.788 (0.703–0.874) and 0.814 
(0.759–0.864), respectively (Fig. 2b, d).
Figure 3A shows cumulative mortality rates of patients 
stratified by DC. The 168 patients with DC ≤2.5  ms had 
the worst prognosis with a 180-day mortality rate of 12.5%, 
while the 1421 patients with DC >4.5  ms had the best 
prognosis with a 180-day mortality rate of 1.8%. The 232 
patients with DC 2.5–4.5 ms had an intermediate prognosis 
with a 180-day mortality rate of 6.0% (p < 0.001 for overall 
difference).
Tables  3 and 4 show uni- and multivariable analyses 
of DC and the single components of the GRACE score 
for prediction of both endpoints. DC was the second 
strongest risk predictor of the primary endpoint following 
cardiac arrest at hospital admission and was the strong-
est risk predictor of the secondary endpoint. Implement-
ing DC into the GRACE-risk model led to a highly sig-
nificant increase of the C-statistics of both endpoints to 
0.825 (0.750–0.900; p < 0.01 for difference, continuous 
NRI 0.593, p < 0.01) and 0.851 (0.808–0.889; p < 0.01 
for difference, continuous NRI 0.698, p < 0.01) for the 
primary and secondary endpoints, respectively (Fig.  2b, 
d).
1121 of the 1821 patients were on betablockers at 
hospital admission, while 700 patients were not. Beta-
blocker treatment was strongly associated with the pres-
ence or absence of an acute coronary syndrome [OR 17.2 
(13.4–22.2), p < 0.001]. DC was significantly lower in 
patients on betablockers than in patients off betablock-
ers (6.2 ± 3.1 vs. 7.3 ± 2.3  ms; p < 0.001), most probably 
related to the different patients’ characteristics. Adjusting 
the multivariable models by betablocker treatment did not 
affect the prognostic value of DC with respect to prediction 
of the primary or secondary endpoint.
We also tested the risk predictive power of DC for pre-
diction of 180-day mortality in subgroups of patients with 
a GRACE score <140 (n = 1604) and ≥140 (n = 217). As 
shown in Fig. 3b and c, risk stratification by DC was highly 
significant in the 1604 patients with a GRACE score <140 
(p < 0.001), while in the 217 patients with a GRACE 
score ≥140, there was no significant separation (p = 0.178). 
Among the 1,604 patients with a GRACE score <140, 
DC ≤2.5  ms identified 111 high-risk patients with a 180-
day mortality of 9.0%. Adding this new high-risk group to 
the established high-risk group of patients with a GRACE 
score ≥140 leads to a statistically significant increase of 
Table 2  Patients’ characteristics of patients reaching and not reaching the primary and secondary endpoints
Variable Primary endpoint Secondary endpoint
Survivors Non-survivors p Survivors Non-survivors p
Number of patients 1793 (98.5%) 28 (1.5%) 1761 (96.7%) 60 (3.3%)
Age (years) 60.5 ± 16.3 72.6 ± 11.6 <0.001 60.2 ± 16.3 74.7 ± 11.3 <0.001
Females 687 (38.3%) 8 (28.6%) 0.332 671 (38.1%) 24 (40%) 0.766
History of previous MI 331 (18.5%) 5 (17.9%) 0.469 326 (18.5%) 12 (20%) 0.905
Known congestive heart failure 237 (13.8%) 7 (25.0%) 0.587 239 (13.6%) 13 (21.7%) 0.107
Cardiovascular risk factors
 Hypertension 1091 (60.8%) 20 (71.4%) 0.686 1070 (60.8) 41 (68.3%) 0.735
 Diabetes mellitus 332 (18.5%) 8 (28.6%) 0.397 317 (18.0%) 23 (39.0%) <0.001
 Hyperlipidemia 608 (33.9%) 7 (25%) 0.320 598 (33.9%) 17 (28.3%) 0.250
 Smoking 376 (21.0%) 2 (7.1%) 0.157 374 (21.2%) 4 (6.7%) 0.008
 Family history of CVD 354 (19.7%) 5 (17.9%) 1.00 354 (20.1%) 5 (8.3%) 0.017
 History of PCI 461 (25.7%) 4 (14.3%) 0.196 454(25.9%) 11 (18.3%) 0.136
Risk factors
 DC (ms) 6.6 ± 2.9 2.9 ± 2.1 <0.001 6.7 ± 2.8 3.8 ± 2.5 <0.001
 GRACE score (pts) 100 ± 33 146 ± 46 <0.001 99 ± 32 143 ± 39 <0.001
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Fig. 2  Receiver–operator characteristic curves for prediction of the 
primary and secondary endpoints. a, c Deceleration capacity (DC), 
b, d GRACE score as well as the combination of the GRACE score 
and DC. The difference between the areas under the receiver-operator 
characteristic curve (AUC) of the GRACE score and the combination 
of the GRACE score and DC was highly significant for both end-
points (p < 0.01)
Fig. 3  Cumulative mortality rate of patients stratified by deceleration capacity (DC) ≤2.5, 2.5–4.5, and >4.5 ms, respectively. a Risk stratifica-
tion in all patients, b, c risk stratification in patients with a GRACE score <140 and ≥140, respectively
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sensitivity from 48.3 to 65.0% (p = 0.027) without affecting 
positive predictive accuracy (p = 0.597) (Table 5).
Discussion
The findings of our study indicate that in patients with 
suspected ACS point-of care testing of cardiac autonomic 
function by means of automatic assessment of short-term 
DC yields important prognostic information on top of 
established risk markers. DC significantly improves risk 
assessment by the GRACE score with respect to predic-
tion of early and late mortalities. Predictive value of DC is 
particularly strong in patients with a GRACE score <140 
in whom impaired DC (≤2.5 ms) identifies a relevant new 
high-risk group of patients. Adding this new high-risk 
group to the established high-risk group with a GRACE 
score ≥140 increases sensitivity by 35% without affecting 
positive predictive accuracy.
Table 3  Uni- and multivariable analyses for prediction of intrahospital and 30-day mortality (primary endpoint)
Analyses were adjusted for betablocker treatment
bpm beats per minute, DC deceleration capacity, HR hazard ratio
Variable Univariable analysis Multivariable analysis
HR (95% CI) z p HR (95% CI) z p
DC (per ms increase) 0.830 (0.774–0.889) 27.85 <0.001 0.806 (0.707–0.919) 10.33 <0.001
Age (per year increase) 1.060 (1.029–1.092) 14.57 <0.001 1.039 (1.006–1.073) 5.49 0.019
Creatinine (per mg/dl increase) 1.375 (1.179–1.604) 16.44 <0.001 1.329 (0.972–1.816) 3.18 0.075
Heart rate (per bpm increase) 1.005 (1.000-1.010) 4.54 0.033 1.006 (0.996–1.017) 1.39 0.238
Systolic blood pressure (per mmHG increase) 0.996 (0.980–1.012) 0.265 0.607
Elevated cardiac enzyme levels (yes/no) 4.826 (2.283–10.202) 16.99 <0.001 3.405 (1.300-8.918) 6.22 0.013
ST-segment deviation (yes/no) 5.055 (2.334–10.951) 16.88 <0.001 3.410 (1.224–9.499) 5.51 0.019
Cardiac arrest at admission (yes/no) 56.808 (13.422-240.438) 30.11 <0.001 15.160 (0.583-394.284) 2.67 0.102
Kilip class (per class increase) 4.051 (2.483–6.607) 31.40 <0.001 1.965 (0.877–4.402) 2.69 0.101
Table 4  Uni- and multivariable analyses for prediction of 180-day mortality (secondary endpoint)
Analyses were adjusted for betablocker treatment
bpm beats per minute, DC deceleration capacity, HR hazard ratio
Variable Univariable analysis Multivariable analysis
HR (95% CI) z p value HR (95% CI) z p value
DC (per ms increase) 0.823 (0.787–0.861) 71.51 <0.001 0.813 (0.746–0.886) 22.43 <0.001
Age (per year increase) 1.076 (1.053–1.100) 42.89 <0.001 1.060 (1.035–1.086) 22.19 <0.001
Creatinine (per mg/dl increase) 1.325 (1.169–1.500) 19.56 <0.001 1.266 (1.007–1.592) 4.07 0.044
Heart rate (per bpm increase) 1.005 (1.002–1.009) 9.878 0.002 1.006 (1.000–1.012) 4.13 0.042
Systolic blood pressure (per 
mmHG increase)
0.999 (0.988–1.010) 0.03 0.873
Elevated cardiac enzyme levels
(yes/no)
4.504 (2.708–7.491) 33.634 <0.001 2.942 (1.560–5.549) 11.12 0.001
ST-segment deviation
(yes/no)
3.072 (1.712–5.510) 14.169 <0.001 1.588 (0.760–3.318) 1.51 0.219
Cardiac arrest at admission
(yes/no)
54.724 (17.024–1775.915) 45.13 <0.001 57.224 (2.439–1342.663) 6.32 0.012
Kilip class (per class increase) 3.746 (2.599–5.401) 50.09 <0.001 1.915 (1.065–3.443) 4.72 0.03
Table 5  Sensitivity and positive predictive accuracy of high-risk 
groups for prediction of 180-day mortality
DC deceleration capacity, GRACE Global registry of acute coronary 
events score
High-risk group n Sens PPA
GRACE ≥140 217 48.3% 13.4%
GRACE ≥140 or 
DC ≤2.5 ms
328 65.0% 11.9%
p value 0.027 0.597
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Many studies demonstrated the strong prognostic value 
of cardiac autonomic dysfunction in cardiac patients [10]. 
The strongest evidence exists for patients after myocardial 
infarction in whom depressed autonomic function predicts 
increased risk of subsequent death independently from left 
ventricular ejection fraction, arrhythmias, and demographic 
factors [7, 9, 17, 18]. In most studies, cardiac autonomic 
function was assessed from ECG- or blood pressure record-
ings that have been either obtained under strictly standard-
ized conditions, over prolonged period of time (e.g., 24 h) 
or in the chronic phase of myocardial infarction [10]. The 
signal processing technology employed in the present 
study allows for an automated point-of-care assessment of 
cardiac autonomic function within minutes after hospital 
admission and thus opens new perspectives for bedside risk 
stratification in the acute clinical setting. This type of risk 
assessment is objective and can be carried out in a stand-
ardized manner. There is no need for elaborate training of 
personnel, such as for echocardiography and its further 
development [19]. In addition, the method might circum-
vent gender-specific aspects that play a role in the diagnosis 
of ACS [20, 21].
In contrast to most previous studies, cardiac autonomic 
function was assessed in patients with potential myocardial 
ischemia prior to any revascularization procedure. Only 
very few studies studied cardiac autonomic function in the 
very acute phase of myocardial infarction. Bonnemeier 
et  al. analyzed heart rate turbulence and heart rate varia-
bility in patients with acute myocardial infarction by start-
ing Holter recordings directly after hospital admission [22, 
23]. Both heart rate turbulence and variability were initially 
depressed but recovered after successful reperfusion. In 
a small study by Sade et  al. including 126 patients, heart 
rate turbulence assessed in the acute phase of myocardial 
infarction was a strong and independent predictor of 1-year 
mortality [24]. The results of our study further strengthen 
the important prognostic role of cardiac autonomic func-
tion assessed in the acute phase of myocardial ischemia.
Importantly, the strong prognostic meaning of cardiac 
autonomic function is not restricted to patients admitted to 
the ED for suspected ACS. In a previous study, we could 
demonstrate that impaired DC was also a strong and inde-
pendent predictor of early and late mortality in 2303 non-
cardiac patients [13], making DC also particularly useful as 
screening test in emergency patients in whom the diagnosis 
is primarily unclear.
Our study also re-evaluates the strong prognostic value 
of the GRACE score in a contemporary treated popula-
tion with suspected ACS. In our study, the GRACE score 
yielded large AUCs of 78.8 and 81.4% for prediction of 
early and 180-mortality, which is in line with previous 
findings from large registries. In a study by Granger et al. 
including 27,503 patients with ACS, the GRACE score 
yielded an AUC of 83% for prediction of intrahospital 
mortality [2]. In a study by Fox et  al. including 43,810 
patients with ACS, the GRACE score yielded an AUC of 
81% for prediction of 180-day mortality [25]. Despite the 
strong predictive value of the GRACE score, DC signifi-
cantly improved its risk predictive power by significantly 
improving C-statistics and NRI.
Our study might have important clinical implications 
for management of patients with suspected ACS. Accord-
ing to the current guidelines, patients with suspected or 
confirmed ACS and a GRACE score <140 are consid-
ered to be at low- or intermediate risk [1, 26], which has 
direct implications for their clinical management. Thus, 
the current ESC guidelines recommend early discharge of 
patients with suspected ACS and a GRACE score <140, 
if high sensitive troponins are sequentially below the 
upper limit of normal, the patient is pain free and differ-
ential diagnoses are excluded [1]. Moreover, the GRACE 
score is also recommended to guide invasive strategies in 
Non-ST-elevation ACS, with a GRACE score ≥140 being 
a high-risk criterion mandating an early invasive strat-
egy (<24 h) [1]. Finally, the GRACE score is the recom-
mended tool to predict outcome after hospital discharge. 
In our study, DC significantly improved risk assessment 
by the GRACE score. Among the 1,604 patients with a 
GRACE score <140, DC ≤2.5 ms identified a new high-
risk group of 111 patients, whose prognosis was not sta-
tistically different to that of patients with GRACE ≥140. 
These patients should, therefore, be considered as high-
risk patients. Future studies should test whether ACS 
patients with DC ≤2.5 ms benefit from intensified moni-
toring and early invasive treatment.
The limitations of our study need to be recognized. First, 
the findings of our study should be independently vali-
dated. Second, compared to the large-scale studies on the 
GRACE score [2, 25, 27], the sample size our study is lim-
ited. However, in contrast to the GRACE score, retrospec-
tive application of DC to large ACS registries for validation 
is impossible. Third, for methodological reasons, DC can 
only be assessed in patients with sinus rhythm. It is known 
that ACS patients with atrial fibrillation or other non-sinus 
rhythms are at increased risk [28]. Fifth, we assessed DC 
only at hospital admission. It is presently unknown whether 
DC assessed prior to hospital discharge might be a better 
predictor of late mortality.
Sixth, the addition of LVEF might improve risk assess-
ment in addition to DC and the GRACE score. In our study, 
however, LVEF was not routinely assessed at hospital 
admission.
Finally, as our study is purely observational, it is 
unknown whether a different treatment based on an 
improved risk assessment by DC translates into a better 
outcome.
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Conclusions
In conclusion, automated point-of-care assessment of 
cardiac autonomic function by means of DC is feasible 
and provides strong and independent prognostic infor-
mation in patients with suspected ACS. DC significantly 
improves the GRACE score, which is considered as 
gold standard for risk assessment in ACS patients. The 
technology is inexpensive, readily available, and can 
be implemented in existing monitoring devices and DC 
could be calculated within minutes. Future studies should 
test whether implementing DC into clinical decision 
making improves patient care.
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Background. Enhanced sympathetic activity at the ventricular myocardium can destabilize repolarization, 
increasing the risk of death. Sympathetic activity is known to cluster in low-frequency bursts; therefore, we 
hypothesized that sympathetic activity induces periodic low-frequency changes of repolarization. We devel-
oped a technique to assess the sympathetic effect on repolarization and identified periodic components in the 
low-frequency spectral range (≤0.1 Hz), which we termed periodic repolarization dynamics (PRD).
Methods. We investigated the physiological properties of PRD in multiple experimental studies, including 
a swine model of steady-state ventilation (n = 7) and human studies involving fixed atrial pacing (n = 10), 
passive head-up tilt testing (n = 11), low-intensity exercise testing (n = 11), and beta blockade (n = 10). We 
tested the prognostic power of PRD in 908 survivors of acute myocardial infarction (MI). Finally, we tested 
the predictive values of PRD and T-wave alternans (TWA) in 2,965 patients undergoing clinically indicated 
exercise testing.
Results. PRD was not related to underlying respiratory activity (P < 0.001) or heart-rate variability (P = 0.002). 
Furthermore, PRD was enhanced by activation of the sympathetic nervous system, and pharmacological 
blockade of sympathetic nervous system activity suppressed PRD (P ≤ 0.005 for both). Increased PRD was the 
strongest single risk predictor of 5-year total mortality (hazard ratio 4.75, 95% CI 2.94–7.66; P < 0.001) after 
acute MI. In patients undergoing exercise testing, the predictive value of PRD was strong and complementary 
to that of TWA.
Conclusion. We have described and identified low-frequency rhythmic modulations of repolarization that are 
associated with sympathetic activity. Increased PRD can be used as a predictor of mortality in survivors of 
acute MI and patients undergoing exercise testing.
Trial registration. ClinicalTrials.gov NCT00196274.
Funding. This study was funded by Angewandte Klinische Forschung, University of Tübingen (252-1-0).
Introduction
Sudden cardiac death (SCD) is the single most common cause 
of death in the industrialized world (1). A substantial propor-
tion of SCD cases occur in patients after myocardial infarction 
(MI). Randomized trials have demonstrated that in high-risk 
patients after MI, mortality can be effectively reduced by pro-
phylactic implantation of a cardioverter-defibrillator (ICD) 
(2). Consequently, identification of high-risk individuals is a 
major objective in cardiology. Current guidelines recommend 
the assessment of left ventricular ejection fraction (LVEF) as the 
gold standard risk predictor (3, 4); however, this approach lacks 
both sensitivity and specificity (1, 5). Therefore, development of 
novel risk markers is of great clinical interest.
Assessment of repolarization instability may more directly esti-
mate the risk of fatal cardiac arrhythmias (6). It is well known 
from experimental and clinical studies that enhanced sympathet-
ic activity is a key factor leading to the destabilization of myocar-
dial repolarization (7–14). However, without directly recording 
neural activity, which is impractical in the clinical setting, assess-
ment of the sympathetic effect on myocardial repolarization has 
not been possible to date. As sympathetic activity is organized in 
a series of low-frequency bursts (15–19), we postulated that repo-
larization changes induced by the sympathetic nervous system 
would exhibit low-frequency periodic features.
In the present study, we propose what we believe is a novel way to 
assess the sympathetic effect on cardiac repolarization. We devel-
oped a technology and uncovered periodic components of repo-
larization in the low-frequency spectral range (≤0.1 Hz), which we 
termed periodic repolarization dynamics (PRD). The first part of 
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this article focuses on the physiological properties of PRD, includ-
ing activation and blockade of the sympathetic nervous system. 
In the second part of this investigation, we assess the prognostic 
meaning of enhanced PRD in patients surviving acute MI (post-
MI cohort; Figure 1A) and patients undergoing clinically indicated 
exercise testing (stress-test cohort; Figure 1B). In the stress-test 
cohort we also tested the prognostic meaning of exercise-induced 
T-wave alternans (TWA), which is presently considered to be the 
strongest existing marker of repolarization instability.
Results
Repolarization is subject to low-frequency periodic modulations. We devel-
oped a technique to dynamically track repolarization dynamics 
and to quantify their periodic components. Details of the method-
ology are reported in Methods. Briefly, we used standard, high-res-
olution, surface ECG recorded in or converted to the orthogonal 
Frank lead configuration. As electrocardiographic repolarization 
is a phenomenon occurring in both space and time, we integrated 
the spatiotemporal information of each T-wave into a single vec-
tor, T°. We used the angle dT° between successive repolarization 
vectors as an estimate of the instantaneous repolarization instabil-
ity (Figure 2, A–C). We observed characteristic low-frequency oscil-
lations in dT° in health and disease (Figure 2D). In order to quan-
tify these low-frequency (≤0.1 Hz) periodic patterns, we employed 
wavelet analysis (Figure 2E).
PRD is not an epiphenomenon of underlying heart rate variability. We 
tested whether PRD was present in the absence of heart rate vari-
ability (HRV). We studied 10 individuals (median age 52 [interquar-
tile range (IQR) 32] years, 5 females), who underwent a clinically 
indicated electrophysiological (EP) study at our institution. Patient 
characteristics are provided in Methods. We compared 5-minute 
episodes of spontaneous sinus rhythm to 5-minute episodes during 
fixed atrial stimulation, which was set above the spontaneous heart 
rate. Fixed atrial pacing almost abolished HRV (P < 0.001; Supple-
mental Table 1; supplemental material available online with this 
article; doi:10.1172/JCI70085DS1), but exerted only minimal, non-
significant effects on PRD (ratio of PRD after provocation to PRD 
before provocation [PRD ratio] 0.75, 95% CI 0.50–1.17, P = 0.193; 
Figure 3A, Supplemental Figure 1A, and Supplemental Table 1).
PRD is not an epiphenomenon of underlying respiratory activity. 
To test whether PRD was present in the absence of spontane-
ous breathing, we performed an experimental study in a swine 
model. Seven female domestic pigs were mechanically ventilated 
and sedated with α-chloralose, which has been shown to induce 
only minimal effects on the cardiac autonomic nervous system 
(20). Respiratory frequency and tidal volume were maintained 
constant by means of volume-controlled ventilation. Details of 
the experimental design are provided in Methods. PRD occurred 
independently of respiratory activity, as illustrated in Figure 4A. 
There was no interference between respiratory activity and PRD 
in any animal, as confirmed by spectral and crossspectral analysis 
(Figure 4, B and C; median coherence 0.044 [IQR 0.026]; P < 0.001 
for the difference from the threshold of 0.5).
PRD is enhanced by sympathetic activation and suppressed by sympathetic 
blockade. We tested the effects of sympathetic activation on PRD in 
11 healthy male volunteers (median age 24 [IQR 3] years). Sympa-
thetic activation was achieved by means of head-up tilt testing and 
low-intensity exercise. Both tilt-table testing (PRD ratio 1.80, 95% 
CI 1.35–2.58, P = 0.005; Figure 3B, Supplemental Figure 1B, and 
Supplemental Table 1) and low-intensity exercise (PRD ratio 3.85, 
95% CI 2.49–5.61, P = 0.001; Figure 3C, Supplemental Figure 1B, 
and Supplemental Table 1) led to substantial enhancement of PRD.
Figure 1
CONSORT flow diagrams. Enrollment, follow-up, and analysis in the post-MI and stress-test cohorts.
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Conversely, we tested the effects of antiadrenergic intervention 
in 10 patients (median age 57 [IQR 21] years, 7 females) under-
going an EP study at our institution. Antiadrenergic intervention 
was achieved by pharmacological beta blockade. The diagnostic 
protocol is described in Methods. Beta blockade caused a strik-
ing suppression of PRD in all patients (PRD ratio 0.41, 95% CI 
0.28–0.61, P = 0.002; Figure 3D, Supplemental Figure 1C, and 
Supplemental Table 1).
For comparison, the effects of sympathetic activation and block-
ade on the low-frequency component of heart-rate variability are 
shown in Supplemental Table 1.
Increased PRD predicts total and cardiovascular mortality after MI. 
We tested the prognostic significance of PRD in a cohort of 908 
patients from the Autonomic Regulation Trial (median age 61 
[IQR 17] years, 174 females) who survived an acute MI (Figure 1A 
and Table 1) (21, 22). Sixty-nine patients died within the first 5 
years of follow-up. Representative resting dT° signals in a patient 
who survived the follow-up period and in a patient who suddenly 
died 8 months after index MI are depicted in Figure 5, A and B, 
respectively. Although low-frequency oscillations in dT° were evi-
dent in both patients, the amplitudes of PRD were much higher 
in the nonsurviving patient. The level of PRD was significantly 
associated with 5-year mortality (6.67 [IQR 8.58] deg2 vs. 2.66 
[IQR 3.93] deg2; P < 0.001). For subsequent survival analyses, we 
dichotomized PRD at the upper quartile of the study population. 
The 227 patients with PRD greater than or equal to 5.75 deg2 (Fig-
ure 5C) had a 5-year risk of death of 18.2% compared with 4.1% in 
the 681 patients with PRD of less than 5.75 deg2 (P < 0.001). Both 
uni- and multivariable analyses for the prediction of 5-year total 
mortality indicated that PRD greater than or equal to 5.75 deg2 was 
the strongest single risk predictor in the study cohort (Table 2 and 
Supplemental Figure 2). The predictive value of PRD greater than 
or equal to 5.75 deg2 was independent of that of established risk 
markers, including reduced LVEF of 35% or less (3, 4), the Global 
Registry of Acute Coronary Events (GRACE) score (23), the pres-
ence of diabetes mellitus, elevated mean heart rate, reduced HRV, 
and increased QT variability index (QTVI) (24). Subsequently, we 
assessed the incremental prognostic value of PRD to established 
risk-prediction models (Supplemental Table 2). PRD significantly 
improved all tested risk-prediction models based on the combina-
tion of LVEF, GRACE score, respiratory rate, and HRV parameters. 
Subgroup analyses revealed that increased PRD was a particularly 
strong predictor of mortality in the 179 post-MI patients who also 
suffered from diabetes mellitus, identifying a group of 179 patients 
with a cumulative 5-year mortality rate of 38.8% (Figure 5D).
Finally, we also investigated whether PRD predicted cardiovascular 
mortality. Of the 69 deaths, 36 were cardiovascular deaths. As shown 
in Table 2, PRD greater than or equal to 5.75 deg2 was also a strong 
and independent predictor of 5-year cardiovascular mortality.
The predictive value of PRD is complementary to that of exercise-induced 
TWA. To test the predictive values of PRD and TWA, we studied 
2,965 patients (median age 57 [IQR 16] years, 1,187 females) from 
the Finnish Cardiovascular Study (median age 57 [IQR 16], 1,187 
females; Figure 1B and Table 1) who underwent a clinically indi-
cated exercise test (25). During a median follow-up of 6 years, 309 
patients died. In all patients, TWA was measured during exercise 
by the modified moving average (MMA) method (25–27). PRD was 
assessed in the preexercise period with patients sitting on a bicy-
Figure 2
Assessment of PRD. (A) Illustration of the weight-averaged vector 
of repolarization (T°) for each T-wave from surface ECG recorded in 
the Frank leads configuration. (B) Three-dimensional visualization of 
successive T° vectors projected into virtual spheres. The angle dT° 
between successive repolarization vectors was used as an estimate 
of instantaneous repolarization instability. (C and D) The dT° signal 
exhibits characteristic low-frequency oscillations. C shows dT° values 
for beats #219-223, corresponding to the spheres in B. (E) Quantifica-
tion of PRD using wavelet analysis. PRD was defined as the average 
wavelet coefficient corresponding to frequencies of 0.1 Hz or less.
Figure 3
Physiological and pharmacological provocations. Effects of fixed atrial stimulation (i), tilt-table testing (ii), exercise (iii), and pharmacological beta 
blockade (iv) on PRD. PRD ratio was plotted on a logarithmic axis and used to quantify the effect of each procedure.
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cle ergometer. As expected, PRD levels in this cohort were higher 
than those in the post-MI cohort, where PRD was estimated in the 
supine resting position (9.2 [IQR 13.37] deg2 vs. 2.82 [IQR 4.34] 
deg2, respectively; P < 0.001). Both PRD and TWA were significant-
ly associated with mortality (8.96 [IQR 13.23] deg2 vs. 12.04 [IQR 
16.32] deg2, P < 0.001, and 23.00 [IQR 15] μV vs. 26.00 [IQR 17] μV, 
P < 0.001, respectively). Univariable Cox regression analysis showed 
that both markers were strong predictors of total mortality (stan-
dardized coefficients 0.203, 95% CI 0.113–0.293, P < 0.001 for PRD; 
and 0.256, 95% CI 0.164–0.348, P < 0.001 for TWA). This remained 
true on multivariable analysis, which also included age, sex, previous 
MI, presence of diabetes mellitus, and treatment with beta-blockers 
(Table 3). The significant crossterm between TWA and PRD (TWA 
× PRD) indicated that the relationship between the outcome and 
one predictor was dependent on the levels of the other predictor. 
We therefore tested the additive prognostic value of PRD for dif-
ferent levels of TWA. As illustrated in Supplemental Figure 3, PRD 
provided incremental prognostic information at all levels of TWA.
Of the 309 deaths, 138 were cardiovascular deaths. Increased 
preexercise PRD was also a significant predictor of cardiovascular 
mortality in univariable (standardized coefficient 0.256, 95% CI 
0.126–0.385; P < 0.001) and multivariable analysis (Table 3).
Discussion
In the present study, we identified periodic oscillations of repolariza-
tion that were localized in the low-frequency spectral range and were 
detectable by conventional surface ECG. PRD was evident in health 
and disease without provocations and occurred autonomously from 
underlying HRV and respiratory activity. PRD was augmented by 
physiological provocations leading to activation of the sympathetic 
nervous system and was suppressed by pharmacological adrenergic 
blockade. Increased PRD obtained under resting conditions was a 
very strong predictor of total and cardiovascular mortality in sur-
vivors of acute MI and patients undergoing a clinically indicated 
exercise test. The prognostic value of PRD was incremental to that 
of established risk markers, including LVEF and TWA.
Figure 4
Effect of respiration on PRD in a volume-controlled ventilated swine. (A) Signals of respiratory activity (green) and dT° (blue). Respiratory activity 
was recorded by a piezoelectric thoracic sensor. The dT° signal exhibits typical low-frequency oscillations occurring independently from respira-
tory activity. (B) Spectral analysis of respiratory activity and the dT° signal. Power spectra were normalized by their maximum value. (C) Cross-
spectral analysis of respiratory activity and the dT° signal showing a lack of interference between both signals.
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Noninvasive assessment of the sympathetic effect on myocar-
dial repolarization is of great clinical interest. A wealth of evi-
dence supports the widely held belief that increased sympathetic 
nervous system activity is associated with increased cardiac vul-
nerability (11–14). In human subjects, noninvasively measured 
parameters, including HRV and baroreflex sensitivity, have been 
employed to study sympathetic activity under routine clinical 
conditions (28). This approach is based on the principle that 
activation of the sympathetic nervous system evokes several 
physiological effects, including increasing systolic contractil-
ity rate and vasomotor tone as well as accelerating heart rate 
and atrioventricular conduction (10). However, these measure-
ments provide only an indirect probe of the sympathetic effect 
on repolarization; they reflect influences on the sinoatrial node 
and blood vessels, not on the ventricular myocardium.
At the level of cardiomyocytes, stimulation of β-adrenergic recep-
tors alters intracellular calcium dynamics (28) and shortens action 
potential duration (10). Importantly, the effect of sympathetic 
stimulation on the 3 cell types of the ventricular myocardium (epi-
cardial cells, M cells, and endocardial cells) is nonuniform (29, 30). 
Adrenergic activation abbreviates the action potential duration of 
epicardial and endocardial cells to a greater degree than the action 
potential duration of M cells (31), leading to an increased trans-
mural dispersion of repolarization (28).
It is well known that sympathetic activity is organized in series 
of low-frequency bursts (15–19). We therefore assumed that phasic 
sympathetic activation induces phasic changes in repolarization 
localized in the low-frequency spectral range, and we developed 
a method to track the sympathetic effect on transmural disper-
sion of repolarization. Our findings confirmed this hypothesis. 
For what we believe is the first time, we detected periodic changes 
in repolarization in the same range as those of the sympathetic 
nervous system. PRD was significantly enhanced by sympathetic 
activation and was substantially suppressed by sympathetic block-
ade. Moreover, increased PRD was a strong predictor 
of total and cardiovascular mortality, which is in 
line with the results of many studies showing that 
enhanced sympathetic activity is associated with an 
increased risk of death (11–14).
In particular, increased PRD was identified as 
the strongest single risk predictor of total and car-
diovascular mortality in a large cohort of post-MI 
patients. The predictive value of PRD was indepen-
dent of established risk markers. PRD substantially 
improved several multivariable models in prediction 
of total mortality, confirming its incremental prog-
nostic value. The mechanism by which PRD identifies 
high-risk patients significantly differs from that of 
structural markers such as LVEF. Directly estimating 
sympathetic activity at the level of myocardial repo-
larization may provide more accurate information 
on cardiac risk. Post-MI patients with increased PRD 
had a very poor prognosis when they also suffered 
from diabetes mellitus. Both MI (32) and diabetes 
mellitus (33) are characterized by spatially heteroge-
neous sympathetic innervation, which is associated 
with negative prognosis (10).
We tested the prognostic significance of PRD in a 
large cohort of patients undergoing clinically indicat-
ed exercise testing. Increased PRD was a strong predic-
tor of total and cardiovascular mortality and provided incremen-
tal prognostic information to that of exercise-induced TWA. This 
indicates that PRD can be used to detect high-risk patients who are 
not identified by TWA. The complementary prognostic informa-
tion provided by PRD and TWA implies that these 2 markers cap-
ture different aspects of repolarization instability. While PRD most 
probably reflects low-frequency oscillations related to sympathetic 
activity, TWA is mainly caused by high-frequency action potential 
oscillations provoked by abnormal calcium handling (34). TWA 
is an important predictor of cardiovascular mortality, including 
sudden death (6, 27, 35, 36). However, it needs to be provoked by 
exercise (37) or invasive procedures (38). Assessment of PRD is inex-
pensive, easily obtainable under resting conditions, and noninvasive 
and significantly improves available risk-stratification strategies.
Our study has several limitations. First, high-resolution ECG is 
required in order to measure PRD. It remains to be demonstrated 
whether our results are reproducible with lower-resolution trac-
ings. Second, in both cohorts, risk markers were only assessed at 
enrollment. Therefore, we cannot comment on the immediate and 
long-term reproducibility of PRD as well as the effect of treatment 
on PRD. Third, the prognostic value of PRD needs to be validat-
ed in independent cohorts. Fourth, as PRD is dependent on the 
patient’s body position and activity level, the proposed cutoff value 
is only valid for recordings obtained in the supine resting position. 
Fifth, we confirmed the prognostic value of PRD for prediction of 
total mortality and cardiovascular mortality. Although it is plau-
sible to assume that increased levels of PRD are also associated 
with arrhythmic mortality, this needs to be tested in future studies. 
Finally, although we have shown that increased PRD is a powerful 
risk predictor, we have no data to show that specific treatments 
based on the use of this predictor will improve patient outcome.
In conclusion, PRD constitutes an electrocardiographic phe-
nomenon that most likely reflects the myocardial response to 
sympathetic activation. Increased PRD is a potent risk predictor 
Table 1
Patient characteristics and treatment in the post-MI and stress-test cohorts
 Post-MI cohort Stress-test cohort
Study characteristics  
Number of patients, n 908 2,965
Median follow-up (IQR), months 60 (0) 75.1 (47.7)
Total deaths, n (%) 69 (7.6) 309 (10.4)
Cardiovascular deaths, n (%) 36 (4.0) 138 (4.7)
Patient characteristics  
Median age (IQR), years 61 (17) 57 (16)
Females, n (%) 174 (19.2) 1187 (40.0)
Diabetes mellitus, n (%) 179 (19.7) 344 (11.6)
History of previous MI, n (%) 86 (9.5) 552 (18.6)
Median LVEF (IQR), % 53 (15) 66 (16)
Known CAD (%) 908 (100) 883 (29.8)
Treatment  
PCI, n (%) 848 (93.4) NA
Thrombolysis, n (%) 13 (1.4) NA
CABG, n (%) 6 (0.7) NA
Beta blockers, n (%) 864 (95.1) 1709 (57.6)
CABG, coronary artery bypass graft; CAD, coronary artery disease; NA, not available; 
PCI, percutaneous coronary intervention.
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of total and cardiovascular mortality, and its use significantly 
improves established risk-stratification concepts. Future studies 
are needed to test whether high-risk patients identified by PRD 
benefit from prophylactic therapies.
Methods
Participants. The physiological properties of PRD were studied in 3 
cohorts at the University Hospital of Tübingen. We tested the effects of 
fixed atrial pacing (atrial-pacing cohort) in 10 individuals (median age 52 
[IQR 42] years, 5 females) undergoing a clinically indicated diagnostic EP 
study. Indications for EP studies were paroxysmal supraventricular tachy-
cardia in 7 patients and evaluation of unexplained syncope in 3 patients. 
We investigated the effect of beta blockade in 10 patients (median age 57 
[IQR 21] years, 7 females) undergoing an EP study for paroxysmal supra-
ventricular tachycardia (adrenergic-blockade cohort). In both EP studies, 
all patients were in sinus rhythm, had normal LVEF, were not suspected 
of suffering from coronary artery disease, and had no significant valve 
stenosis or insufficiency on echocardiography. We also studied the effects 
of passive head-up tilt and low-intensity exercise in 11 healthy male vol-
unteers (median age 24 [IQR 3] years, adrenergic-activation cohort).
The prognostic power of PRD was tested in 908 survivors (median age 
61 [IQR 17] years, 174 females) of acute MI (post-MI cohort; Figure 1A and 
Table 1) and 2,965 patients (median age 57 [IQR 16] years, 1,187 females) 
undergoing clinically indicated exercise testing (stress-test cohort; Figure 
Figure 5
PRD in post-MI patients. (A) Typical dT° signal (blue line) obtained from a 50-year-old post-MI patient who survived the 5-year follow-up 
period. The signal shows characteristic low-frequency oscillations. For better illustration of these oscillations, a low-pass filter was applied 
and plotted on top of the original signal (black line). (B) Typical dT° signal (red line) from a 75-year-old post-MI patient who suddenly died 
8 months after MI. Compared with the survivor, the amplitude of PRD was substantially enhanced. (C) Cumulative mortality rates of patients 
stratified by PRD of 5.75 deg2 or more. (D) Cumulative mortality rates of patients stratified by PRD of 5.75 deg2 or more and presence 
of diabetes mellitus.
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1B and Table 1). Patients in the post-MI cohort were enrolled between May 
2000 and March 2005 at 2 university centers in Munich, Germany: the 
German Heart Centre and the Klinikum Rechts der Isar (21, 22). Eligible 
patients had survived acute MI (<4 weeks), were aged 80 years or more, 
had sinus rhythm, and did not meet the criteria for secondary prophylactic 
implantation of ICD before hospital discharge. Patients in the stress-test 
cohort were included between October 2001 and December 2008 at the 
Tampere University Hospital (Finnish Cardiovascular Study) (25). Eligible 
patients were aged 30–80 years, were in sinus rhythm, and underwent a 
clinically indicated exercise test.
Procedures. We performed EP studies according to the hospital’s stan-
dard operating procedures. No study-specific invasive procedures were 
performed on any patient. We did not sedate the patients. All EP studies 
required placement of a pacing electrode in the right atrium. Atrial pac-
ing was performed at a fixed cycle length (CL), below sinus rhythm CL 
and slightly above Wenckebach CL. In the atrial-pacing cohort, we com-
pared a 5-minute recording during undisturbed sinus rhythm to a 5-min-
ute recording during fixed atrial stimulation. In the adrenergic-blockade 
cohort, we compared 5-minute tracings before and after i.v. administration 
of 0.1 mg/kg metoprolol. Fixed atrial pacing during the entire procedure 
was used to ensure constant heart rate.
Subjects in the adrenergic-activation cohort were not allowed to eat or 
drink coffee for 12 hours before the tests. Vigorous exercise and alcohol 
were forbidden for 48 hours before the tests. All healthy volunteers lay in 
a supine position in a quiet room for at least 15 minutes before data col-
lection. We used 2 provocations: 2-minute passive head-up tilt-test at 45° 
and 5-minute low-intensity exercise using a bicycle ergometer. For the lat-
ter test, the individual workload was set to achieve a constant heart rate of 
110 bpm. For all physiological studies, we used high-resolution (2,048 Hz) 
digital ECG (TMS; Porti System) recorded in Frank leads configuration 
throughout the entire procedure.
For the post-MI cohort, we used 30-minute high-resolution (1,600 Hz) 
digital ECG (TMS; Porti System) recorded in Frank leads configuration. 
Recordings were performed within the second week after MI in resting 
conditions in the morning hours and in a supine position. We addition-
ally performed a 24-hour Holter recording (Oxford Excel Holter System, 
Oxford Instruments; Pathfinder700, Reynolds Medical; and Mortara 
Holter System, Mortara Instrument) within the second week after MI. 
For the stress-test cohort, an upright bicycle was used for the exercise 
test. The workload was increased from 20 to 30 W in a step-wise man-
ner (10 to 30 W/min). For calculation of PRD, a preexercise period of at 
least 2.5 minutes was recorded using 12-channel digital ECG (500 Hz), 
which was converted into the Frank leads configuration by means of the 
inverse Dower matrix (39).
Assessment of PRD. The technique used to calculate PRD is illustrated in 
Figure 2 and in Supplemental Figures 4–6. The prerequisite for comput-
ing dT° is an ECG tracing recorded in or converted to the 3 orthogonal 
axes X, Y, and Z. The time positions of the T-waves were identified using 
previously published algorithms (40, 41). The end of each T-wave was set 
as the reference point (amplitude = 0 mV). The first step in calculating 
the new parameter was to transform the Cartesian coordinates X, Y, and Z 
(Supplemental Figure 4A) into a time series of polar coordinates defined 
by 2 angles (elevation and azimuth) and the resultant-force amplitude XYZ 
(Supplemental Figure 4B). For example, we selected a time point t1 (Sup-
plemental Figure 4B) and decomposed the XYZ vector into 2 orthogonal 
vectors on the y axis and the transverse (XZ) plane. The angle between the 
vector and the y axis was termed the elevation (42) (Supplemental Figure 
4D), with an angle of 0° defined as the vector pointing to the caudal direc-
tion. The angle between the vector on the transverse plane and the x axis 
was termed the azimuth (42).
On the basis of the 3 new time signals of the polar coordinates, we 
defined the weight-averaged direction of repolarization, which can be 
Table 2
Univariable and multivariable association of risk markers with 5-year all-cause and cardiovascular mortality  
in 908 survivors of acute MI (post-MI cohort)
  All-cause mortality
Risk variable Univariable Cox regression Multivariable Cox regression
 Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
LVEF ≤ 35% 3.81 (2.23 to 6.51) <0.001 2.13 (1.22 to 3.70) 0.008
GRACEA score ≥120 5.54 (3.24 to 9.46) <0.001 3.61 (2.06 to 6.31) < 0.001
Diabetes mellitus 2.61 (1.61 to 4.23) <0.001 2.07 (1.25 to 3.41) 0.005
Mean HR > 75 bpm 1.98 (1.11 to 3.55) 0.020 1.10 (0.56 to 2.17) 0.783
SDNN ≤ 70 ms 2.01 (1.22 to 3.33) 0.007 1.71 (0.96 to 3.07) 0.072
QTVI > –0.47 2.54 (1.55 to 4.19) <0.001 1.12 (0.65 to 1.93) 0.688
PRD ≥ 5.75 deg2 4.75 (2.94 to 7.66) <0.001 3.03 (1.79 to 5.11) <0.001
  Cardiovascular Mortality
Risk variable Univariable Cox regression Multivariable Cox regression
 Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
LVEF ≤ 35% 4.69 (2.32 to 9.50) < 0.001 2.71 (1.30 to 5.67) 0.008
GRACEA score ≥120 5.82 (2.75 to 12.33) < 0.001 3.80 (1.73 to 8.35) < 0.001
Diabetes mellitus 2.72 (1.40 to 5.31) 0.003 2.16 (1.08 to 4.31) 0.029
Mean HR > 75 bpm 2.22 (1.02 to 4.86) 0.046 1.36 (0.55 to 3.38) 0.510
SDNN ≤ 70 ms 1.89 (0.93 to 3.82) 0.080 1.48 (0.65 to 3.36) 0.350
QTVI > –0.47 1.99 (1.02 to 3.88) 0.044 0.81 (0.39 to 1.70) 0.586
PRD ≥ 5.75 deg2 4.50 (2.33 to 8.69) < 0.001 2.99 (1.45 to 6.17) 0.003
AThe GRACE score combines several clinical risk factors, including patient age, history of previous MI and congestive heart failure, ST-segment deviation, 
elevated cardiac enzymes, renal impairment, systolic blood pressure and HR upon admission, and percutaneous coronary interventions during the hospital 
stay. HR, heart rate.
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    (Equation 3)
Assessment of TWA. We assessed TWA by the time-domain MMA method 
according to previously established technologies (26) (GE Healthcare ver-
sion 5.2). In brief, the MMA algorithm separates odd from even beats. The 
average morphologies of both the odd and even beats were calculated sepa-
rately and continuously updated by a weighting factor of 1/8 or 1/32 of 
the difference between the ongoing average and the new incoming beats. 
The update was calculated for every incoming beat, resulting in continual 
moving averages of the odd and even beats. This approach makes the MMA 
suitable for TWA analysis during the period of activity or during periods of 
fluctuating heart rates (non–steady state periods) (45). In addition, algo-
rithms were incorporated to reduce the influence of noise and artifacts, 
such as those caused by pedaling and respiration (46). The TWA values 
were calculated continuously during the entire exercise test, from rest to 
recovery, using all precordial leads. Finally, the maximum TWA value at 
heart rates of less than 125 bpm was derived.
Assessment of other risk predictors. We assessed LVEF by echocardiography 
or angiography. We obtained short-term and 24-hour HRV in time and 
frequency domains as previously proposed (47). Since the standard devia-
tion of all normal-to-normal intervals (SDNN) provided the strongest 
prognostic power of all HRV measures, we used SDNN as a marker of 
HRV. We assessed QTVI from the resting ECGs according to previously 
published technological methods (24). We calculated the GRACE score, 
which combines several clinical risk factors, specifically patient age, his-
tory of previous MI and congestive heart failure, ST-segment deviation, 
elevated cardiac enzymes, renal impairment, systolic blood pressure and 
heart rate upon admission, and percutaneous coronary interventions 
during the hospital stay (23).
Animal study. Seven female domestic pigs (60–78 kg) were preanesthe-
tized with propofol (2 mg/kg i.v.) and anesthetized with α-chloralose 
(150 mg/kg i.v. with supplemental doses of 600 mg in 60 ml saline as 
required), which has been shown to induce only minimal effects on the 
cardiac autonomic nervous system (20). Immediately after induction of 
anesthesia, the trachea was cannulated and the lungs were mechanically 
ventilated with room air. Constant respiratory frequency and tidal vol-
ume were maintained by means of volume-controlled ventilation with 
a fixed tidal volume (6 ml/kg) and a fixed respiratory rate. In each ani-
described by a set of 2 polar coordinates that we called the weight-aver-
aged azimuth (WAA) and the weight-averaged elevation (WAE). WAA and 
WAE can be calculated using Equations 1 and 2, respectively. For each 
time point t, the resultant-force amplitude XYZ, represented as Amp(t) 
in Equations 1 and 2, was multiplied by the corresponding values for 
azimuth and elevation at the same time point. The (Amp(t) × Angle(t)) 
products were initially summed for the entire duration of the T-wave and 
thereafter divided by the sum of all resultant-force amplitudes. The result 
of each equation represents the “with-the-amplitude weighted” average 
angle, which is measured by means of the same units (deg rad) as the angle 
in Equations 1 and 2. Using the repolarization wave of Supplemental 
Figure 4 as a backbone, exemplary WAA and WAE values were calculated 
as illustrated in Supplemental Figure 5.
  (Equation 1)
  (Equation 2)
We used the angle dT° between successive repolarization vectors as 
an estimate of the instantaneous degree of repolarization instability 
(Figure 2, A–C). The angle dT° was calculated using the dot product 
(scalar product) equation (43), which by 2 vectors of the same length 
r can be simplified to Equation 3 as illustrated in Supplemental Figure 
6. The dT° signal was linearly interpolated with a sampling rate of 2 Hz 
and filtered using a low-pass filter to remove artifacts. In order to quan-
tify the periodic components of dT°, we employed continuous wavelet 
transformation (Figure 2D). The continuous wavelet transformation 
provides wavelet coefficients for each scale at each time point. For each 
scale, the average wavelet coefficient was computed. Finally, scales were 
converted to pseudofrequencies using an established algorithm (44). 
PRD was defined as the average wavelet coefficient in the frequency 
range of 0.1 Hz or less (Figure 2E).
Table 3
Multivariable association of TWA and PRD with all-cause and cardiovascular mortality in 2,965 patients  
undergoing a clinically indicated exercise test (stress-test cohort)
  Multivariable Cox regression analysis
Risk variable All-cause mortality  Cardiovascular mortality
 Beta (95% CI) P value Beta (95% CI) P value
Age, continuous 0.055 (0.042 to 0.068) <0.001 0.044 (0.027 to 0.063) <0.001
Sex (yes, no) –0.535 (–0.790 to –0.280) < 0.001 –0.960 (–1.386 to –0.531) <0.001
Diabetes mellitus (yes, no) –0.393 (–0.675 to –0.111) 0.006 –0.291 (–0.721 to 0.139) 0.184
Previous MI (yes, no) 0.205 (–0.049 to 0.459) 0.115 0.288 (–0.080 to 0.656) 0.126
Beta blocker (yes, no) 0.350 (0.085 to 0.614) 0.010 0.582 (0.164 to 0.999) 0.006
TWA, continuous 0.175 (0.007 to 0.284) 0.002 0.274 (0.133 to 0.414) <0.001
PRD, continuous 0.198 (0.103 to 0.292) < 0.001 0.269 (0.136 to 0.401) < 0.001
TWA × PRD –0.091 (–0.160 to –0.022) 0.010 –0.136 (–0.244 to –0.048) 0.002
Beta, standardized coefficients.
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mal end-tidal CO2. Respiratory activity was recorded by a piezoelectric 
thoracic sensor (48). Two hours after the administration of Propofol, a 
high-resolution 30-minute ECG (2,048 Hz) was recorded in the Frank 
leads configuration.
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and cardiovascular mortality. We used the standardized definition of 
cardiovascular death (53, 54). The median follow-up time in the post-MI 
cohort was 5 years. PRD was dichotomized at the upper quartile of the 
study population. For dichotomization of other risk markers, we used 
established cutoff values of 35% or less for LVEF (55), –0.47 or more for 
QTVI (24), greater than 75 for mean heart rate (56), 70 ms or less for 
SDNN (56), and 120 or more for the GRACE score (23). We estimated 
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Experimental and clinical studies have demonstrated that enhanced 
sympathetic autonomic nervous system (SANS) activity can destabilise 
myocardial repolarisation,1–4 increasing vulnerability to developing 
fatal cardiac arrhythmias.5–8 Accordingly, assessment of SANS activity 
has always been a major goal for cardiac risk stratification methods. 
Various non-invasive methods including assessment of heart rate 
variability (HRV) and baroreflex sensitivity have been employed to 
study the activity of the SANS under routine clinical conditions.9 These 
methods are based on two principles. First, activation of the SANS 
evokes physiological effects on the cardiovascular system, such 
as acceleration of heart rate, increased vasomotor tone or systolic 
contractility.4 Second, as SANS activity is clustered in low-frequency 
bursts, SANS-induced physiological responses are likely to exhibit 
low-frequency dynamics.10–14 
Previous studies have shown that SANS assessment based on HRV 
and baroreflex sensitivity is a marker of increased vulnerability to fatal 
cardiac arrhythmias.15,16 However, both methods are limited by the 
fact that they only provide an indirect probe of the sympathetic effect 
on cardiac repolarisation, as they reflect influences on the sinoatrial 
node and blood vessels and not on the ventricular myocardium. In 
addition, both HRV and baroreflex sensitivity are confounded by the 
concomitant action of other systems exhibiting periodic dynamics, such 
as the parasympathetic nervous system and the renin–angiotensin–
aldosterone system, respectively. 
We proposed a novel approach to SANS assessment that substantially 
differs from previous methods.17 So-called periodic repolarisation 
dynamics (PRD) evaluates sympathetic activity-associated low-
frequency periodic changes of cardiac repolarisation instability and 
opens new perspectives for identifying high-risk patients, who would 
potentially benefit from prophylactic interventions. The first section 
of this review briefly depicts the methodology of PRD assessments. 
The second section focuses on potential mechanisms of PRD. In the 
third section, the clinical application of PRD as risk predictor after 
myocardial infarction (MI) is presented. In the fourth section, we 
present an alternative method for PRD assessment, which provides 
some technical advantages over the standard method. The final 
sections are dedicated to ongoing and future projects aimed at 
developing individualised treatment strategies.
Methodology of Periodic Repolarisation 
Dynamics Assessment
PRD is typically assessed using a high-resolution ECG recorded in 
or converted to the three orthogonal axes X, Y and Z (‘Frank lead 
configuration’). As low-frequency patterns are of interest, the recording 
Abstract
Periodic repolarisation dynamics (PRD) refers to low-frequency (≤0.1Hz) modulations of cardiac repolarisation instability. Spontaneous PRD 
can be assessed non-invasively from 3D high-resolution resting ECGs. Physiological and experimental studies have indicated that PRD 
correlates with efferent sympathetic nerve activity, which clusters in low-frequency bursts. PRD is increased by physiological provocations 
that lead to an enhancement of sympathetic activity, whereas it is suppressed by pharmacological b-blockade. Electrophysiological 
studies revealed that PRD occurs independently from heart rate variability. Increased PRD under resting conditions is a strong predictor 
of mortality in post-myocardial infarction (post-MI) patients, yielding independent prognostic value from left-ventricular ejection fraction 
(LVEF), heart rate variability, the Global Registry of Acute Coronary Events score and other established risk markers. The predictive value 
of PRD is particularly strong in post-MI patients with preserved LVEF (>35 %) in whom it identifies a new high-risk group of patients. 
The upcoming Implantable Cardiac Monitors in High-Risk Post-Infarction Patients with Cardiac Autonomic Dysfunction and Moderately 
Reduced Left Ventricular Ejection Fraction (SMART-MI) trial will test prophylactic strategies in high-risk post-MI patients with LVEF 36–50 % 
identified by PRD and deceleration capacity of heart rate (NCT02594488).
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time should be >10 minutes, although PRD has also been assessed 
in shorter time periods.17 Ideally, the ECG is performed under strict 
standardised conditions in the supine position. 
The technique used to calculate PRD is briefly illustrated in Figure 1.17 
In a first step, the ECG is converted to a set of polar coordinates 
defined by two angles (azimuth and elevation) and the ‘resultant-
force’ amplitude (Amp). The beginning and ending of each T-wave are 
identified using previously published algorithms.18,19 In a second step, 
the spatiotemporal characteristics of each T-wave are mathematically 
integrated into a single vector T° (see Figure 2), defined by the 
so-called weight-averaged azimuth (WAA) and weight-averaged 
elevation (WAE). The computation of WAA and WAE are given by 
Equations 1 and 2, respectively: 
 
Of note, WAE and WAA are weighted by Amp. This means that each point 
of the T-wave contributes proportionately to its absolute amplitude to 
the final direction of vector T°. Accordingly, the boundaries of the 
T-wave are less crucial than the T-wave peak. 
In a third step, the instantaneous degree of repolarisation instability 
is estimated by the angle dT° between successive repolarisation 
vectors. dT° can be calculated as the scalar product of two successive 
repolarisation vectors T°, which by two vectors of the same length r 
can be simplified by Equation 3 (see Figure 2):
dT º =  acos [sin(WAE1)*cos(WAA1)*sin(WAE2)*cos(WAA2) + 
cos(WAE1)*cos(WAE2) +  
sin(WAE1)*sin(WAA1)*sin(WAE2)*sin(WAA2)] 
(Equation 3)
In a final step, low-frequency (≤0.1 Hz) oscillations are quantified 
within the dT° signal by means of a continuous wavelet transformation 
(PRDwavelet; see Figure 1D).17 
Potential Mechanisms of Periodic  
Repolarisation Dynamics   
The exact mechanisms underlying PRD are still unknown. However, 
it is most likely that PRD represents the effect of the sympathetic 
nervous system on the myocardium. 
First, PRD mimics the characteristic low-frequency pattern of 
efferent sympathetic activity.11,12,14 Low-frequency patterns can also 
be found in other biological time series such as heart rate or arterial 
blood pressure, where they have been shown to correlate with 
low-frequency sympathetic bursts (muscle sympathetic nervous 
activity).10 Moreover, the amplitude of these oscillations has been 
shown to be related to the level of sympathetic stimulation. 
For instance, Pagani et al. showed that sympathetic activation 
provoked by infusion of nitroprusside in healthy human subjects 
increased low-frequency oscillations of heart rate and systolic 
arterial blood pressure.10
Figure 1. Calculation of Periodic Repolarisation Dynamics
A: Assessment of PRD using a surface ECG recorded in the Frank leads configuration. B: Each T-wave is condensed into a weight-averaged vector of repolarisation (T°). B and C: The angle dT° 
between two successive repolarisation vectors T° is illustrated in the virtual spheres (B) and is calculated for the entire ECG (C). D: The emerging signal features periodic modulations in the 
low-frequency range (red line). PRD was quantified by means of wavelet analysis. PRD = periodic repolarisation dynamic.
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Second, indirect evidence comes from physiological and 
pharmacological studies. Provocations such a tilt test or exercise led to 
increased PRD in healthy individuals, while pharmacological blockade 
of the sympathetic nervous system by b-blockers suppressed PRD.17 
PRD remained intact after elimination of HRV and respiratory variability 
using fixed atrial pacing in patients during an electrophysiological 
study and fixed-rate, volume-controlled ventilation in a swine model, 
respectively.17
 
Third, a potential electrophysiological correlate of PRD was identified by 
Hanson et al.20 The authors assessed action potential durations (APDs) 
from unipolar electrograms in patients with heart failure invasively 
recorded during an electrophysiology study and demonstrated a 
low-frequency pattern of APD. Although the correlation of oscillations 
of APD with PRD was not tested in that study, it is likely that both 
oscillations are driven by the same mechanism. 
The mechanistic link of low-frequency sympathetic activity to periodic 
changes in cardiac repolarisation requires further investigation. A 
possible mechanism could involve non-uniform response of ventricular 
myocardial cells to sympathetic activation. Generally, sympathetic 
activation results in a shortening of APD. Studies conducted over the 
past few decades demonstrated that the ventricular myocardium 
is not homogenous, but is comprised of at least three different cell 
types (epicardial cells, M cells and endocardial cells) with distinct 
electrophysiological characteristics and pharmacological properties.21 
The electrical heterogeneity between the three cell types of ventricular 
myocardium creates transmural and apico-basal voltage gradients 
during the repolarisation phase, causing inscription of the T-wave 
on the surface ECG.22 It has been shown that the myocardial cells of 
the various cell layers respond differently to sympathetic activation. 
Therefore, theoretically sympathetic activation should lead to changes 
in the spatio-temporal properties of the T-wave in the surface ECG, 
which are captured by PRD. The heterogeneity of sympathetically 
induced APD changes can be augmented in various diseases, 
including MI,4 diabetes mellitus23 and inherited channelopathies.2,24 
Periodic Repolarisation Dynamics as a Risk 
Predictor After Myocardial Infarction
The prognostic significance of PRD has been tested in a cohort of 908 
survivors of acute MI of the Autonomic Regulation Trial.17 The primary 
endpoint was all-cause mortality. In the first 5 years of follow-up, 69 
patients died. Figure 3 shows typical dT° signals in surviving and non-
surviving patients. In both signals, low-frequency oscillations of dT° 
Figure 2: Calculation of the Angle dT° Between Two 
Successive Repolarisation Vectors T1 and T2
Figure 3: Periodic Repolarisation Dynamics in post-MI Patients
Projection of a vector T on the three orthogonal axes X, Y and Z (upper panel). Two 
repolarisation vectors T1 and T2 with length r are projected on a virtual sphere (lower panel). 
The dot product of the two vectors is used to calculate the angle dT° between T1 and T2. 
WAA = weight-averaged azimuth; WAE = weight-averaged elevation.
Typical dT° signals obtained from post-MI patients who survived (A, green line) and did 
not survive (B, red line) the 5-year follow-up period. Both signals show characteristic 
low-frequency oscillations (black line). However, the amplitude of those oscillations is 
substantially enhanced in the non-survivor. Cumulative mortality rates of patients stratified 
by PRD ≥5.75 deg2 (C). PRD = periodic repolarisation dynamic.
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were present, but in the non-surviving patient the amplitude of these 
oscillation was much more pronounced. For survival analyses, PRDwavelet 
was dichotomised at the upper quartile of the study population.17 The 
5-year mortality rate in the group of the 227 patients with PRDwavelet ≥5.75 
deg2 was 18.2 % compared with 4.1 % in the 681 patients with PRDwavelet 
<5.75 deg2 (P<0.001; see Figure 3B). In multivariable analyses PRDwavelet 
was revealed to be a strong predictor of mortality after MI and its 
predictive ability was independent from established risk predictors, such 
as left-ventricular ejection fraction (LVEF), the Global Registry of Acute 
Coronary Events (GRACE) score, presence of diabetes mellitus, reduced 
HRV and increased QT-variability index.
Alternative Quantification of Periodic 
Repolarisation Dynamics by Means of  
Phase-rectified Signal Averaging
The original assessment of PRD from the dT° signal includes continuous 
wavelet transformation, which requires some computational resources 
and which might not be available in all software packages. In this 
section, we therefore describe an alternative method to quantify 
PRD from the dT° signal using the technique of phase-rectified signal 
averaging (PRSA). PRSA is a mathematical procedure that allows the 
extraction of periodicities from complex time series that might include 
non-stationarities, noise and artefacts.25 PRSA has been originally 
used to detect deceleration-related (deceleration capacity; DC) and 
acceleration-related (acceleration capacity; AC) modulations of heart 
rate. DC has been shown to yield strong and independent prognostic 
information in survivors of acute MI.26 The PRSA technique consists 
of a three-step procedure and allows for several adjustments, which 
can optimise the method to the particular signal analysed and the 
frequency range of the detected oscillations. In the first step, anchor 
points are selected according to certain properties of the signal. In the 
case of the dT° signal we defined absolute angle increases greater 
than 1.25° (deg rad) as anchor points. To amplify the low-frequency 
periodicities, a low-pass filter of T=9 (average of nine successive beats) 
is intentionally set up for the selection of anchor points. Although the 
PRSA technique is able to detect oscillations in a wide frequency range, 
it has been shown mathematically to be more sensitive for strictly 
periodic oscillations with frequency {f=1/[2.7*T]}. This means that for 
frequencies between 0.025 and 0.1 Hz the optimal T ranges between 
4 and 15. To maximise the sensitivity at the centre of our spectrum 
while maintaining a good sensitivity at the boundaries of the frequency 
range, we used the mean value of T=9. In the second step of the PRSA 
method, windows (L) around each anchor points are defined to both 
the left and right of the anchor point (in this case L=60 beats). Finally, 
in the third step, a new PRSA signal is obtained by averaging over all 
windows. The central part of the PRSA signal (see Figure 4A) is then 
quantified by Haar wavelet analysis and is defined as PRDPRSA.
Table 1 depicts the Spearman’s correlation coefficients between 
different repolarisation parameters in the 908 patients of the Autonomic 
Regulation Trial. The correlation coefficient between PRDPRSA and 
PRDwavelet was 0.854 (95  % CI [0.835–0.871]; P<0.001; see Table 1). 
Of interest, the correlation of PRDPRSA and PRDwavelet with other ECG-
based measures of repolarisation was weak (see Table 1). Figure 4A 
illustrates the corresponding PRSA transformations of the dT° signals 
illustrated in Figure 3. PRDPRSA was significantly associated with mortality 
(4.99° [interquartile range (IQR) 3.19] in non-survivors versus 2.58° [IQR 
2.29] in survivors; P<0.001). To identify the optimal cut-off value for 
Figure 4: PRDPRSA as Predictor of Mortality after Myocardial Infarction
A: PRSA transformation of the signals in Figures 3A and 3B. The emerging PRSA signals highlight the periodic components of the dT° signals into a condensed signal consisting of a total 
of 120 beats around a the central convergence of all anchor points (point 0). The magnitude of the oscillations is quantified by means of PRDPRSA, which is a measure of the amplitude of 
central part of the PRSA curves. B: Cumulative mortality rates of patients stratified by PRDPRSA ≥4.16 deg2. C: Receiver-operator characteristic curve of PRDPRSA for prediction of 5-year 
total mortality in the subgroup of patients with DM (n=179). The AUC for this curve was computed to 83.58 %. D: Cumulative mortality rates of patients stratified by PRDPRSA ≥4.16 deg2 and 
presence of DM. AUC = area under the curve; DM = diabetes mellitus; PRD = periodic repolarisation dynamic; PRSA = phase-rectified signal averaging. 
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PRDPRSA we used log-rank statistics for all possible cut-off values. The 
maximum log-rank value was achieved with a cut-off value of 4.16. 
Figure 4B shows 5-year cumulative mortality rates stratified according 
to patients with PRDPRSA ≥4.16° and <4.16°. The 242 patients classified to 
the high-risk group (PRDPRSA ≥4.16°) had a 5-year mortality rate of 19.1 
%, compared with 3.5 % for the 666 patients belonging to the low-risk 
group (PRDPRSA <4.16°). Multivariable analyses revealed that PRDPRSA was 
a strong predictor of mortality that was independent from LVEF ≤35 %, 
the GRACE score, HRV and other established risk markers.
Sympathetic-associated modulations of repolarisation might be of 
great prognostic value in patients with inhomogeneous innervation 
of the ventricular myocardium. We therefore tested the predictive 
power of PRDPRSA in a subgroup of 179 patients suffering from diabetes 
mellitus. PRDPRSA was significantly associated with all-cause mortality 
in this subgroup. Receiver operating characteristics analysis revealed 
an area under the curve (AUC) of 83.58  % (see Figure 4C; 95  % CI 
[73.10–91.00]) for prediction of 5-year mortality. Figure 4D depicts risk 
stratification by PRDPRSA in patients with diabetes (red and blue curves) 
and those without diabetes (green and black curves). The 49 patients 
with diabetes with abnormal PRDPRSA values have the worst prognosis 
with a cumulative 5-year mortality rate of 40.80 %.
New Perspectives in Risk Stratification and  
Risk Reduction Strategies
Periodic Repolarisation Dynamics in Patients With 
Inherited Channelopathies
Increased sympathetic activity is associated with unfavourable 
outcomes not only in post-MI patients, but also in patients with 
inherited channelopathies such as the long-QT syndrome.2 Assessment 
of PRD in this group of patients would be of great clinical interest and 
might open a new era in the identification of high-risk individuals.
The SMART-MI Study
Future interventional studies are needed to test whether high-risk 
patients identified by PRD or other markers benefit from prophylactic 
strategies. Considering the fact that prevention of malignant 
arrhythmias is one of the main goals, prophylactic implantable 
cardioverter defibrillator implantation might appear to be the most 
logical approach. However, it might not be the only one. In the 
Cardiac Arrhythmias and Risk Stratification After Acute Myocardial 
Infarction (CARISMA) trial, implantable cardiac monitors (ICMs) were 
used to ultimately detect arrhythmias in high-risk post-MI patients 
characterised by LVEF ≤40 %.27 Predefined arrhythmias including AF 
as well as relevant brady- and tachyarrhythmias could be recorded 
with a high prevalence (46 % of the patients). Importantly, most of 
the detected arrhythmias (86 %) were initially asymptomatic, but 
predicted increased mortality risk, suggesting a potential window of 
opportunity for pre-emptive interventions. 
The upcoming Implantable Cardiac Monitors in High-Risk Post-
Infarction Patients With Cardiac Autonomic Dysfunction and 
Moderately Reduced Left Ventricular Ejection Fraction (SMART-MI) 
study will test such an approach (Clinicaltrials.gov ID NCT02594488). 
Survivors of acute MI and LVEF 36–50 % will undergo autonomic testing 
for the presence of abnormal PRD17or DC.26 Patients with autonomic 
abnormalities will be randomised to ICM-based or conventional 
follow-up. Treatment paths have been developed for different kinds 
of arrhythmias including diagnostic work-up as well as medical or 
interventional treatments. The primary endpoint will be the time to 
detection of predefined relevant brady- and tachyarrhythmic events. 
The effect on clinical endpoints will be tested secondarily.
 
Conclusion
Spontaneous cardiac repolarisation instability is subject to rhythmic 
modulations in the low-frequency range (≤0.1Hz), which can be non-
invasively assessed using 3D high-resolution ECGs. PRD most likely 
reflects the response of the ventricular myocardium to sympathetic 
activation. Factors that predispose to an inhomogeneous sympathetic 
innervation such as history of MI or diabetes mellitus are associated 
with increased PRD. In post-MI patients, increased PRD is a strong and 
independent predictor of mortality. PRSA-based assessment of PRD 
is a valuable alternative to the more complex conventional wavelet-
based PRD assessment. Future interventional studies are needed to 
test whether PRD-based risk prediction can be translated into risk 
reduction. n
1. Lown B, Verrier RL. Neural activity and ventricular fibrillation. 
N Engl J Med 1976;294:1165–70. PMID: 57572.
2. Verrier RL, Antzelevitch C. Autonomic aspects of 
arrhythmogenesis: the enduring and the new. Curr Opin Cardiol 
2004;19:2–11. PMID: 14688627.
3. Cao JM, Fishbein MC, Han JB, et al. Relationship between 
regional cardiac hyperinnervation and ventricular arrhythmia. 
Circulation 2000;101:1960–9. PMID: 10779463. 
4. Rubart M, Zipes DP. Mechanisms of sudden cardiac death.  
J Clin Invest 2005;115:2305–15. PMID: 16138184.
5. Han J, Garcia de Jalon P, Moe GK. Adrenergic effects on ventricular 
vulnerability. Circ Res 1964;14:516–24. PMID: 14169970.
6. Maling HM, Moran NC. Ventricular arrhythmias induced by 
sympathomimetic amines in unanesthetized dogs following 
coronary artery occlusion. Circ Res 1957;5:409–13.  
PMID: 13447186.
7. Kliks BR, Burgess MJ, Abildskov JA. Influence of sympathetic 
tone on ventricular fibrillation threshold during experimental 
coronary occlusion. Am J Cardiol 1975;36:45–9. PMID: 1146697.
8. Butrous GS, Gough WB, Restivo M, et al. Adrenergic effects 
on reentrant ventricular rhythms in subacute myocardial 
infarction. Circulation 1992;86:247–54. PMID: 1617776.
9. Verrier RL, Kumar K, Nearing BD. Basis for sudden cardiac 
death prediction by T-wave alternans from an integrative 
physiology perspective. Heart Rhythm 2009;6:416–22. DOI: 
10.1016/j.hrthm.2008.11.019; PMID: 19251221. 
10. Pagani M, Montano N, Porta A, et al. Relationship between 
spectral components of cardiovascular variabilities and direct 
measures of muscle sympathetic nerve activity in humans. 
Circulation 1997;95:1441–8. PMID: 9118511.
11. Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular 
neural regulation explored in the frequency domain. Circulation 
1991;84:482–92. PMID: 1860193.
12. Pagani M, Lombardi F, Guzzetti S, et al. Power spectral 
analysis of heart rate and arterial pressure variabilities as a 
marker of sympatho-vagal interaction in man and conscious 
dog. Circ Res 1986;59:178–93. PMID: 2874900.
13. Montano N, Lombardi F, Gnecchi Ruscone T, et al. Spectral 
analysis of sympathetic discharge, R-R interval and systolic 
arterial pressure in decerebrate cats. J Auton Nerv Syst 
1992;40:21–31. PMID: 1401724.
14. Furlan R, Porta A, Costa F, et al. Oscillatory patterns in 
sympathetic neural discharge and cardiovascular variables 
during orthostatic stimulus. Circulation 2000;101:886–92.  
PMID: 10694528.
Table 1: Spearman’s Correlation Coefficient Between Different Repolarisation Parameters
r [95 % CI] PRDwavelet PRDPRSA Tduration Tpeak-end TAUC
PRDwavelet 1 0.85 [0.83 - 0.87] 0.21 [0.14 - 0.27] 0.27 [0.21 - 0.33] -0.33 [-0.28 - -0.39]
PRDPRSA 0.85 [0.83 - 0.87] 1 0.20 [0.13 - 0.26] 0.24 [0.18 - 0.30] -0.16 [-0.10 - -0.22]
Tduration 0.21 [0.14 - 0.27] 0.20 [0.13 - 0.26] 1 0.91 [0.89 - 0.92] 0.16 [0.10 - 0.22]
Tpeak-end 0.27 [0.21 - 0.33] 0.24 [0.18 - 0.30] 0.91 [0.89 - 0.92] 1 0.08 [0.01 - 0.14]
TAUC –0.33 [-0.28 - -0.39] –0.16 [-0.10 - -0.22] 0.16 [0.10 - 0.22] 0.08 [0.01 - 0.14] 1
AUC = area under the curve; PRD = periodic repolarisation dynamic; PRSA = phase-rectified signal averaging.
AER5.1_Bauer_FINAL.indd   35 14/05/2016   21:26
Arrhythmia Mechanisms
A R R H Y T H M I A  &  E L E C T R O P H Y S I O L O G Y  R E V I E W36
15. Billman GE, Schwartz PJ, Stone HL. Baroreceptor reflex 
control of heart rate: a predictor of sudden cardiac death. 
Circulation 1982;66:874–80. PMID: 7116603.
16. Schmidt G, Malik M, Barthel P, et al. Heart-rate turbulence 
after ventricular premature beats as a predictor of mortality 
after acute myocardial infarction. Lancet 1999;353:1390–6. 
PMID: 10227219.
17. Rizas KD, Nieminen T, Barthel P, et al. Sympathetic activity-
associated periodic repolarization dynamics predict 
mortality following myocardial infarction. J Clin Invest 
2014;124:1770–80. DOI: 10.1172/JCI70085; PMID: 24642467.
18. Laguna P, Jané R, Caminal P. Automatic detection of wave 
boundaries in multilead ECG signals: validation with the CSE 
database. Comput Biomed Res 1994;27:45–60. PMID: 8004942.
19. Pan J, Tompkins WJ. A real-time QRS detection algorithm. IEEE 
Trans Biomed Eng 1985;32:230–6. PMID: 3997178.
20. Hanson B, Child N, Van Duijvenboden S, et al. Oscillatory 
behavior of ventricular action potential duration in heart 
failure patients at respiratory rate and low frequency.  
Front Physiol 2014;5:414. DOI: 10.3389/fphys.2014.00414;  
PMID: 25389408. 
21. Antzelevitch C. Transmural dispersion of repolarization  
and the T wave. Cardiovasc Res 2001;50:426–31.  
PMID: 11376617.
22. Antzelevitch C. Cellular basis for the repolarization waves of 
the ECG. Ann N Y Acad Sci 2006;1080:268–81. PMID: 17132789.
23. Wei K, Dorian P, Newman D, Langer A. Association between 
QT dispersion and autonomic dysfunction in patients with 
diabetes mellitus. J Am Coll Cardiol 1995;26:859–63. PMID: 
7560609.
24. Antzelevitch C. Role of spatial dispersion of repolarization 
in inherited and acquired sudden cardiac death syndromes. 
Am J Physiol Heart Circ Physiol 2007;293:H2024–38. 
PMID: 17586620.
25. Bauer A, Kantelhardt J, Bunde A, et al. Phase-rectified signal 
averaging detects quasi-periodicities in non-stationary data. 
Physica A 2006;364:423–34. DOI:10.1016/j.physa.2005.08.080.
26. Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration 
capacity of heart rate as a predictor of mortality after 
myocardial infarction: cohort study. Lancet 2006;367:1674–81. 
PMID: 16714188.
27. Bloch-Thomsen P-E, Jons C, Raatikainen MJ, et al. Long-
term recording of cardiac arrhythmias with an implantable 
cardiac monitor in patients with reduced ejection fraction 
after acute myocardial infarction: the Cardiac Arrhythmias 
and Risk Stratification After Acute Myocardial Infarction 
(CARISMA) study. Circulation 2010;122:1258–64. DOI: 10.1161/
CIRCULATIONAHA.109.902148; PMID: 20837897.
AER5.1_Bauer_FINAL.indd   36 14/05/2016   21:26
504 Übersicht
Rizas K, Bauer A. Periodic Repolarization ... Dtsch Med Wochenschr 2016; 141: 504–508
Bisher wurden Patienten nach Herzinfarkt als Hochrisikogruppe für plötzlichen Herztod einge-
stuft, wenn die linksventrikuläre Auswurffraktion weniger als 35 % betrug. Doch auch wenn die 
Pumpfunktion nur moderat oder gar nicht eingeschränkt ist, kann das Mortalitätsrisiko hoch sein. 
Lebensbedrohliche Situationen kündigen sich häufig als asymptomatische Arrhythmien an. Eine 
neue Methode, um das Risiko genauer einzuschätzen, ist die Bestimmung der sogenannten 
Periodic Repolarization Dynamics. Für seine Untersuchungen erhielt Prof. Dr. Axel Bauer 2015 den 
Präventionspreis der DGIM.
Periodic Repolarization Dynamics – neue Strategien zur 
Bekämpfung des plötzlichen Herztods 
Konstantinos Rizas, Axel Bauer
Der plötzliche Herztod
Häufigste Todesursache | Während der letzten 
40 Jahre sind die altersadjustierten Sterberaten 
aufgrund kardiovaskulärer Ursachen deutlich 
 zurückgegangen. Dennoch bleibt der plötzliche 
Herztod eine der häufigsten Todesursachen in 
der westlichen Welt [6]. 
Man geht davon aus, dass bis zur Hälfte aller 
kardiovaskulären Todesursachen auf den 
plötzlichen Herztod zurükzuführen sind.
Meistens handelt es sich dabei um ventrikuläre 
Tachyarrhythmien. Jedoch spielen auch Bradyar­
rhythmien wie höhergradige AV-Blockierungen 
und Asystolien eine wichtige Rolle. In etwa 80 % 
der Fälle besteht eine strukturelle Herzerkran­
kung, meist in Form einer koronaren Herzer­
krankung. Ein Herzinfarkt erhöht das Risiko, am 
plötzlichen Herztod zu sterben, um den Faktor 
6–10 [6]. 
Prophylaxe mit Defibrillator | In den letzten Jahr­
zehnten hat sich der implantierbare Defibrillator 
(implantable cardioverter defibrillator, ICD) als 
wirkungsvolles Instrument zur Primärprophylaxe 
des plötzlichen Herztods etabliert. Studien an 
Hochrisikopatienten konnten klar belegen, dass 
eine primärprophylaktische ICD-Implantation die 
Sterblichkeit um bis zu 30 % senken kann [1, 8].
Identifikation von Hochrisikopatienten 
– bisherige Strategien
Auswurffraktion als Kriterium | Trotz hoher ab­
soluter Zahlen ist die Inzidenz des plötzlichen 
Herztods in der Allgemeinbevölkerung gering. 
Bisherige Strategien zur Primärprophylaxe ziel­
ten daher auf Patientengruppen, in denen eine 
gewisse Vortestwahrscheinlichkeit für maligne 
Herzrhythmusstörungen besteht. Patienten, die 
einen Myokardinfarkt hatten und / oder klini­
schen Zeichen einer Herzinsuffizienz, sind dabei 
die beiden Hauptgruppen [1]. In allen Studien 
zur primärprophylaktischen ICD-Implantation 
wurden Hochrisikopatienten durch Bestimmung 
der linksventrikulären Auswurffraktion identifi­
ziert (left ventricular ejection fraction – LVEF). Je 
nach Studie musste die LVEF 30–35 % oder weni­
ger betragen, damit ein Patient für die ICD-Im­
plantation in Betracht kam [1]. 
Neue Verfahren notwendig | Wendet man das 
Kriterium einer eingeschränkten linksventriku­
lären Funktion jedoch auf modern therapierte 
Infarktpatienten an, ist es unzureichend. Nur die 
Minderheit der Patienten, die nach überlebtem 
Herzinfarkt in den Folgejahren sterben, haben 
eine LVEF ≤ 35 % [2].
Zwei von drei Todesfällen ereignen sich bei 
Patienten,  deren Pumpfunktion nur moderat 
oder nicht eingeschränkt ist (▶ Abb. 1). 
Neue Verfahren, die Hochrisikopatienten nach 
Myokardinfarkt mit erhaltener oder moderat 
eingeschränkter Pumpfunktion identifizieren 
können, sind daher von großer klinischer Bedeu­
tung.
Abb. 1 Dilemma der 
Risikostratifizierung nach 
Myokardinfarkt mittels 
Bestimmung der LVEF: Bei 
modern therapierten 
Patienten werden durch das 
Kriterium einer einge-
schränkten LVEF nur weniger 
als ein Drittel aller Hochrisi-
kopatienten als solche 
erkannt [2].
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Das kardiale autonome Nervensystem
Schlechte Prognose | Aus klinischen und experi­
mentellen Studien ist bekannt, dass Funktions­
störungen des kardialen autonomen Nerven-
systems nach Myokardinfarkt eine schlechte 
Prognose anzeigen [11]. Insbesondere eine er­
höhte Sympathikusaktivität bzw. eine Empfind­
lichkeit myokardialer Zellen auf Sympathikus-
aktivierung erhöht die Neigung zu malignen 
Herzrhythmusstörungen [7]. 
Herzfrequenzvariabilität | Eine Messung der 
Sympathikuswirkung am Herzen ist jedoch 
schwierig. Parameter der sog. Herzfrequenzvari­
abilität (heart rate variability – HRV) analysieren 
die Modulation der Sinusknoten­Entladungsfre­
quenz durch die beiden Schenkel des autonomen 
Nervensystems, den N. sympathicus und den 
N. vagus. Sie stellen meist ein integrales Maß au­
tonomer Aktivität auf der Ebene des Sinuskno­
tens dar. Rückschlüsse auf die spezifischen Effek­
te des N. sympathicus auf die Kardiomyozyten 
des linken Ventrikels sind nicht möglich. 
Periodic Repolarization Dynamics
Störung der Repolarisation | Die komplexeste 
und empfindlichste Phase der elektrischen Herz­
aktivität ist die Repolarisation. Bereits geringe In­
stabilitäten können daher fatale Folgen haben. 
Eine erhöhte Sympathikusaktivität am Herzen 
gilt als ein Schlüsselfaktor zur Destabilisierung 
der Repolarisation.
Effekte des N. sympathicus auf die kardiale Repo­
larisation waren jenseits experimenteller Bedin­
gungen nicht messbar. 
Niederfrequente Entladungen | Aus direkten Ner­
venableitungen ist bekannt, dass sympathische 
Entladungen am Herzen in sog. niederfrequenten 
„Bursts“ organisiert sind (< 0,1 Hz; entsprechend 
λ > 10 s) [5]. Mit Hilfe mathematischer Methoden 
konnte 2014 erstmalig nachgewiesen werden, 
dass sich auch niederfrequente Modulationen in 
der kardialen Repolarisation finden [9]. Dieses 
elektrokardiografische Phänomen wird „Periodic 
Repolarization Dynamics“ (PRD) genannt. 
Bestimmung per EKG | Um die PRD zu bestim­
men, ist eine hochaufgelöste EKG-Aufzeichnung 
(> 1000 Hz) notwendig. Da dieses Phänomen sen­
sibel auf extrinsische wie intrinsische Störfakto­
ren reagiert, sollte sich der liegende, spontan at­
mende Patient in einer ruhigen Umgebung 
befinden. Schematisch erfolgt die PRD-Bestim­
mung so: 
 ▶ Die Untersuchung sollte in den orthogonalen 
Frank-Ableitungen (x, y, z) über einen Zeit­
raum von mindestens 20 min durchgeführt 
werden (▶ Abb. 2A).
 ▶ Vereinfachend wird aus den x-, y- und z-Wer­
ten einer jeden T-Welle ein jeweils repräsenta­
tiver Vektor bestimmt. Dieser steht für die 
räumliche und zeitliche Informationen der 
ventrikulären Repolarisation (▶ Abb. 2B). 
 ▶ In einem 2. Schritt wird jeweils der Winkel dT° 
zwischen 2 aufeinanderfolgenden T-Wellen-
Vektoren berechnet (▶ Abb. 2B). Dieser Winkel 
dient als Maß der momentanen Repolarisati­
onsinstabilität. Meist betragen die Winkelän­
derungen dT° von T-Welle zu T-Welle nur we­
nige Grad. 
 ▶ Trägt man die Winkel jedoch über die Zeit auf, 
so demaskieren sich periodische dT°-Anstiege 
etwa alle 15–30 s (▶ Abb. 2C). 
 ▶ Die Ausprägung der niederfrequenten, periodi­
schen dT°-Anstiege kann mittels einer Wave-
let-Analyse quantifiziert werden (▶ Abb. 2D). 
Die PRD-Werte werden als deg2 angegeben und 
 ergeben sich mathematisch durch Quantifzierung 
des Wavelet­Spektrums (Fläche unterhalb von 
0,1 Hz). 
Mechanismen
Ventrikuläre Repolarisation | Die exakten Me­
chanismen, die PRD zugrunde liegen, sind noch 
nicht hinreichend erforscht. 
Abb. 2 Schematische 
Darstellung der Berechnung 
der „Periodic Repolarization 
Dynamics“: orthogonale 
Frank-Ableitungen (A), 
Winkel zwischen 2 T-Wellen-
Vektoren (B), periodische 
dT°-Anstiege (C), Wavelet-
analyse der periodischen 
dT°-Anstiege (D). 
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Experimentelle Befunde und theoretische 
Überlegungen sprechen jedoch dafür, dass 
PRD die Effekte niederfrequenter sympathi-
scher Entladungen auf die ventrikuläre 
Repolarisation der Kammermuskulatur 
widerspiegelt.
Eine physiologische sympathische Aktivierung 
durch körperliche Belastung oder bei einem 
Kipptischversuch führen bei Gesunden zu einer 
deutlichen Zunahme der PRD. Betablocker sup­
primieren dagegen die PRD. Wie elektrophysiolo­
gische Untersuchungen zeigen konnten, ist die 
PRD  zudem unabhängig von der Herzfrequenzva­
riabilität [9]. 
Auswirkung sympathischer Aktivierung | Sympa­
thische Stimulation verkürzt bekanntlich die 
 Aktionspotenziale der Kardiomyozyten. Unter­
schiedlich stark beeinflusst werden dabei die Zel­
len der einzelnen Schichten des Herzens [10].  So 
verkürzt sympathische Stimulation die Aktions­
potenziale der äußeren Myokardschichten stär­
ker als die der mittleren Myokardschicht. Die T-
Welle des Oberflächen-EKGs ist die integrale 
Repräsentation der Phasen 2 und 3 der Aktions­
potenziale aller Kardiomyozyten. Es ist daher da­
von auszugehen, dass sympathische Aktivierung 
die T-Welle im EKG verändert – wenn auch nicht 
mit bloßem Auge sichtbar. Da efferente sympa­
thische Aktivität am Herzen in niederfrequenten 
Clustern (< 0,1 Hz) auftritt [5], sind sympathisch 
induzierte T-Wellen-Modulationen auch in die­
sem Frequenzbereich zu erwarten. 
„Autonome Narben“ | Eine besondere Situation 
findet sich bei Patienten nach Myokardinfarkt 
oder bei Diabetes mellitus. Bei beiden können 
sich myokardiale Bereiche finden, deren Zellen 
zwar vital, jedoch autonom denerviert sind („au­
tonome Narben“). Diese Zellen können nicht auf 
sympathische Stimulation reagieren, wodurch 
sich die transmurale Dispersion und dement­
sprechend die PRD erhöht.
PRD als Risikoprädiktor nach 
Myokardinfarkt
ISAR-Risk-Studie | Eine gesteigerte ventrikuläre 
Vulnerabilität gegenüber sympathischen Entla­
dungen gilt als ein Hauptfaktor für die Arrhyth­
mogenese nach Myokardinfarkt. Die prognosti­
sche Bedeutung einer erhöhten PRD wurde in der 
ISAR-Risk-Studie an 908 Post-Infarktpatienten 
getestet [9]. Einschlusskriterien waren 
 ▶ ein Herzinfarkt innerhalb der letzten 4 Wo­
chen, 
 ▶ Sinusrhythmus sowie 
 ▶ ein Alter von 80 Jahren oder weniger. 
Bei allen Patienten wurde unter standardisierten 
Bedingungen mittels 30-minütiger Ruhe-EKG-
Aufzeichnung die PRD gemessen. Sie wurden 
über einen Beobachtungszeitraum von 5 Jahren 
nachbeobachtet; primärer Endpunkt war die 
5-Jahres-Mortalität.
Erhöhter PRD-Wert zeigt Risiko | Während des 
Beobachtungszeitraums starben 69 Patienten 
(7,6 %). ▶ Abb. 3 zeigt die dT°-Signale
 ▶ eines Patienten, der überlebt hat (A), sowie 
 ▶ eines Patienten, der einige Monate nach Infarkt 
plötzlich verstorben ist (B). 
In den Signalen beider Patienten sind niederfre­
quente Modulationen sichtbar, die jedoch bei 
dem verstorbenen Patienten deutlich ausgepräg­
ter sind. Dieser Unterschied bestand hochsignifi­
kant in der gesamten Studienpopulation. So be­
trug die PRD bei Überlebenden durchschnittlich 
2,66 deg2 (IQR 3,93), bei Verstorbenen hingegen 
6,67 deg2 (IQR 8,58) (p < 0,0001). Multivariable 
Analysen zeigten, dass der prädiktive Wert von 
PRD unabhängig von dem anderer etablierter Ri­
sikoparameter wie der LVEF, klinischen Markern 
oder dem GRACE-Score war (▶ Tab. 1). Ein erhöh­
Univariable Analysis Multivariable Analysis
Hazard Ratio p Hazard Ratio p
LVEF ≤ 35 % 3,8 (2,2–6,5) < 0,001 2,1 (1,2–3,7) 0,008 
GRACE Score ≥ 120 5,5 (3,2–9,5) < 0,001 3,6 (2,1–6,3) < 0,001 
Diabetes mellitus 2,6 (1,6–4,2) < 0,001 2,1 (1,3–3,4) 0,005 
mittlere HF > 75 / min 2,0 (1,1–3,6) 0,020 1,1 (0,6–2,2) 0,783 
SDNN ≤ 70 s 2,0 (1,2–3,3) 0,007 1,7 (1,0–3,1) 0,072 
QTVI > –0,47 2,5 (1,6–4,2) < 0,001 1,1 (0,7–2,0) 0,688 
PRD ≥ 5,75 deg2 4,8 (2,9–7,7) < 0,001 3,0 (1,8–5,1) < 0,001 
GRACE Score: Global Registry of Acute Coronary Events Score; HF: Herzfre-
quenz; LVEF: linksventrikuläre Ejektionsfraktion; PRD: Periodic Repolarization 
Dynamics; SDNN: Standardabweichung aller Normal-zu-Normal Intervalle; 
QTVI: QT-Variabilitäts-Index
Tab. 1 Uni- und multivariable Analyse für die Prädiktion der 5-Jahres-Mortalität in 908 
Post-Infarktpatienten der ISAR-Risk Studie[9].
Abb. 3 Typische dT°-Signale bei einem Niedrig- (A) und Hochrisikopatienten (B) nach 
Myokardinfarkt. Die Amplitude der Modulationen ist bei dem Hochrisikopatienten 
wesentlich höher [9].
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ter PRD-Wert zeigte dabei ein ähnlich erhöhtes 
Risiko wie eine eingeschränkte LVEF (≤ 35 %) an. 
Hochrisikopatienten identifizieren 
Risiko auch bei LVEF > 35 % | Gegenwärtige Leitli­
nien betrachten Post-Infarktpa tienten mit erhal­
tener oder nur moderat ein geschränkter 
 LV-Funk tion als Niedrigrisikopatienten. Dies ig­
noriert jedoch die Tatsache, dass sich die Mehr­
zahl der  Todesfälle nach Myokardinfarkt in der Pa­
tientengruppe mit LVEF > 35 % ereignet (▶ Abb. 1) 
[2].  Insbesondere auch auf Fälle plötzlichen Herz­
tods trifft dies zu [2]. 
Risikomarker | Um solche Hochrisikopatienten 
zu identifizieren, eignen sich Marker der kardia­
len autonomen Funktion hervorragend. Zielfüh­
rend ist besonders die Kombination verschiede­
ner Marker, die autonome Funktionsstörungen 
auf unterschiedlichen anatomischen und funk­
tionellen Ebenen abbilden. ▶ Abb. 4 zeigt die Ef­
fektivität der Risikostratifizierung mittels der 
Kombination von 
 ▶ PRD und 
 ▶ eines weiteren autonomen Markers, der sog. 
Dezelerationskapazität des Herzens (decelera­
tion capacity, DC) [3]. 
Die DC lässt sich ebenfalls aus einem Kurzzeit-
EKG berechnen und ist ein integrales Maß der 
vagalen Aktivität auf der Ebene des Sinuskno­
tens. 
In der Patientengruppe mit leichtgradig oder 
moderat eingeschränkter LV-Funktion (LVEF 
35–50 %) identifiziert die Kombination aus PRD 
und DC eine neue Hochrisikogruppe.
Deren Prognose unterscheidet sich nicht von der 
von Patienten mit eingeschränkter LV-Funktion 
(LVEF ≤ 35 %). Diese Patientengruppe, die zahlen­
mäßig der Hochrisikogruppe mit LVEF ≤ 35 % ent­
spricht, bleibt in aktuellen Leitlinien jedoch un­
berücksichtigt.
Innovative personalisierte 
Therapieansätze
CARISMA-Studie | Diese Studie erbrachte we­
sentliche Erkenntnisse bezüglich Art und zeitli­
chem Auftreten von Arrhythmien bei Hochrisiko­
patienten nach Myokardinfarkt [4]: Bei 297 
Überlebenden eines akuten Herzinfarkts mit 
LVEF ≤ 40 % wurde ein kardialer Monitor implan­
tiert (implantable cardiac monitor – ICM). Wäh­
rend eines Beobachtungszeitraums von durch­
schnittlich 1,9 Jahren konnte dieser bei 46 % der 
Patienten signifikante arrhythmische Ereignisse 
detektieren. Bemerkenswerterweise waren die 
meisten Arrhythmien primär asymptomatisch 
(86 %). Sie zeigten jedoch ein erhöhtes Mortali­
tätsrisiko an. Insbesondere höhergradige AV-Blo­
ckierungen waren ein starker Mortalitätsprädik­
tor. Bei 28 % der Patienten kam es zum meist 
asymptomatischem Vorhofflimmern. 
Die Ergebnisse der CARISMA-Studie legen 
demnach nahe: Lebensbedrohliche Ereignisse 
bei Hochrisikopatienten nach Myokardinfarkt 
kündigen sich in Form von meist asymptomati-
schen arrhythmischen Ereignissen an.
Diese rechtzeitig zu erkennen, eröffnet ein Fens­
ter für präventive Maßnahmen.
SMART-MI-Studie | Diese in Kürze startende Stu­
die verfolgt diesen Therapieansatz (Implantable 
cardiac monitorS in high­risk post­infarction pa­
tients with cardiac autonoMic dysfunction And 
modeRaTely reduced left ventricular ejection 
fraction; clinicaltrials.gov NCT02594488). Post­
infarktpatienten mit LVEF 35–50 % werden auf 
eine kardiale autonome Dysfunktion getestet. 
Dabei werden Patienten mit abnormaler PRD 
Abb. 4 Risikostratifizierung 
in 908 Postinfarktpatienten 
der ISAR-Risk Studie[9]:
kumulative Mortalitätskur-
ven bei Post-Infarktpatienten 
mit LVEF 35–50 % stratifiziert 
durch die Kombination von 
PRD und DC (A); kumulative 
Mortalitätskurven von 
Postinfarktpatienten mit 
LVEF ≤ 35 % (blaue Kurve) 
sowie von Post-Infarktpatien-
ten mit LVEF 35–50 % und 
abnormaler autonomer 
Funktion (PRD oder DC 
abnormal, rote Kurve) (B).
DC: Deceleration Capacity; 
LVEF: linksventrikuläre 
Ejektionsfraktion; PRD: 
Periodic Repolarization 
Dynamics.
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oder abnormaler DC als Risikopatienten be­
trachtet. Diese werden 1:1 auf die Implantation 
eines ICMs mit telemetrischer Überwachung 
randomisiert. Entdeckt man vordefinierte Ar­
rhythmien, so erfolgt innerhalb von 48 h eine 
spezifische  Intervention – entsprechend defi­
nierter Behandlungspfade im Sinn eines multi­
faktoriellen  Ansatzes. Dies kann z. B. eine orale 
Antikoagula tion im Fall von Vorhofflimmern 
oder eine Ischämiediagnostik im Fall von nicht-
anhaltenden ven trikulären Tachykardien be­
deuten. Bei höhergra digen AV-Blockierungen 
kann eine Schrittmacherimplantation indiziert 
sein, bei anhaltenden ventrikulären Tachykar­
dien eine Ablation oder ICD-Implantation. 
Konsequenz für Klinik und Praxis
 ▶ Der plötzliche Herztod ist eine der 
häufigsten Todesarten in Deutschland. Die 
meisten Patienten haben eine erhaltene 
oder nur moderat reduzierte linksventriku-
läre Funktion.
 ▶ Periodic Repolarization Dynamics (PRD) 
beschreibt niederfrequente Modulationen 
der Repolarisation, die mutmaßlich die 
Empfindlichkeit des ventrikulären 
Myokards auf Sympathikusaktivierung 
widerspiegeln.
 ▶ Nach Myokardinfarkt zeigt eine erhöhte 
PRD ein erhöhtes Mortalitätsrisiko an – 
unabhängig von anderen Risikofaktoren.
 ▶ Die Kombination von Markern der 
autonomen Dysfunktion erlaubt es, eine 
neue Hochrisikogruppe von Post-
Infarktpatienten mit erhaltener linksvent-
rikulärer Funktion abzugrenzen.
 ▶ Eine Biomonitoring-gesteuerte, personali-
sierte Therapie bei Hochrisikopatienten 
mit autonomer Dysfunktion könnte ein 
vielversprechender Ansatz sein.
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Prediction of sudden and non-sudden cardiac
death in post-infarction patients with reduced
left ventricular ejection fraction by periodic
repolarization dynamics: MADIT-II substudy
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Aims To test the value of Periodic Repolarization Dynamics (PRD), a recently validated electrocardiographic marker
of sympathetic activity, as a novel approach to predict sudden cardiac death (SCD) and non-sudden cardiac death
(N-SCD) and to improve identification of patients that profit from ICD-implantation.
...................................................................................................................................................................................................
Methods
and results
We included 856 post-infarction patients with left-ventricular ejection fraction (LVEF) <_30% of the MADIT-II trial
in sinus rhythm. Of these, 507 and 348 patients were randomized to ICD or conventional treatment. PRD was
assessed from multipolar 10-min baseline ECGs. Primary and secondary endpoints were total mortality, SCD and
N-SCD. Multivariable analyses included treatment group, QRS-duration, New York Heart Association classification,
blood-urea nitrogen, diabetes mellitus, beta-blocker therapy and LVEF. During follow-up of 20.4 months, 119 pa-
tients died (53 SCD and 36 N-SCD). On multivariable analyses, increased PRD was a significant predictor of mor-
tality (standardized coefficient 1.37[1.19–1.59]; P < 0.001) and SCD (1.40 [1.13–1.75]; P¼ 0.003) but also predicted
N-SCD (1.41[1.10–1.81]; P¼ 0.006). While increased PRD predicted SCD in conventionally treated patients
(1.61[1.23–2.11]; P < 0.001), it was predictive of N-SCD (1.63[1.28–2.09]; P < 0.001) and adequate ICD-therapies
(1.20[1.03–1.39]; P¼ 0.017) in ICD-treated patients. ICD-treatment substantially reduced mortality in the lowest
three PRD-quartiles by 53% (P¼ 0.001). However, there was no effect in the highest PRD-quartile (mortality
increase by 29%; P¼ 0.412; P < 0.001 for difference) as the reduction of SCD was compensated by an increase of
N-SCD.
...................................................................................................................................................................................................
Conclusion In post-infarction patients with impaired LVEF, PRD is a significant predictor of SCD and N-SCD. Assessment of
PRD is a promising tool to identify post-MI patients with reduced LVEF who might benefit from intensified
treatment.
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Introduction
Current guidelines suggest prophylactic implantation of a cardi-
overter defibrillator (ICD) in post-infarction patients with reduced
left-ventricular ejection fraction (LVEF <_35%).1,2 This class I recom-
mendation is based, among others, on the results of the Multicenter
Automatic Defibrillator Implantation Trial II (MADIT-II),3 which
randomized high-risk post-infarction patients characterized by
reduced LVEF (<_30%) to ICD and non-ICD medical therapy.
Although, ICD-treatment was associated with an overall 31%-reduc-
tion in the risk of death, 17 ICDs had to be implanted to save one
life.3 One important reason might be that a substantial number of pa-
tients in whom sudden cardiac death (SCD) is prevented by ICD-
therapy die from non-sudden cardiac death (N-SCD). Indeed, post-
hoc analyses of the MADIT-II trial showed that patients who survived
an adequate shock for ventricular tachycardia (VT)/ventricular fibril-
lation (VF) were exposed to a markedly 3.4-fold increased risk of
death within 1 year after arrhythmia termination, with a high preva-
lence of N-SCD.4 Early identification of these patients might help to
initiate pre-emptive strategies for prevention and management of
progressive left ventricular dysfunction during long-term follow-up.4
Sympathetic activation is an important compensatory mechanism
of the failing heart, aiming to restore cardiac output. However, during
disease progression sympathetic hyperactivity can become part of
the disease, exerting own deleterious effects on the heart.5 Various
studies demonstrated a strong relationship between the level of sym-
pathetic activation and development of adverse cardiac events,
including both, arrhythmic but also non-arrhythmic complications.
Accordingly, assessment of sympathetic activity in MADIT-II patients
might have an important prognostic meaning.
Periodic Repolarization Dynamics (PRD) is a novel electrocardio-
graphic phenomenon that refers to previously unknown oscillations of
cardiac repolarization instability.6 Those oscillations take place in the low
frequency range (<_0.1Hz), occur independently from underlying heart
rate variability and can be assessed by means of a multipolar high-
resolution resting electrocardiography (ECG). Although the exact mech-
anisms still need to be identified, electrophysiological and other studies
indicated that PRD most likely reflects the effect of phasic sympathetic
activation on the myocardial cells.6 In the Autonomic Regulation Trial
(ART), which included 908 survivors of acute MI, increased PRD was a
highly significant predictor of 5-year mortality, independently from LVEF
and other established risk factors. In that study, however, the vast major-
ity of patients (95%) had LVEF>30%. The prognostic value of PRD in
post-MI patients with LVEF<_30% is currently unknown.
In this work, we therefore tested the prognostic meaning of PRD
in MADIT-II patients and hypothesized that increased PRD is a signifi-
cant predictor of mortality, SCD, and N-SCD. We also hypothesized
that PRD might identify patients that need intensified treatment in
addition to ICD-therapy. We subsequently validated the prognostic
value of PRD in predicting total mortality and cardiac mortality in a
contemporary cohort of post-infarction patients with reduced LVEF.
Methods
Study populations
A cohort of 856 patients of the original MADIT-II population3 were
included in the study. The MADIT-II trial included 1232 patients with
a previous MI and a LVEF <_30%. These patients were randomized to
receive prophylactic ICD implantation or conventional medical ther-
apy in a 3:2 ratio. Screened patients were excluded if they were in
New York Heart Association (NYHA) functional class IV at inclusion;
had a MI within the last month; had undergone coronary revasculari-
zation within the preceding 3 months; had advanced cerebrovascular
or renal disease and suffered from any non-cardiac condition that
was associated with a high likelihood of death during the trial. A 12-
lead ECG recording was acquired at baseline in supine position using
a H12þHolter device (Mortara Instrument Inc., Milwaukee, WI).
This system delivers a high-resolution (1000 Hz), resting continuous
ECG recording at baseline for around 10 min. Mason-Likar lead con-
figuration was used. Medication was not changed prior to ECG-
recording. Of the 1232 patients 330 patients had to be excluded be-
cause no ECG was available. Another 46 patients had to be excluded
because of atrial fibrillation (Figure 1). The protocol was approved by
the ethics committees of each participating centre, and each patient
provided written informed consent before inclusion.
The prognostic value of PRD in post-infarction patients with
reduced LVEF was prospectively validated in a contemporary cohort
of 153 patients who participated in the PRD-MI study (NCT02128477)
and were enrolled at the university of Tuebingen between 10/2010
and 2/2014 (details presented in the Supplementary material online).
Assessment of periodic repolarization
dynamics
For calculation of PRD Mason-Likar leads were transformed into Frank
leads using inverse Dower’s transformation. The technical details of PRD
assessment have been described elsewhere.6 Briefly, X-,Y-, and Z-leads
are converted to a set of polar coordinates defined by two angles (azi-
muth and elevation) and the amplitude Amp. The beginning and ending
of each T-wave are identified using previously published algorithms.7,8
Figure 1 Consort flow-diagram for the MADIT-II population.
Periodic repolarization dynamics in the MADIT-II study 2111
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In a second step, the spatiotemporal characteristics of each T-wave are
mathematically integrated into a single vector T, defined by the so-called
weight-averaged azimuth (WAA) and weight-averaged elevation (WAE):
Weight-averaged Azimuth WAAð Þ ¼
PTend
t¼Tstart
Ampt  Azimuthtð Þ
PTend
t¼Tstart
Ampt
(Equation 1)
Weight-averaged Elevation WAEð Þ ¼
PTend
t¼Tstart
Ampt  Elevationtð Þ
PTend
t¼Tstart
Ampt
(Equation 2)
In a third step, the instantaneous degree of repolarization instabil-
ity is estimated by the angle dT between two successive repolariza-
tion vectors. dT can be calculated as the scalar product of two
successive repolarization vectors T, which by two vectors of the
same length can be simplified by Equation 3.
dT8 ¼ a cos ½sin ðWAE1Þ  cos ðWAA1Þ  sin ðWAE2Þ  cos ðWAA2Þ
þ cos ðWAE1Þ  cos ðWAE2Þ þ sin ðWAE1Þ  sin ðWAA1Þ
 sin ðWAE2Þ  sin ðWAA2Þ
(Equation 3)
The spectral properties of the dT-signal are quantified by means
of continuous wavelet transformation that provides wavelet coeffi-
cients for each scale at each time point. PRD is defined as the average
wavelet coefficient corresponding to frequencies of 0.1 Hz or less.6
Other risk markers
Following risk markers, that have been previously shown to be asso-
ciated with outcome in the MADIT-II population9 were assessed:
LVEF (continuous variable), NYHA functional class >_II, QRS-duration
(continuous variable), diabetes mellitus, treatment with beta-
blockers at the time of ECG and renal dysfunction defined as blood-
urea nitrogen (BUN) level >25 mg/dL. To rule out an interaction with
other repolarization markers we compared PRD to Tpeak-to-Tend
(TpTe), which was calculated from lead V5 as previously described.10
Study endpoints
The primary endpoint of this study was death from any cause. We
also tested secondary endpoints including cardiac mortality, SCD, N-
SCD, appropriate ICD therapy (A-ICD-Rx), the composite endpoint
of SCD and A-ICD-Rx, and the composite endpoint of SCD, N-SCD,
A-ICD-Rx, and acute decompensated heart failure (ADHF). All ana-
lyses were performed according to the intention-to-treat principle.
Statistical analysis
Continuous variables are presented as means with standard devi-
ations and are compared using the Wilcoxon rank sum test.
Categorical data are presented as percentages and are analysed using
the v2 test. Multivariable analyses were implemented by the adapta-
tion of Cox regression models. PRD was included as continuous
marker. All models were adjusted for risk factors as described above.
We used concordance statistic (C-index)11,12 to estimate the general
predictive discrimination of the multivariable models. The coefficients
of continuous variables are expressed in standardized units (increase
per standard deviation [SD]). ICD efficacy was tested in PRD quar-
tiles. Subgroup analyses were performed by means of the regression
technique.13 More specifically, we used interaction terms between
ICD-treatment and PRD, as well as therapy with beta-blockers and
PRD in order to test the predictive power of PRD in the different
subgroups. Internal validation for all endpoints was applied using
bootstrapping (n¼ 500).12,14,15 Correlation between PRD and TpTe
was assessed using Pearson’s correlation coefficient and was com-
pared against zero. Differences were considered statistically signifi-
cant when the two-sided P-value was <0.05. All statistical analyses
were performed using SAS, version 9.4 and CRAN R 3.2.3.
Results
Table 1 shows the demographic and clinical characteristics, as well as
treatment and outcome in the studied MADIT-II population. Mean
age was 63 ± 11 years. Seventeen percent of the patients were fe-
males. Fifty nine percent of the patients were treated with an ICD.
Sixty-four percent were treated with beta-blockers. During a mean
follow-up time of 20.4 (±12.6) months, 119 patients died. One hun-
dred and one deaths were classified as cardiac deaths. Out of them,
53 were classified as SCD and 36 as N-SCD. Twelve cardiac deaths
remained unclassified. One hundred and forty-eight patients were
hospitalized for ADHF.
Association of periodic
repolarization dynamics with
clinical endpoints in the total
population
Table 2 shows the statistical association of risk variables with total
mortality. Periodic repolarization dynamics was significantly higher in
patients who died during the follow-up period than in those who sur-
vived (11.1 ± 7.7 deg2 vs. 8.4 ± 6.2 deg2, P < 0.001). Accordingly,
increased PRD was also a significant predictor of mortality in univari-
able analysis, yielding a HR of 1.38 (standardized coefficient; 95% CI
1.20–1.59; P < 0.001). Figure 2 shows cumulative mortality rates of pa-
tients stratified by PRD-quartiles.
Tables 3 and 4 show the association of PRD with different end-
points in multivariable analyses including established risk markers
(LVEF, NYHA-classification, renal impairment, QRS-duration, treat-
ment with beta-blockers and presence of diabetes mellitus).
Increased PRD was significantly associated with all tested endpoints,
including total mortality (1.37 [1.19–1.59]; P < 0.001), cardiac mortal-
ity (1.39 [1.19–1.63]; P < 0.001), SCD (1.40 [1.13–1.75]; P¼ 0.003),
N-SCD (1.41 [1.10–1.81]; P¼ 0.006) as well as the combination of
SCD, N-SCD, A-ICD-Rx, and ADHF (1.27 [1.15–1.41]; P < 0.001).
2112 K.D. Rizas et al.
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Predictive value of PRD was also independent from that of TpTe (see
Supplementary material online, Table S5). Addition of PRD improved
the predictive power of the multivariable model for prediction of
total mortality (increase of C-index from 0.682 [0.628–0.737] to
0.710 [0.656–0.765]), cardiac mortality (increase of C-index from
0.689 [0.632–0.747] to 0.719 [0.661–0.776]), SCD (increase of C-
index from 0.652 [0.598–0.706] to 0.685 [0.631–0.740]) and N-SCD
(increase of C-index from 0.653 [0.593–0.711] to 0.685 [0.629–
0.742]).
The prognostic value of PRD was internally (see Supplementary
material online, Table S7) and externally validated (see
Supplementary material online, Figure S2 and Table S3). In the external
validation cohort, the prognostic value of PRD in predicting total and
cardiac mortality was comparable to that observed in MADIT-II pa-
tients. Adding PRD to the risk prediction model improved C-statistics
from 0.714 (0.582–0.892) to 0.826 (0.717–0.911) and from 0.807
(0.693–0.904) to 0.889 (0.827–0.942) for prediction of total and car-
diac mortality, respectively.
Association of PRD with clinical
endpoints in conventionally and
ICD-treated patients
The prognostic value of PRD in predicting total mortality was present
in both, the 507 patients randomized to ICD-therapy (1.40 [1.17–
1.67]; P < 0.001) and the 349 patients randomized to conventional
therapy (1.34 [1.06–1.69]; P¼ 0.014). Expectedly, the prognostic
value of PRD in predicting SCD was present only in conventionally
treated patients (1.61 [1.23–2.11], P < 0.001). In ICD-treated patients
increased PRD did not predict SCD (1.09 [0.71–1.68]; P¼ 0.677) but
A-ICD-Rx (1.20 [1.03–1.39]; P¼ 0.017). Confirmatively, in ICD-
treated patients increased PRD also predicted the composite of SCD
and A-ICD-Rx (1.17 [1.01–1.36]; P¼ 0.033) as well as the composite
of all-cause mortality and A-ICD-Rx (1.21 [1.06–1.38]; P¼ 0.004).
On the contrary, PRD was only predictive of N-SCD in ICD-treated
(1.63 [1.28–2.09]; P < 0.001) but not in conventionally treated pa-
tients (0.61 [0.28–1.33]; P¼ 0.213).
Effect of beta-blockers
At the time of the ECG-measurement 64% of the MADIT-II patients
were treated with beta-blockers. PRD was lower in patients treated
with beta-blockers than in those who were not (8.13 ± 5.99 deg2 vs.
9.82 ± 8.41 deg2, P < 0.001). Nevertheless, there was no significant
interaction between PRD and beta-blocker treatment for all tested
endpoints (see Supplementary material online, Table S6).
Mortality reduction by ICD-
treatment according to PRD
values
In the study population, ICD-treatment was associated with a 23.7%
(95% CI 5.1–53.7%; P¼ 0.025) mortality reduction. As shown in
Figures 3 and 4 ICD-efficacy was strikingly different in the different
quartiles of PRD. In the lowest three quartiles, ICD-treatment was
.................................................................................................
Table 2 Statistical association of risk variables with
mortality in the MADIT-II population
Clinical characteristics Survivors Non-survivors P-value
N 737 119
PRD, deg2 (SD) 8.4 (6.2) 11.1 (7.7) <0.001
LVEF, % (SD) 23 (5) 22 (6) 0.003
NYHA classification >_II, n (%) 450 (62) 79 (67) 0.301
Diabetes mellitus, n (%) 247 (34) 51 (43) 0.049
BUN, mg/dL (SD) 21 (10) 29 (17) <0.001
Beta-blockers, n (%) 496 (67) 54 (45) <0.001
QRS duration, sec (SD) 0.11 (0.03) 0.13 (0.03) <0.001
BUN, blood urea nitrogen; LVEF, left-ventricular ejection fraction; NYHA, New
York Heart Association; PRD, periodic repolarization dynamics; SD, standard
deviation.
.................................................................................................
Table 1 Demographic and clinical characteristics, as
well as treatment and outcome in the MADIT-II popula-
tion (n 5 856)
Patients’ characteristics
Age >_65, n (%) 394 (46)
Females, n (%) 144 (17)
White race, n (%) 737 (86)
NYHA classification >_II 529 (63)
LVEF <25%, n (%) 396 (46)
Diabetes mellitus, n (%) 298 (35)
Smoking, n (%) 690 (81)
Arterial hypertension, n (%) 484 (54)
BUN >25 mg/dL, n (%) 220 (26)
QRS Duration >120 ms, n (%) 245 (29)
Treatment
ICD, n (%) 507 (59)
Beta-blockers, n (%) 550 (64)
ACE Inhibitor, n (%) 665 (78)
Diuretics, n (%) 621 (73)
Amiodarone, n (%) 46 (5)
Outcome
Death, n (% 3-year rate) 119 (23)
Cardiac Deaths, n (% 3-year rate) 101 (18)
SCD, n (% 3-year rate) 53 (9)
N-SCD, n (% 3-year rate) 36 (8)
Not-specified, n (% 3-year rate) 12 (3)
Non-cardiac deaths, n (% 3-year rate) 15 (5)
Unclassified deaths, n (% 3-year rate) 3 (1)
VT/VF, n (% 3-year rate) 119 (35)
ADHF, n (% 3-year rate) 148 (26)
ADHF/Death, n (% 3-year rate) 211 (36)
ADHF, acute decompensated heart failure; ACE, angiotensin converting enzyme;
BUN, blood urea nitrogen; ICD, implantable cardioverter defibrillator; LVEF, left-
ventricular ejection fraction; NYHA, New York Heart Association; SCD, sudden
cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia.
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..associated with a marked 52.9% (95% CI 25.0–70.4%) mortality re-
duction (P¼ 0.001;Figures 3A and 4) while in the highest quartile no
net effect of ICD-treatment was observed (non-significant mortality
increase by 28.7% [95%CI -29.6–135.1%]; P¼ 0.412; P < 0.001 for the
difference between PRD Q1–Q3 and Q4; Figures 3B and 4).
Expectedly, ICD-therapy was associated with a reduction of SCD in
all PRD quartiles, which was most pronounced in the lowest three
quartiles (71.2% [95% CI 40.7–86.1%] SCD-reduction in multivariable
analysis; P < 0.001; Figures 3C and 4). In the highest PRD-quartile, a sig-
nificant SCD-reduction was observed in univariable analysis (Figure
3D), which did not reach the level of statistical significance in multi-
variable analysis (53.1% [95% CI -20.0–81.7%] SCD-reduction;
P¼ 0.114; Figure 4).
Discussion
Our findings clearly demonstrate that increased PRD is a significant
predictor of mortality, SCD and N-SCD in MADIT-II patients. The
predictive value of increased PRD was additive to that of established
Figure 2 Cumulative 3-year mortality rates in the MADIT-II population. Patients are stratified by PRD quartiles (PRD Q1 <_4.09 deg2, PRD Q2
4.10–7.27 deg2, PRD Q3 7.28–11.51 deg2, PRD Q4 >_11.52 deg2). Because of low number of patients with follow-up time greater than 3 years,
Kaplan–Meier curves were right-censored at year 3.
.......................................................................... ..........................................................................
....................................................................................................................................................................................................................
Table 3 Multivariable analyses for prediction of total mortality and cardiac mortality in the MADIT-II population
Risk predictors Death Cardiac death
HR (95% CI) X2 P-value HR (95% CI) X2 P-value
Tx with ICD 0.66 (0.46–0.95) 5.0 0.026 0.57 (0.38–0.85) 7.7 0.006
PRD (deg2), per SD 1.37 (1.19–1.59) 17.7 <0.001 1.39 (1.19–1.63) 16.8 <0.001
LVEF (%), per SD 0.91 (0.76–1.09) 1.0 0.313 0.89 (0.73–1.08) 1.4 0.245
NYHA class >_II 1.08 (0.73–1.60) 0.2 0.694 1.16 (0.76–1.78) 0.5 0.500
Diabetes mellitus 1.17 (0.80–1.72) 0.7 0.407 1.25 (0.83–1.89) 1.2 0.281
BUN >25 mg/dl 2.26 (1.54–3.31) 17.2 <0.001 2.24 (1.48–3.39) 14.4 <0.001
Beta-blockers 0.63 (0.44–0.92) 5.8 0.016 0.62 (0.42–0.93) 5.3 0.022
QRS (s), per SD 1.42 (1.19–1.69) 15.2 <0.001 1.42 (1.17–1.71) 12.8 <0.001
BUN, blood urea nitrogen; HR, hazard ratio; ICD, implantable cardioverter defibrillator; LVEF, left-ventricular ejection fraction; NYHA, New York Heart Association; PRD, peri-
odic repolarization dynamic; Tx, Treatment.
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....................................................................................................................................................................................................................
Table 4 Multivariable analyses for prediction of sudden cardiac death and non-sudden cardiac death in the MADIT-II
population
Risk predictors Sudden cardiac death Non-sudden cardiac death
HR (95% CI) X2 P-value HR (95% CI) X2 P-value
Tx with ICD 0.33 (0.19–0.58) 14.5 <0.001 1.41 (0.68–2.91) 0.9 0.351
PRD (deg2), per SD 1.40 (1.13–1.75) 9.1 0.003 1.41 (1.10–1.81) 7.4 0.006
LVEF (%), per SD 0.79 (0.61–1.03) 3.0 0.082 1.22 (0.86–1.74) 1.2 0.266
NYHA class >_II 1.31 (0.72–2.41) 0.8 0.379 1.47 (0.68–3.17) 0.9 0.330
Diabetes mellitus 1.25 (0.71–2.21) 0.6 0.407 1.16 (0.58–2.31) 0.2 0.684
BUN >25 mg/dl 1.71 (0.96–3.06) 3.3 0.070 3.65 (1.79–7.41) 12.8 <0.001
Beta-blockers 0.68 (0.39–1.18) 1.9 0.166 0.63 (0.32–1.25) 1.7 0.189
QRS (s), per SD 1.25 (0.95–1.64) 2.6 0.106 1.61 (1.16–2.22) 8.3 0.004
BUN, blood urea nitrogen; HR, hazard ratio; ICD, implantable cardioverter defibrillator; LVEF, left-ventricular ejection fraction; NYHA, New York Heart Association; PRD, peri-
odic repolarization dynamic; Tx, Treatment.
Figure 3 Effect of ICD therapy on mortality- and sudden cardiac death- reduction (SCD) for different levels of periodic repolarization dynamics
(PRD). (A) In the lowest three quartiles, ICD-treatment was associated with a mortality reduction from 30 to 16% (P¼ 0.003). (B) In the highest quar-
tile no significant effect of ICD-treatment was observed (P¼ 0.853). ICD-therapy was associated with a reduction of SCD in all PRD quartiles (C) In
the lowest three quartiles SCD was reduced from 15 to 5% (P <0.001) and (D) in the highest quartile from 18 to 8% (P¼ 0.049).
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risk factors that have previously been shown to be associated with
outcome in the MADIT-II trial9 and was present in both, convention-
ally and ICD-treated patients. While increased PRD was a significant
predictor of SCD in conventionally treated patients, it was predictive
of N-SCD and adequate ICD-therapy for VT/VF in ICD-treated pa-
tients. There was a significant relationship between PRD-level and
mortality reduction by ICD-therapy. ICD-therapy substantially
reduced mortality by 53.1% in the lowest three PRD-quartiles, while
there was no net effect on mortality reduction in the upper quartile,
as the observed reduction of SCD was outbalanced by a compensa-
tory increase of N-SCD. The prognostic value of PRD in predicting
total and cardiac mortality was externally validated in a contempor-
ary cohort of post-infarction patients with reduced LVEF.
Although the exact mechanisms of PRD need to be identified, pre-
vious studies suggested that PRD most likely reflects the dynamic ef-
fects of sympathetic activity on the ventricular myocardium.6 Phasic
sympathetic activity predominantly takes place in the low-frequency
spectral range16–20 and exerts different effects on the three cell layers
of the ventricular myocardium (epicardial cells, M cells, and endocar-
dial cells).21,22 Thus, adrenergic activation abbreviates the action po-
tential duration (APD) of epicardial and endocardial cells to a greater
degree than the APD of M cells,23 leading to an increased transmural
dispersion of repolarization.24 Consequently, phasic sympathetic acti-
vation induces phasic changes in repolarization localized in the low-
frequency spectral range, which might be captured by PRD. This con-
trasts to static measurements of spatial dispersion of ventricular
repolarization such as TpTe, which showed only a very weak correl-
ation with PRD in the present study (r¼ -0.12). Electrophysiological
studies in healthy individuals showed that pharmacological blockade
of beta-receptors resulted in a striking suppression of PRD, while
physiological sympathetic activation by means of physical stress and
tilt-testing caused a pronounced augmentation of PRD.6 Recently,
Hanson et al. demonstrated oscillatory behaviour of ventricular APD
in the same low-frequency range in heart failure patients.25 Using a
modelling study the same group could show that these low-
frequency oscillations were enhanced by phasic beta-adrenergic
stimulation and phasic mechanical stretch. In the presence of calcium
overload and reduced repolarization reserve, both characteristics of
heart failure, these oscillations predisposed to early afterdepolariza-
tions and arrhythmic events.26
So far, two clinical studies demonstrated a strong link between
increased PRD resting levels and adverse events.6 Periodic repolari-
zation dynamics was evaluated in 908 survivors of acute MI6,27 en-
rolled in the ART as well as in 2965 patients of The Finnish
Cardiovascular Study (FINCAVAS) who underwent a clinically indi-
cated exercise testing.6,28,29 In both cohorts, increased level of PRD
was highly predictive of total mortality as well as cardiovascular mor-
tality, independently from established risk predictors. However, pa-
tients of both cohorts substantially differ from patients of the present
study. Both, the ART- and FINCAVAS-studies included low-risk pa-
tients with generally preserved LVEF (median 53 and 66%, respect-
ively) without prophylactic ICD-indication. This is in contrast to the
current study, which included high-risk patients with severely im-
paired LVEF in the chronic phase of MI.
In the MADIT-II trial ICD-treatment was associated with an overall
31%-reduction of total mortality. However, previous studies indi-
cated that there is considerable risk heterogeneity within the low-
LVEF group, resulting in divergent effects of ICD-therapy on
Figure 4 Effect of ICD therapy on mortality- and sudden cardiac death- reduction (SCD) for different levels of periodic repolarization dynamics
(PRD). Hazard ratios are calculated from multivariable models adjusted for left-ventricular ejection fraction (cont.), New York Heart Association
classification >_ II, diabetes mellitus, blood urea nitrogen >25 mg/dL, treatment with beta-blockers and QRS-duration.
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mortality reduction.9 Previous studies have shown that a substantial
number of patients in whom SCD has been successfully prevented by
ICD-therapy subsequently die from non-sudden cardiac causes.4
Early identification of these patients is crucial for development of
pre-emptive strategies against N-SCD. The results of our study show
that these patients can be identified by PRD. In the present study,
PRD >_11.5 deg2 (fourth quartile) identified 25% of the patients who
had the highest rates of death and SCD. However, although ICD-
treated patients with PRD >_11.5 deg2 also had the highest rates of ap-
propriate ICD-therapies for VT/VF (33.0 vs. 20.6% in the lowest
three quartiles; P¼ 0.004), ICD-treatment did not lead to a survival
benefit in this group of patients due to an outbalancing increase of N-
SCD. Importantly, this group of patients could not be identified by
clinical markers, including age, gender, diabetes mellitus, NYHA-class,
LVEF, renal function and QRS-duration, which were all evenly distrib-
uted (see Supplementary material online, Table S8). These findings
are in line with pathophysiological considerations. It is well known
that sympathetic over-activity predisposes not only to cardiac ar-
rhythmias but also to other unfavourable cardiac conditions, including
progression of heart failure and cardiac decompensation.5,30 In this
context, it is noteworthy that PRD was not only predictive of N-SCD
but also of ADHF. Patients with PRD in the upper quartile had 67%
more ADHF than patients with PRD in the lower three quartiles (see
Supplementary material online, Table S8).
Our findings have important clinical implications for post-MI man-
agement. Thus, PRD might become an important tool to stratify
post-MI patients with reduced LVEF into those who already have a
substantial benefit from prophylactic ICD-treatment (53.1% mortality
reduction by ICD-treatment in patients with PRD <11.5 deg2) and
into those who are at high competing risk of N-SCD and therefore
are in need of additional pre-emptive therapies. Such strategies might
include optimization of heart failure management, better monitoring
and closer follow-up visits. In the studied MADIT-II patients, patients
with high PRD levels were less frequently treated with beta-blockers
(see Supplementary material online, Table S8). Those with high PRD-
levels despite beta-blocker therapy might be undertreated. It is well
known from epidemiological studies that there is a considerable risk-
treatment mismatch in the pharmacotherapy of heart failure, with pa-
tients at greatest risk being least likely to receive ACE-inhibitors and
beta-blockers at optimal doses.31 In previous studies, we have shown
that beta-blocker treatment can reduce PRD6. Therefore, PRD as-
sessment might help to guide individualized beta-blocker therapy.
Our study has several limitations. First, we assessed PRD from 10-
min recordings in Mason-Likar configuration, while in the seminal
study PRD was assessed from 30-min recordings in Frank-leads con-
figuration. Low-frequency oscillations could be underrepresented in
very short-term recordings. Second, patients with atrial fibrillation
were excluded from the study, as is presently unknown whether
PRD can also be applied to patients with atrial fibrillation. Third, ICD-
programming significantly changed over the last decade. We cannot
rule out that optimized ICD-programming with longer detection
intervals might have led to different findings. Fourth, patients of the
MADIT-II trial did not receive medical treatment according to today’s
standards. Fifth, patients in the original MADIT-II trial were followed
up for a relatively short time during the trial (20.4 ± 12.6 months).
Sixth, assessment of treatment effects in PRD-quartiles might be lim-
ited by small sample size. Seventh, the sample size of the validation
cohort was small. Therefore, we were not able to test additional sec-
ondary endpoints. Although we also applied internal and external
validation techniques to confirm our findings, further prospective
studies are needed.
In conclusion, PRD is a significant predictor of mortality and SCD
in the MADIT-II trial. Treatment with ICD reduced SCD-rate at all
levels of PRD. However, in the highest PRD-quartile, there was no
net effect of ICD-therapy on total mortality, as the reduction of SCD
was outbalanced by an increase of N-SCD.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Aim:Most deaths after myocardial infarction (MI) occur in patients with normal ormoderately reduced left ven-
tricular ejection fraction (LVEF N35%). Periodic repolarization dynamics (PRD) and deceleration capacity (DC) are
novel ECG-based markers related to sympathetic and vagal cardiac autonomic nervous system activity. Here, we
test the combination of PRD and DC to predict risk in post-infarction patients with LVEF N35%.
Methods and results:We included 823 survivors of acuteMIwith LVEF N35%, aged ≤80 years and in sinus rhythm.
PRD and DC were obtained from 30-min ECG-recordings within the second week after index infarction and di-
chotomized at established cut-off values of ≥5.75 deg2 and ≤2.5ms, respectively. Patients were classified as hav-
ing normal (CAF 0), partly abnormal (DC or PRD abnormal; CAF 1) or abnormal cardiac autonomic function (DC
and PRDabnormal; CAF 2). Primary endpointwas 5-year all-causemortality.Within thefirst 5 years of follow-up,
51 patients died (6.2%). PRD and DC effectively stratified patients into low-risk (CAF 0; n = 562), intermediate-
risk (CAF 1; n= 193) and high-risk patients (CAF 2; n= 68)with cumulative 5-yearmortality rates of 2.9%, 9.4%
and 25.2%, respectively (p b 0.001). Onmultivariable analyses, CAFwas independent from established risk factors
(GRACE-score, diabetes mellitus, mean heart rate, heart rate variability). Addition of CAF significantly improved
the model (increase of C-statistics from 0.732 (0.651–0.812) to 0.777 (0.703–0.850), p = 0.047; continuous NRI
(0.400, 95% CI 0.230–0.560, p b 0.001); IDI (0.056, 95% CI 0.022–0.122, p b 0.001)).
Conclusion: CAF identifies newhigh-risk post-MI patientswith LVEF N35%whichmight benefit fromprophylactic
strategies.
© 2017 Elsevier B.V. All rights reserved.
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1. Introduction
Survivors of an acute myocardial infarction (MI) face an increased
risk for cardiovascular complications including development of malig-
nant arrhythmias, progression of heart failure, myocardial infarction
anddeath [1].Most preventive strategies such as prophylactic implanta-
tion of a cardioverter defibrillator focus on post-infarction patients with
reduced left ventricular ejection fraction (LVEF ≤35%). However, most
deaths after MI occur in patients in whom left ventricular ejection
fraction is not particularly compromised (LVEF N35%) [1–3]. Accurate
identification of high-risk individuals in post-MI patients with
LVEF N35% is of crucial importance to guide prophylactic interventions
and reduce mortality. This is currently considered to be an unmet clini-
cal need.
Experimental and clinical studies indicated that important prognos-
tic information can be derived from the functional status of the cardiac
autonomic nervous system [4–6]. Sympathetic overactivity and loss of
vagal tone have been independently associated with adverse events
after myocardial infarction [7–9]. Recently, we identified sympathetic-
activity associated low-frequency oscillations of cardiac repolarization
which we termed periodic repolarization dynamics (PRD) [10]. In-
creased PRD has been shown to be associatedwith poor outcome in pa-
tients aftermyocardial infarction and stable coronary artery disease [10]
aswell as in patients with severely impaired LVEF [11]. Deceleration ca-
pacity (DC) of heart rate quantifies predominantly vagally mediated os-
cillations of heart rate, with low DC indicating increased risk of adverse
events [12]. It is plausible to assume that patients with abnormalities of
both branches of the cardiac autonomic nervous system are at highest
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risk. Here, we test the usefulness of a combined risk assessment by
means of PRD and DC in post-infarction patients with LVEF N35%.
2. Methods
2.1. Patients
The present study is a post-hoc analysis of the Autonomic Regulation Trial [13]. The
study included 823 survivors of acute MI with LVEF N35% in sinus rhythm and aged
≤80 years. Fig. S1 shows the flow chart of patient selection. Patients were enrolled at
two university hospitals (German Heart Centre and Klinikum Rechts der Isar, both TU
Munich, Germany) between March 2000 and May 2005; last follow-up was performed
on May 2010. LVEF was assessed by angiography or biplane echocardiography per
Simpson's method within the second week (median 7 days, inter-quartile range (IQR)
5–9 days) after the index MI. The study was approved by the institutional ethical
committee.
2.2. Assessment of DC and PRD
PRD and DC were assessed from 30-min high-resolution (1.600 Hz) resting ECGs
(TMS; Porti System) according to previously published technologies [10,12]. Recordings
were performed within the second week after index infarction in supine position under
standardized conditions. The details of both technologies have been described elsewhere
[10,12,14]. Fig. S2 shows the scheme of DC and PRD calculation.
Briefly, PRD refers to low frequency modulations of cardiac repolarization instability.
To calculate PRD, the spatiotemporal characteristics of each T-wave aremathematically in-
tegrated into a single vector T°, defining themain direction of the T-wave in space. The in-
stantaneous degree of repolarization instability is estimated by the angle dT° between two
successive repolarization vectors. The dT°-signal typically exhibits low-frequency
(≤0.1Hz) oscillations that are quantifiedbymeansof a continuouswavelet transformation
[10].
Computation of DC is based on the transformation of the RR-interval time series by a
novel signal processing technology termed Phase-Rectified Signal Averaging (PRSA). RR
intervals that are longer than their respective preceding RR interval are identified
(so-called anchors). Segments around anchors are averaged to obtain the so-called
PRSA-signal. The PRSA-signal can be considered as a condensed version of the original
RR-interval time series, including all periodic components of heart rate variability related
to decelerations. The central part of the PRSA-signal is quantified by wavelet-analysis to
obtain the numerical measure of DC. Thus, DC is an integral measure of all deceleration-
related oscillations that take place during the observational period [12]. PRD and DC
were dichotomized at established cut-off values, with PRD ≥5.75 deg2 and DC ≤2.5 ms in-
dicating high risk [10,12].
2.3. Classification of cardiac autonomic function (CAF)
According to PRDandDCpatientswere classified in three groups of cardiac autonomic
function (CAF): normal (CAF 0: PRD b5.75 deg2 and DC N2.5 ms), partly abnormal (CAF 1:
PRD ≥5.75 deg2 or DC ≤2.5 ms) and abnormal (CAF 2: PRD ≥5.75 deg2 and DC ≤2.5 ms).
2.4. Other risk markers
Mean heart rate (MHR) and standard deviation of all normal-to-normal intervals
(SDNN) were calculated according to the recommendations of the Task Force of
the European Society of Cardiology and the North American Society of Pacing and
Electrophysiology [15] and dichotomized at previously established cut-off values of
75 bpm and 70 ms, respectively [10,12,16].
We also estimated the GRACE score proposed for the prediction of long-term
prognosis [17]. The GRACE score combines eight factors (age of the patient, heart rate at
admission, systolic blood pressure at admission, Killip classification, serum creatinine at
admission, ST-segment deviation at admission, cardiac arrest at admission, cardiac bio-
marker status at admission). The GRACE score's dichotomy was set at 120, optimizing
the separation between high- and low-risk cases (log-rank optimization) as no indepen-
dent guidance for prospective dichotomy is available.
2.5. Statistical analyses
Continuous variables are presented asmedian and interquartile range, and qualitative
data are expressed as percentages. Primary endpoint was 5-year total mortality. Survival
curves were estimated by the Kaplan-Meier method and compared using the log-rank
test. Multivariable analyses were performed using the Cox proportional-hazards model.
The effects of the factors investigated are given as hazard ratioswith 95% confidence inter-
vals (CI). Tests in the Cox model and log-rank tests were 2-sided. To test the incremental
prognostic value of CAF on top of established risk predictors we implemented C-statistics,
integrateddiscrimination improvement (IDI) score and continuousnet reclassification im-
provement analysis (NRI) [18]. To test for differences between C-statistics, bootstrapping
Table 1
Patients' characteristics.
All patients Patients with
LVEF ≤35%
Patients with LVEF N35% (study population)
All study patients CAF 0 CAF 1 CAF 2 p
Study characteristics
Number of patients, n 908 85 823 562 193 68
Total deaths, n (%) 69 (7.6) 18 (21.2) 51 (6.2) 16 (2.8) 18 (9.3) 17 (25.0) b0.001
Cardiovascular deaths, n (%) 36 (4.0) 11 (12.9) 25 (3.0) 8 (1.4) 9 (4.7) 8 (11.8) b0.001
Patients' characteristics
Median age (IQR), years 61 (17) 64 (16) 61 (17) 58 (17) 65 (16) 68 (10) b0.001
Females, n (%) 174 (19.2) 13 (15.3) 161 (19.6) 107 (19.0) 41 (21.2) 13 (19.1) 0.798
Diabetes mellitus, n (%) 179 (19.7) 22 (25.9) 157 (19.1) 95 (16.9) 41 (21.2) 21 (30.9) 0.015
Median LVEF (IQR), % 53 (15) 30 (13) 54 (14) 55 (15) 53 (14) 51 (14) 0.001
History of prev. MI, n (%) 84 (9.3) 17 (20.0) 69 (8.4) 40 (7.1) 18 (9.3) 11 (16.2) 0.034
NYHA status
NYHA I 860 (93.2) 78 (91.8) 782 (95.0) 543 (96.6) 178 (92.2) 61 (89.7) 0.006
NYHA II 31 (3.4) 5 (5.9) 26 (3.2) 13 (2.3) 10 (5.2) 3 (4.4) 0.120
NYHA III 5 (0.6) 0 (0) 5 (0.6) 2 (0.4) 3 (1.6) 0 (0) 0.145
NYHA IV 12 (1.3) 2 (2.4) 10 (1.2) 4 (0.7) 2 (1.0) 4 (5.9) 0.001
Treatment
PCI, n (%) 848 (93.4) 82 (96.5) 766 (93.1) 534 (95.0) 172 (89.1) 60 (88.2) 0.005
Thrombolysis, n (%) 153 (16.9) 11 (12.9) 142 (17.3) 109 (19.4) 30 (15.5) 3 (4.4) 0.007
CABG, n (%) 17 (1.9) 2 (2.4) 15 (1.8) 7 (1.2) 5 (2.6) 3 (4.4) 0.121
Beta blockers, n (%) 865 (95.3) 85 (100) 780 (94.8) 537 (95.6) 179 (92.7) 64 (94.1) 0.310
CABG, coronary artery bypass graft; CAF, cardiac autonomic function; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.
Table 2
Statistical association of risk variables with 5-year mortality.
Risk variable All patients
(n = 823)
Survivors
(n = 772)
Non-survivors
(n = 51)
p
Age (IQR), years 61 (17) 60 (17) 68 (13) b0.001
Diabetes, n (%) 157 (19.1) 137 (17.7) 20 (39.2) b0.001
GRACE score (IQR) 109 (32) 108 (33) 126 (25) b0.001
LVEF (IQR), % 54 (14) 55 (13) 52 (14) 0.192
DC (IQR), ms 4.9 (4.0) 5.0 (3.9) 2.6 (4.1) b0.001
PRD (IQR), deg2 2.66 (3.98) 2.57 (3.73) 5.84 (7,91) b0.001
CAF 0, n (%) 562 (68.3) 546 (70.1) 16 (31.4) b0.001
CAF 1, n (%) 193 (23.5) 175 (22.7) 18 (35.3) 0.039
CAF 2, n (%) 68 (8.3) 51 (6.6) 17 (33.3) b0.001
MHR (IQR), bpm 64 (11) 63 (12) 70 (13) 0.001
SDNN (IQR), ms 93 (39) 94 (39) 81 (39) b0.001
CAF cardiac autonomic function;DCdeceleration capacity; GRACEGlobal Registry of Acute
Coronary Events; IQR inter-quartile range; LVEF left ventricular ejection fraction; MHR
mean heart rate; PRD periodic repolarization dynamics; SDNN standard deviation of NN
intervals.
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was employed based on the creation of pseudo-replicate data sets by random resampling
of the data set n times for error estimation (n=2000 in this study). Differences were con-
sidered statistically significant when P b 0.05. Statistical analyses were performed using
SPSS (Release 23; SPSS Inc) and CRAN R 3.3.2.
3. Results
The study and patients' characteristics are shown in Table 1. Median
age of the 823 patients was 61 years, 161 patients (19.6%) were female.
766 patients (93.1%) were treated with PCI, 780 (94.8%) received beta-
blockers. During 5 years of follow-up, 51 patients died (6.2%). 25 of
these patients (49%) died due to cardiovascular causes. Among them,
11 (44%) were classified as sudden cardiac death.
Both, PRD and DC were highly significantly associated with 5-year
total mortality (Table 2). Thus, PRD was 2.57 deg2 (IQR 3.73 deg2) in
surviving patients and 5.84 deg2 (IQR 7.91 deg2) in non-surviving pa-
tients (p b 0.001). DC was 5.0 ms (IQR 3.9 ms) in surviving patients
and 2.6 ms (IQR 4.1 ms) in non-surviving patients (p b 0.001).
According to DC andPRD, 562 (68.3%), 193 (23.5%) and 68 (8.3%) pa-
tients were classified as low (CAF 0), intermediate (CAF 1) and high
(CAF 2) risk patients. Patients with CAF 1 had abnormal PRD in 61.1%
of the cases and abnormal DC in 38.9% of the cases.
On univariable Cox regression analysis, presence of CAF 2 was the
strongest predictor of mortality, yielding a hazard ratio of 9.9 (95%
CI 5.0–19.6; p b 0.0001) (Table 3A). Cumulative 5-year mortality rates
of patients with CAF 0, 1 and 2 were 2.9%, 9.4% and 25.2%, respectively
(Fig. 1A; p b 0.001). Fig. 1B comparatively shows cumulative 5-year
mortality rates of patients with LVEF ≤35% who were enrolled during
the same time period but not included in the present study. Of note,
the mortality rate of patients with CAF2 and LVEF N35% was not
statistically different from that of patients with LVEF ≤35% (25.2% vs.
21.3; p = 0.671).
We used two different models to test the independent contribution
of the different risk markers to prediction of 5-year all-cause mortality
(Table 3B): Model 1 shows the multivariable Cox regression model
including PRD ≥5.75 deg2 and DC ≤2.5 ms as separate variables. Both,
PRD ≥5.75 deg2 and DC ≤2.5 ms were independently associated
with the primary endpoint, yielding hazard ratios of 2.4 (1.4–4.4; p =
0.003) and 2.6 (1.4-4.8; p = 0.002), respectively. Model 2 shows
the multivariable Cox regression model using the combination of PRD
and DC by means of CAF. CAF2 indicated the highest hazard ratio of
6.4 (3.1-13.2; p b 0.001) of all markers tested.
Adding CAF to the risk model led to a significant increase of
C-statistics from 0.732 (0.651–0.812) to 0.777 (0.703–0.850; p = 0.047
for difference), continuous NRI (0.400, 95% CI 0.230–0.560, p b 0.001)
and IDI (0.056, 95% CI 0.022–0.122, p b 0.001).
4. Discussion
In the present study,we used the combination of two autonomic risk
markers to stratify patients after myocardial infarction with normal or
moderately reduced LVEF. The findings of our study indicate that prev-
alence of CAF 2, reflecting abnormalities in both branches of the cardiac
autonomic nervous system, is 8% among survivors of acuteMIwith LVEF
N35% who underwent primary PCI and received up-to-date treatment.
Abnormalities in at least one branch of the autonomic nervous systems
could be detected in 32% of the cases. Patients with CAF 2 had theworst
Table 3A
Univariable Cox regression analysis of the association of risk markers with 5-year all-cause mortality.
Univariable Cox regression
Risk variable HR (95% CI) p Risk variable HR (95% CI) p
CAF 1 vs. CAF 0 3.4 (1.7–6.7) b0.001 GRACE score ≥ 120 4.2 (2.4–7.5) b0.001
CAF 2 vs. CAF 0 9.9 (5.0–19.6) b0.001 Diabetes 2.9 (1.7–5.1) b0.001
DC (≤2.5 ms) 4.9 (2.9-8.6) b0.001 Sex (female) 1.6 (0.9–2.9) b0.001
PRD (≥5.75 deg2) 4.1 (2.4–7.1) b0.001 MHR (N75/min) 2.2 (1.1–4.3) 0.022
LVEF (≤45%) 1.6 (0.8-3.0) 0.171 SDNN (≤70 ms) 2.3 (1.3–4.1) 0.005
Fig. 1. Risk stratification by CAF and LVEF: Panel A: cumulative mortality curves for patients with LVEF N35% stratified by CAF 0, 1 and 2 (green, yellow and red curves, respectively).
Panel B: cumulative mortality curve of all patients with LVEF N35% (actual study population, black curve). For comparison, mortality rate of the 85 excluded patients with LVEF ≤35% is
shown (grey curve). CAF, cardiac autonomic function; LVEF, left ventricular ejection fraction.
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prognosis with an estimated 5-year mortality rate of 25.2% which is
comparable to that of patients with severely reduced LVEF (≤35%).
Multivariable analyses revealed that both components of CAF, PRD
and DC independently contributed to risk prediction. This can be ex-
plained by the fact that both, PRD and DC assess complimentary proper-
ties of cardiac autonomic function, linked to sympathetic and vagal
modulations, respectively. Similar combinations have been proven suc-
cessful for risk stratification in other diseases such as the long-QT syn-
drome [19]. While assessment of vagal control of the heart by means
of heart rate variability is well established, assessment of sympathetic
influences on the ventricles has always remained challenging. The
analysis of repolarization variability might, to some degree, provide a
solution for this problem. In an elegant study, Porta and colleagues
mathematically separated repolarization variability into components
related and unrelated to RR-interval and respiration variability [20]. It
could be demonstrated that increasing sympathetic activation by
gradual tilt testing lead to an augmentation of RR-interval and respira-
tion unrelated repolarization variability. PRD substantially differs from
global markers of repolarization variability such as QT-variability
index as it specifically captures periodic components of T-vector vari-
ability in the low frequency range that occur independently from
heart rate variability and respiration [10]. Electrophysiological studies
indicated that on the cellular level PRD corresponds to phasic changes
of ventricular action potential duration [21]. Although the exact physio-
logicalmechanisms of PRD still need to be identified it ismost likely that
PRD reflects the effect of phasic sympathetic activation on the ventricu-
larmyocardium. It has been shown that PRD can be suppressed by beta-
blockers while physiological activation of the sympathetic nervous sys-
tem by exercise or tilt testing augments PRD [10]. Recent studies using
computer models integrating ventricular electrophysiology, calcium
dynamics,mechanics and beta-adrenergic signaling indicated that addi-
tional synergistic mechanisms might be involved in the genesis of PRD
[22]. In addition to phasic sympathetic activation PRD is also enhanced
by phasic changes of hemodynamic loading, a phenomenon which is
known to accompany sympathetic overactivity. Of interest, increased
PRD could also be linked to calciumoverload and reduced repolarization
reservewhich are known to be associatedwith increased risk of adverse
events [22].
DC quantifies deceleration-related oscillations of heart rate and is a
measure of vagal activity at the level of the sinus node [12]. DC inte-
grates the amplitudes of heart rate oscillations driven by different
mechanisms including respiratory activity, baroreflex activity and hu-
moral mechanisms. Thus, DC is an integral measure of autonomic
vagal activity and not linked to a specific physiological process [12].
Both markers, PRD and DC, have been shown to be strong predictors
of mortality after myocardial infarction in different cohorts [11,12,23],
but their combined use has not been studied so far.
The results of our study demonstrate that CAF 2 identifies a
new high-risk group among post-infarction patients with LVEF N35%
which is comparable with respect to size and prognosis to that of pa-
tients with severely reduced LVEF (≤35%). Also, patients with CAF 1
are at a 3.4-fold increased risk of 5-year mortality compared to patients
without autonomic abnormalities. These patients are currently not ad-
dressed by specific guideline recommendations but might benefit
from prophylactic interventions [24]. The ongoing randomized multi-
center Implantable Cardiac Monitors in High-Risk Post-Infarction Patients
with Cardiac Autonomic Dysfunction trial (SMART-MI; NCT02594488)
tests a holistic preventive strategy in this high-risk group of patients
[25]. High-risk post-infarction patients with LVEF 36-50% and abnormal
PRD and/or DC are randomized in a 1:1 fashion to implantation of a car-
diac monitor (ICM) including remote monitoring or conventional
follow-up. In the experimental group, pre-defined arrhythmias trigger
diagnostic and therapeutic treatment paths that might include optimi-
zation of medical treatment, revascularization, ablation or device im-
plantation. This concept is based on the results of the CARISMA study
which showed that most arrhythmias after MI are asymptomatic but
can indicate a substantially increased risk of future adverse events [26].
The limitations of our study need to be recognized. First, the findings
of our study are restricted to patients in sinus rhythm and aged
≤80 years. Second, autonomic markers were assessed relatively shortly
after indexMI. Third, several riskmarkers including T-wave alternans or
baroreflex sensitivity have not been assessed in our study. Forth, prima-
ry endpoint was total mortality. Although total mortality is themost ro-
bust and unbiased endpoint, the association with arrhythmic mortality
might be lost. Finally, findings of our study should be validated by pro-
spective studies.
In conclusion, the combined assessment cardiac autonomic function
by means of PRD and DC is a promising approach to identify high-risk
individuals after MI with LVEF N35%. Whether risk stratification trans-
lates into risk reduction needs to be tested by future interventional
studies such as the ongoing SMART-MI trial.
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Background: Identification of new risk markers in aortic valve stenosis (AS) is of great interest. Here, we hypoth-
esized that the presence of severe autonomic failure (SAF) is an important prognosticmarker in both, symptom-
atic patients undergoing invasive treatment for severe AS, and in asymptomatic patients with severe AS who
were primarily treated conservatively.
Methods: We prospectively enrolled 300 patients with severe AS (aortic valve area b1.0 cm2 or mean aortic
gradient N40 mm Hg) in sinus rhythm. All patients underwent a 24-h Holter recording for assessment of heart
rate turbulence (HRT) and deceleration capacity (DC). Patientswith both, abnormalDC andHRTwere considered
to suffer from SAF.
Results: The first hypothesis was tested in 216 symptomatic patients who underwent successful aortic valve re-
placement (AVR) or transcatheter aortic valve implantation (TAVI). During follow-up of 2 years, 29 of these pa-
tients died. SAF was the strongest independent predictor of mortality (hazard ratio 5.6, 95% confidence interval
2.6–12.0; p b 0.001) with 2-year mortality rates of 50.0% and 10.7% in SAF-positive and SAF-negative patients,
respectively (p b 0.001). The second hypothesis was tested in 71 patients, who were asymptomatic at study
entry and forwhom a primarily conservative treatment strategywas proposed. During follow-up, 10 of these pa-
tients died. SAF also predicted death in asymptomatic patients with 2-year mortality rates of 52.4% and 8.7% in
SAF-positive and SAF-negative patients, respectively (p = 0.010).
Conclusions: SAF is a strong and independent predictor of mortality in symptomatic and asymptomatic patients
with severe AS.© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Aortic valve stenosis (AS) is themost common type of valvular heart
disease in the industrialized world and affects up to 7% of the general
population age 65 years and over [1,2]. The natural prognosis of AS
varies widely, ranging from rather favorable to deleterious. Therefore,
accurate risk assessment is crucial for the selection of the best treatment
strategy in the individual patient. According to current guidelines, inva-
sive treatment of severe AS is usually delayed until symptoms occur
[3–5]. However, this “wait for symptoms” strategy can be dangerous,
as the symptomatic status cannot be reliably assessed in many patients.
Hence, novel markers that allow for objective and unbiased estimation
of patient risk are of great general interest.d Poliklinik I, Marchioninistr.
.
Assessment of cardiac autonomic function provides important in-
sights into the regulatory properties of the cardiovascular system.
Markers of cardiac autonomic dysfunction are strong predictors of mor-
tality in post-infarction [6] andheart failure patients [7], yielding indepen-
dent prognostic information from left ventricular ejection fraction (LVEF)
and NYHA class. Alterations of cardiac autonomic function have also been
reported in AS [8] but their prognostic meaning is largely unknown.
Here, we hypothesized that cardiac autonomic dysfunction is an im-
portant prognosticmarker in patients with severe AS.We used a combi-
nation of two established Holter-based risk predictors to assess
autonomic function. Heart rate turbulence (HRT) [9] quantifies the
baroreflex-mediated short-term oscillation of the heart rate following
ventricular premature complexes (VPCs). Deceleration capacity (DC)
[10] is considered to be representative of tonic vagal activity. Combined
abnormalities of HRT andDC have been defined as “severe cardiac auto-
nomic failure” (SAF) [6] and have shown to indicate poor prognosis in
post-infarction patients [6]. We tested two different hypotheses: SAF
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treatment for severe AS, as well as in (2) asymptomatic patients with
severe AS who were primarily treated conservatively at study entry.
2. Methods
2.1. Recruitment and follow-up
We prospectively studied consecutive patients with severe AS who were referred
from September 2009 toNovember 2012 for evaluation of therapeutic options at a tertiary
university center. Patients were included if aortic valve area (AVA) was b1.0 cm2, mean
aortic gradient was N40 mm Hg or jet velocity was N4.0 m/s, confirmed either invasively
or by echocardiography. Patients were excluded if they were not in sinus rhythm, if they
had an acute coronary syndrome or significant coronary artery stenosis requiring revascu-
larization b4 weeks, if an additional significant valve lesion was present or if the patient's
life expectancy was assumed to be less than one year because of non-cardiac diseases.
Therapeutic options for every patient were discussed at a weekly interdisciplinary
conference of cardiologists and cardiac surgeons, who were not involved in the study.
All recommendations (medical treatment, aortic valve replacement (AVR), transcatheter
aortic valve implantation (TAVI)) were based on current guidelines [3–5]. The local ethics
committee approved the study. Every patient gave written informed consent.
2.2. Assessment of severe autonomic failure
At enrollment, all patients underwent 24-h Holter recordings (Cardio CM 3000,
Getemed, Teltow, Germany) for assessment of HRT and DC. An experienced technician
blinded to the patient's clinical status manually reviewed and processed all recordings
using standard commercial equipment (CardioDay, Getemed, Teltow, Germany) to obtain
the sequence of individual R–R intervals together with beat classification (sinus beat, VPC,
artifact).
HRT and DC were calculated according to previously published technologies using
established cut-off values by use of customized and validated software [9–11]. Briefly,
HRT quantifies the baroreflex-mediated short-term oscillation of the cycle lengths follow-
ing ventricular premature complexes [9]. The oscillation is composed of an initial acceler-
ation of heart rate followed by a gradual deceleration of heart rate. The two phases of HRT
are quantified by two numerical parameters, turbulence onset and turbulence slope. Tur-
bulence onset is calculated as:
TO ¼ RR1 þ RR2ð Þ− RR−2 þ RR−1ð Þ
RR−2 þ RR−1ð Þ
 100 %½ 
where RR−2 and RR−1 are the two RR intervals immediately preceding the VPC coupling
interval, and RR1 and RR2 are two RR intervals immediately following the compensatory
pause [11]. Turbulence slope is defined as themaximumpositive regression slope assessed
over any 5 consecutive sinus rhythmR–R intervals within the first 15 sinus rhythmRR in-
tervals after the VPC [11]. Hence, in normal subjects, the initial brief acceleration of sinus
rate after the VPC is characterized by negative TO, and the subsequent rate deceleration
is characterized by positive TS.
DC quantifies themean amplitude of all deceleration-related oscillations of heart rate
observed in the recording period [10]. Assessment of DC is based on a new signal process-
ing algorithm termed phase-rectified signal averaging (PRSA) which is capable of
extracting periodic components out of non-stationary, noisy signals [12]. Briefly, the tech-
nique consists of five steps. In the first step, RR intervals are identified which are longer
than their preceding intervals. In order to exclude artifacts, RR-intervals that are longer
than 105% of the preceding RR-interval are excluded. These RR-intervals are called an-
chors. In the second step, segments around anchors are defined. Please note that segments
surrounding adjacent anchors may overlap. In the third and fourth steps, segments are
aligned at the anchors and subsequently averaged. The so-called PRSA-signal is quantified
by Haar-wavelet analysis [10]:
DC ¼ 1
.
4
 x0 þ x1−x−1−x−2ð Þ
where x0 and x1 are the averages of the anchors and the following RR-intervals, while x−1
and x−2 are the averages of the two RR-intervals preceding the anchors.
In line with previous investigations, patients with combined abnormalities of HRT
(turbulence onset ≥0% and turbulence slope ≤2.5 ms/RR interval) and DC (≤4.5 ms)
were considered to have SAF [6,13].
2.3. Conventional risk predictors
In all patients, peak and mean aortic gradient, AVA, and LVEF were assessed. In pa-
tients who underwent left and right heart catheterization, hemodynamic variables were
obtained invasively, as follows: LVEF obtained by the area-length method from a single-
plane right anterior oblique projection [14] and AVA calculated using the Gorlin formula
[15]. In patients in whom no catheterization was performed, hemodynamic variables
were obtained by echocardiography (iE33, Philips Medical Systems). In these patients,
LVEF was assessed by the modified Simpson rule with images obtained from apical 4-
and 2-chamber views. AVA was estimated by the continuity equation using the veloci-
ty–time integral of the aortic and left ventricular outflow tract flows.The presence of chronic obstructive pulmonary disease (COPD) was defined by long
term use of bronchodilators or steroids for lung disease. Extracardiac arteriopathy was
considered present if the patient suffered from claudication, carotid occlusion or N50%
stenosis, previous or planned intervention on the abdominal aorta, limb arteries or ca-
rotids. Neurological dysfunction was defined as a neurological disease severely affecting
ambulation or day-to-day functioning. Renal insufficiency was considered present if
serum creatinine was N200 μmol/l. Systolic pulmonary artery pressure (PAPsys) was
assessed by continuous wave Doppler echocardiography based on tricuspid pressure gra-
dient by adding mean right arterial pressure estimated from inferior vena cava diameter
and motion during respiration. The presence of pulmonary hypertension was considered
present if PAPsys was N60 mm Hg. Based on these and other risk factors, the logistic
EuroSCORE was calculated as previously described [16].
Brain natriuretic peptide (BNP) levelswere assessed by immunoassay at study enroll-
ment (ADVIA Centaur® BNP assay, Siemens Healthcare Diagnostics). In 88 patients, N-
terminal proBNP (Nt-proBNP) was assessed instead of BNP (Immulite 2000, Siemens
Healthcare Diagnostics) because of a change in hospital laboratory standards. In 59 symp-
tomatic and 35 asymptomatic patients, neither BNP nor Nt-proBNP levels were available.
BNP and Nt-proBNP were dichotomized at 550 pg/ml [17] and 4691 pg/ml [18], respec-
tively. Patients with BNP ≥550 pg/ml or Nt-proBNP ≥4691 pmol/l were classified as
being BNP positive.
2.4. Study endpoints
The primary endpoint was total mortality within the first 2 years of follow-up; the
secondary endpoints were cardiac mortality as well as the composite of cardiac mortality
and hospitalization resulting from decompensated heart failure within the first 2 years of
follow-up. If a patient died during follow-up, the cause of deathwas verified fromhospital
and autopsy records and from either the primary physician or those witnessing the death.
An independent endpoint committee adjudicated themode of death. Deathswere catego-
rized as cardiac and non-cardiac. Patients who were asymptomatic at study entry but
underwent AVR or TAVI during follow-upwere censored at the date of invasive treatment.
2.5. Statistical analysis
Continuous variables are presented as median and IQR and were compared using the
Mann–Whitney U test. Qualitative data are expressed as percentages and were analyzed
using the chi-square test. The relations of risk variables to the primary and secondary end-
points were investigated with the use of Cox proportional-hazards models. The propor-
tional hazard assumption of the various parameters was investigated by using
Schoenfeld residuals. Multivariable Cox regression analysis was adjusted for age and gen-
der. Continuous variableswere dichotomized at themedian.Mortality rateswere estimat-
ed by the Kaplan–Meier method. Hazard ratios (HRs) are presented with 95% confidence
intervals (CIs). Differences were considered statistically significant if p b 0.05. Statistical
analyses were performed using SPSS 20.0.
3. Results
During recruitment period, 678 patients presented for evaluation of
AS. 300 patients fulfilled the inclusion criteria. Of these, 229 and 71
patients were classified as being symptomatic and asymptomatic,
respectively (Fig. 1).
3.1. Prognostic value of SAF in symptomatic patients undergoing AVR or
TAVI
The first hypothesis was tested in 216 of the 300 patients, whowere
classified as being symptomatic at study entry andwho underwent suc-
cessful AVR (n = 61) or TAVI (n = 155) 16 (median, IQR 3–48) days
after enrollment. Patients were aged 79 (73–84) years and 110
(50.5%) were women. AVA was 0.7 (0.5–0.8) cm2 and LVEF was 55
(45–60) (Table 1). 32 of the 216 patients (14.8%) were SAF-positive.
During a median follow-up of 450 (IQR 184–739) days, 29 patients
(13.4%) died.
SAF was highly significantly associated with the primary endpoint.
The 32 SAF-positive patients had a cumulative 2-year mortality rate of
50.0% compared to 10.7% in the 184 SAF-negative patients (p b 0.001;
Table 2, Fig. 2A). SAF was also highly significantly associated with the
secondary endpoints including cardiac deaths and the composite of car-
diac deaths and heart failure-related hospitalizations (Table 2, Fig. 2B).
Multivariable analysis revealed that SAF was the strongest predictor of
mortality (hazard ratio of 5.6, 95% CI 2.6–12.0; p b 0.001)whichwas in-
dependent of elevated serum levels of BNP (hazard ratio of 2.7, 95% CI
1.2–5.9; p = 0.013) and other risk factors (Table 3).
Fig. 1. Flow chart of patient selection.
Table 1
Baseline characteristics of the 216 symptomatic patients, who underwent successful AVR or TAVI.
All patients (n = 216) Survivors (n = 187) Non-survivors (n = 29) p value
Demographics
Age (years, IQR) 79 (73–84) 79 (73–83) 82 (75–87) 0.160
Females (%) 109 (50.5%) 90 (48.1%) 19 (65.5%) 0.081
Diabetes mellitus (%) 75 (34.7%) 65 (34.8%) 10 (34.5%) 0.977
Arterial hypertension (%) 169 (78.2%) 146 (78.1%) 23 (79.3%) 0.881
Coronary artery disease (%) 133 (61.6%) 117 (62.6%) 16 (55.2%) 0.446
AVA (cm2, IQR) 0.7 (0.5–0.8) 0.7 (0.5–0.8) 0.7 (0.6–0.8) 0.811
p mean (mm Hg) 43 (33–52) 43 (33–53) 39 (32–46) 0.176
Risk variables
COPD (%) 20 (9.3%) 18 (9.6%) 2 (6.9%) 0.637
Extracardiac arteriopathy (%) 22 (10.2%) 19 (10.2%) 3 (10.3%) 0.976
Neurological dysfunction (%) 17 (7.9%) 14 (7.5%) 3 (10.3%) 0.708
Renal insufficiency (%) 69 (31.9%) 54 (28.9%) 15 (51.7%) 0.014
Previous MI (%) 16 (7.4%) 13 (7.0%) 3 (10.3%) 0.457
PAPsys ≥60 mm Hg (%) 14 (6.5%) 11 (5.9%) 3 (10.3%) 0.409
LVEF (%, IQR) 55 (45–60) 55 (45–60) 55 (43–60) 0.504
BNP (pg/ml, IQR) 258 (118–781) 236 (108–617) 815 (237–1389) 0.018
Nt-pro BNP (pg/ml, IQR) 2083 (671–8912) 2406 (694–8971) 838 (412–5401) 0.277
Logistic EuroSCORE (%, IQR) 11.4 (6.3–20.6) 11.3 (5.8–19.8) 14.5 (9.2–36.2) 0.023
SAF 32 (14.8%) 18 (9.6%) 14 (48.3%) b0.001
Medication
β-Blockers (%) 158 (73.1%) 139 (74.3%) 19 (65.5%) 0.319
ACEIs/ARBs (%) 177 (81.9%) 154 (82.4%) 23 (79.3%) 0.692
MRAs (%) 87 (40.3%) 72 (38.5%) 15 (51.7%) 0.177
Statins (%) 169 (78.2%) 147 (78.6%) 22 (75.9%) 0.739
ACEI— angiotensin-converting enzyme inhibitor, ARB — angiotensin receptor blocker, AVA — aortic valve area, BNP — brain natriuretic peptide, COPD— chronic obstructive pulmonary
disease, IQR— interquartile range, LVEF— left ventricular ejection fraction, MI—myocardial infarction, MRA—mineralocorticoid receptor antagonist, PAPsys — systolic pulmonary artery
pressure, and SAF — severe cardiac autonomic failure.
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Table 2
Endpointswithin 2 years in the 216 symptomatic patientswhounderwent successful AVR
or TAVI.
All patients
(n = 216)
SAF-negative
(n = 184)
SAF-positive
(n = 32)
p
value
Primary endpoint
All deaths (%) 29 (13.4) 15 (8.2) 14 (43.8) b0.001
Secondary endpoints
Cardiac deaths (%) 20 (9.3) 10 (5.4) 10 (31.3) b0.001
Cardiac deaths &
HF-related hospi-
talizations (%)
37 (17.1) 24 (13.0) 13 (40.6) b0.001
AVR — aortic valve replacement, HF — heart failure, SAF — severe cardiac autonomic fail-
ure, and TAVI — transcatheter aortic valve implantation.
Table 3
Univariable and multivariable regression analyses for prediction of all-cause mortality in
the 216 symptomatic patients who underwent successful AVR or TAVI.
Univariable analysis Multivariable analysis
Variable Hazard ratio
(95% CI)
p value Hazard ratio
(95% CI)
p value
Logistic EuroSCORE ≥11% 4.5 (1.4–14.8) 0.014 2.8 (0.8–9.8) 0.098
BNP positive 2.1 (1.0–4.5) 0.041 2.7 (1.2–5.9) 0.013
Mean gradient ≥43 mm Hg 0.6 (0.3–1.2) 0.142 0.5 (0.2–1.2) 0.125
AVA ≤0.7 cm2 1.2 (0.6–2.7) 0.590 1.5 (0.7–3.5) 0.322
SAF 6.4 (3.1–13.2) b0.001 5.6 (2.6–12.0) b0.001
AVA— aortic valve area, AVR— aortic valve replacement, BNP— brain natriuretic peptide,
CI— confidence interval, SAF— severe cardiac autonomic failure, and TAVI— transcatheter
aortic valve implantation. Continuous variables were dichotomized at the median.
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tomatic at study entry, refused invasive treatment.3.2. Prognostic value of SAF in asymptomatic patients
The second hypothesis was tested in 71 of the 300 patients, who
were classified as being asymptomatic at study entry and for whom a
primarily conservative treatment strategy was proposed. Patients
were aged 74 (68–81) years, 33.8% were women, AVA was 0.9
(0.7–0.9) cm2 (Table 4). All patients had normal LVEF. Of the 71
patients, 12 (16.9%) were SAF positive. During a median follow-up of
439 (IQR 132–838) days, 15 patients (21.1%) developed symptoms
and underwent AVR or TAVI 5.2 ± 4.1 months after enrollment. These
patients were censored at the time of interventions. Ten of the 71
patients died before they underwent invasive treatment. SAF also
predicted death in the 71 asymptomatic patients (p = 0.010), with
estimated 2-year mortality rates of 52.4% and 8.7% in SAF-positive and
SAF-negative patients, respectively (Table 5, Fig. 3A). SAFwas also high-
ly significantly associated with the secondary endpoints including
cardiac deaths and the composite of cardiac deaths and heart failure-
related hospitalizations (Fig. 3B).Fig. 2. Cumulative event rates of symptomatic patients with severe aortic stenosis who under
presence of severe cardiac autonomic failure (SAF). (A) Primary endpoint (all-cause mortality
decompensated heart failure).4. Discussion
Our findings demonstrate that SAF is a novel and powerful predictor
of mortality in patients with severe AS. SAF predicted mortality in both
symptomatic patients who underwent invasive treatment as well as
asymptomatic patients who were primarily treated conservatively. In
symptomatic patients, the predictive value of SAF was independent
from established risk factors, including the logistic EuroSCORE and BNP.
Risk stratification in AS is an important clinical problem as it is cru-
cial for treatment decision and timing of intervention in patients sched-
uled for operation. In every individual patient with AS, the patient's
natural outcome under a conservative treatment strategy needs to be
balanced against the combined risks of intervention and late complica-
tions of the prosthesis. Prognosis in asymptomatic patients is assumed
to be favorable [19–21], and intervention is thus often delayed until
symptoms occur. However, for several reasons, many physicians feel
uncomfortable about a “wait for symptoms” strategy [22]. First, dichot-
omization of patients according to their symptomatic status is problem-
atic because the disease is better described by a continuous spectrum.
Concerns arise particularly in patients with mild or nonspecific symp-
toms, patients who are limited by comorbidities, and elderly patients
who are frequently used to adapting their activities to their currentwent aortic valve replacement or transcatheter aortic valve implantation stratified by the
) and (B) secondary endpoint (composite of cardiac mortality and hospitalizations due to
Table 4
Baseline characteristics of the 71 asymptomatic patients.
All patients (n = 71) Survivors (n = 61) Non-survivors (n = 10) p value
Demographics
Age (years, IQR) 74 (68–81) 73 (68–80) 75 (71–82) 0.472
Females (%) 24 (33.8%) 22 (36.1%) 2 (20%) 0.477
Diabetes mellitus (%) 21 (29.6%) 16 (26.2%) 5 (50%) 0.148
Arterial hypertension (%) 48 (67.6%) 41 (67.2%) 7 (70%) 0.861
Coronary artery disease (%) 38 (53.5%) 31 (50.8%) 7 (70%) 0.320
AVA (cm2, IQR) 0.9 (0.7–0.9) 0.9 (0.7–0.9) 0.9 (0.7–1.0) 0.857
p mean (mm Hg) 31 (24–43) 31 (24–43) 34 (16–50) 0.987
Risk variables
COPD (%) 1 (1.4%) 1 (1.6%) 0 (0%) 0.683
Extracardiac arteriopathy (%) 9 (12.7%) 5 (8.2%) 4 (40%) 0.019
Neurological dysfunction (%) 5 (7.0%) 4 (6.6%) 1 (10%) 0.543
Renal insufficiency (%) 23 (32.4%) 18 (29.5%) 5 (50%) 0.275
Previous MI (%) 17 (23.9%) 12 (19.7%) 5 (50%) 0.052
PAPsys ≥60 mm Hg (%) 1 (1.4%) 0 (0%) 1 (10%) 0.141
LVEF (%, IQR) 55 (50–60) 55 (50–60) 50 (39–55) 0.004
BNP (pg/ml, IQR) 164 (65–424) 123 (54–293) 386 (125–802) 0.097
Nt-pro BNP (pg/ml, IQR) 2086 (356–7714) 2086 (208–11233) 2493 (771–9987) 1.000
Logistic EuroSCORE (%) 7.1 (3.7–14.4) 6.7 (3.6–13.2) 12.9 (5.9–32.2) 0.048
SAF 12 (16.9%) 6 (9.8%) 6 (60%) 0.001
Medication
β-Blockers (%) 45 (63.4%) 40 (65.0%) 5 (50.0%) 0.343
ACEIs/ARBs (%) 57 (80.3%) 50 (82.0%) 7 (70.0%) 0.378
MRAs (%) 25 (35.2%) 18 (29.5%) 5 (50.0%) 0.199
Statins (%) 52 (73.2) 46 (75.4%) 6 (60.0%) 0.308
ACEI— angiotensin-converting enzyme inhibitor, ARB — angiotensin receptor blocker, AVA — aortic valve area, BNP — brain natriuretic peptide, COPD— chronic obstructive pulmonary
disease, IQR— interquartile range, LVEF— left ventricular ejection fraction, MI—myocardial infarction, MRA—mineralocorticoid receptor antagonist, PAPsys — systolic pulmonary artery
pressure, and SAF — severe cardiac autonomic failure.
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risk patients can be dangerous because patients often do not immedi-
ately present to their physicians at symptom onset. Third, in high-risk
patients, peri-operative mortality is increased and long-term outcome
might be reduced because of sequelae of longstanding and potentially
irreversible left ventricular damage.
The exact mechanisms linking SAF to mortality in patients with se-
vere AS are unknown, but are most likely related to themajor neurohu-
moral adaptations that occur in heart failure, including activation of the
sympathetic nervous system and the renin–angiotensin–aldosterone
system [23]. However, also additional mechanisms might be involved,
including abnormal activation of autonomic cardiac reflexes, such as
the Bezold–Jarisch reflex [24]. By assessing both tonic and reflex abnor-
malities of autonomic function, SAF might cover a wide spectrum of
abnormal autonomic dysregulations that can occur in AS. HRT tests
the responsiveness of the cardiovascular autonomic nervous system to
intrinsic micro-disturbances in the form of VPCs which induce small,
transient falls of arterial blood pressure [9,11]. Normal HRT requires
an intact interplay among the vagal, sympathetic, and vascular systems
[25]. DC is an integral measure of all deceleration-related oscillations ofTable 5
Endpoints within 2 years in the 71 asymptomatic patients.
All patients
(n = 71)
SAF-negative
(n = 59)
SAF-positive
(n = 12)
p
value
Primary endpoint
All deaths (%) 10 (14.1) 4 (6.8) 6 (50.0) b0.001
Secondary endpoints
Cardiac deaths (%) 5 (7.0) 1 (1.7) 4 (33.3) b0.001
Cardiac deaths & HF-related
hospitalizations (%)
11 (25.5) 4 (6.8) 7 (58.3) b0.001
HF — heart failure and SAF — severe cardiac autonomic failure. Patients who underwent
aortic valve replacement or transcatheter aortic valve implantation during follow-up
were censored at the date of operation.heart rate over 24 h related to respiratory, vascular, and humoral regu-
lation processes [10]. Both HRT and DC capture different facets of auto-
nomic control which facilitates making their combination such a strong
risk predictor.
The limitations of our study requiremention. First, SAF assessment is
not applicable to patients with atrial fibrillation [26]. Second, BNP levels
were not available in 59 of the 216 symptomatic patients. However,
prognosis of these patients did not differ from those inwhomBNP levels
were available (p = 0.896). Third, the number of endpoints in
asymptomatic patients was small. We were therefore not able test the
independency of SAF from other risk factors in this patient group.
Forth, data on reproducibility of SAF are lacking which might limit the
results of our study and clinical applicability of SAF as risk predictor in
AS patients. As we did not re-assess SAF after intervention we also
cannot comment onwhether SAFmight improve by effective treatment
of AS. Both aspects need to be addressed by future studies. Fifth, it is
known that pharmacological treatment may alter autonomic function
including heart rate turbulence [27]. We therefore cannot exclude that
pharmacological treatment of AS patients may have influenced SAF
results. However, in our study we did not find a significant association
between pharmacological treatment and the presence of SAF. Finally,
although we have shown that SAF is a strong predictor of outcome we
have no data at present to show that specific treatments guided by
SAF will improve patients' prognosis.
In conclusion, the results of our study indicate that SAF is a strong
and independent predictor of mortality in patients with severe AS.
Future studies are needed to test whether implementation of SAF into
current risk stratification concepts leads to a better outcome in patients
with AS.
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Fig. 3. Cumulative event rates of asymptomatic patients with severe aortic stenosis for whom a primarily conservative treatment strategy was proposed at study entry stratified by the
presence of severe cardiac autonomic failure (SAF). Patients who underwent aortic valve replacement or transcatheter aortic valve implantation during follow-up were censored at the
time of invasive treatment. (A) Primary endpoint (all-cause mortality) and (B) Secondary endpoint (composite of cardiac mortality and hospitalizations due to decompensated heart
failure).
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0022-0736/© 2017 Elrepolarization, most likely related to phasic sympathetic activation. Increased PRD is a validated
predictor of mortality after myocardial infarction and in ischemic heart disease, but has not been tested in
aortic valve stenosis (AS). Here, we assessed PRD in patients with AS and tested its correlation with
clinical and hemodynamic parameters as well as markers of heart rate variability (HRV).
Materials and methods: We prospectively enrolled 139 consecutive patients with moderate to
severe AS in sinus rhythm. In all patients we performed a 24-h Holter ECG in Frank–leads
configuration. We assessed PRD according to previously published technologies from the nocturnal
hours (0 am–6 am) and dichotomized PRD at the established cut-off value of ≥5.75 deg2. In
addition to clinical and hemodynamic markers, we also assessed deceleration capacity (DC) of heart
rate, heart rate turbulence and standard HRV parameters.
Results: In the patients studied, PRD was 6.55 ± 3.96 deg2. Seventy-three patients (52.5%) had
increased PRD. Among them, 36 (49.9%) patients were classified as being asymptomatic. There was
no association between increased PRD and clinical or hemodynamic markers, including presence of
symptoms, NYHA-classification, aortic valve area, and left-ventricular ejection fraction. Thirty-three
of the 73 (45.2%) patients with PRD ≥5.75 deg2 also suffered from decreased vagal tonic activity
by means of abnormal DC (≤2.5 ms) indicating severe autonomic dysfunction.
Conclusion: Prevalence of increased PRD is high among patients with moderate to severe AS.
Patients with increased PRD cannot be identified by clinical or hemodynamic markers Future studies
should test the prognostic value of PRD in patients with AS.
© 2017 Elsevier Inc. All rights reserved.Keywords: Periodic repolarization dynamics; Sympathetic nervous system; Aortic stenosisIntroduction
Aortic valve stenosis (AS) is the most prevalent heart
valve disorder and the third most common cardiovascular
disease after coronary artery disease (CAD) and hyperten-
sion in developed countries [1]. The natural prognosis of AS
varies widely, ranging from good to unfavorable. Therefore,
accurate risk stratification is crucial for treatment decision.
According to current guidelines an invasive treatment is
delayed until development of symptoms or impairment of
left-ventricular ejection fraction (LVEF) [2,3]. However, this
“wait for symptoms” strategy might prove deleterious, as thell authors have declared that no conflict of interest
author at: Medizinische Klinik und Poliklinik I,
inic, Marchioninistr. 15, 81377 Munich, Germany.
: Konstantinos.Rizas@repolarization.eu
16/j.jelectrocard.2017.08.004
sevier Inc. All rights reserved.symptomatic status cannot be reliably assessed especially in
the elderly patients.
Increased sympathetic nervous system (SNS) activity is a
sign of progression of the disease, which can be effectively
reversed after trancatheter aortic valve replacement (TAVR)
[4]. AsASworsens, cardiac output is reduced, and this situation
leads to increased SNS activity, which finally predisposes to
fatal cardiac arrhythmias and cardiac decompensation. As of
yet, accurate assessment of SNS required an invasive approach
using microneurographic measurements from the peroneal
nerve [4].
Recently, we proposed a novel approach to non-invasively
assess the effect of SNS-activity on the heart that substantially
differs from previous methods [5]. So-called “Periodic
Repolarization Dynamics (PRD)” evaluates sympathetic-
activity-associated low-frequency periodic changes of cardiac
repolarization and opens new perspectives for identifying
803K.D. Rizas et al. / Journal of Electrocardiology 50 (2017) 802–807high-risk patients, which cannot be identified by other
methods. PRD has been shown to be an important predictor
ofmortality and cardiovascular mortality in patients with acute
[5] and chronic myocardial infarction (MI) [6]. Therefore, the
aim of the present study is to evaluate PRD in patients with
moderate to severe AS and to test its association with clinical
and hemodynamic parameters, as well as markers of HRV.
The present study is a substudy of the Risk Prediction inAortic
Stenosis study (PREDICT-AS; ClinicalTrials.gov number
NCT01422044).Material and methodsStudy population
Between September 2009 to November 2012 we prospec-
tively enrolled patients who presented for evaluation of known
or suspectedAS at the Eberhard-Karls-University of Tuebingen,
Germany (Fig. 1). Eligible patients were in sinus rhythm and
had moderate to severe AS (aortic valve area [AVA]≤1.5 cm2
and/or mean aortic pressure gradient≥25 mm Hg), which was
confirmed invasively or by echocardiography. Patients were
excluded if they were not in sinus rhythm, if they had an acute
coronary syndrome or significant coronary stenosis requiring
revascularization, or when an additional hemodynamically
significant valve lesion was present. In this post-hoc analysis we
also excluded patients for whom a Holter ECG in Frank leads
configuration was either not available or did not meet the
standards for PRD assessment.Fig. 1. Consort flow-diagram for patienAssessment of periodic repolarization dynamics
In all patients, 24-h Holter recordings (Cardio CM 3000,
Getemed, Teltow, Germany) were performed in Frank leads
configuration at a sample rate of 256 Hz. As long as PRD
assessment requires standardized conditions in supine,
resting position, we only used the nocturnal phase between
00 a.m. to 06 a.m. for evaluation of PRD. The technical
details of PRD assessment have been described elsewhere
[5]. Briefly, X-,Y- and Z–leads are converted to a set of polar
coordinates defined by two angles (azimuth and elevation)
and the amplitude Amp. We used established algorithms in
order to define the beginning and ending of each T-wave [7].
In a second step, we integrated the spatiotemporal charac-
teristics of each T-wave into a single vector T°, which is
defined by the so-called weight-averaged azimuth (WAA)
and weight-averaged elevation (WAE):
Weight Averaged Azimuth WAAð Þ
¼
Pt¼Tend
t¼Tstart Ampt  Azimuthtð ÞPt¼Tend
t¼Tstart Amptð Þ
ð1Þ
Weight Averaged Elevation WAEð Þ
¼
Pt¼Tend
t¼Tstart Ampt  Elevationtð ÞPt¼Tend
t¼Tstart Amptð Þ
ð2Þ
In a third step, we estimated the instantaneous degree of
repolarization instability by means of the angle dT° between
successive repolarization vectors. dT° was calculated usingt selection. AS = aortic stenosis.
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T° according to Eq. (3) [5, Supplemental Fig. 6].
dT ° ¼ acos sin WAE1ð Þ½  cos WAA1ð Þ  sin WAE2ð Þ  cos WAA2ð Þ
þ cos WAE1ð Þ  cos WAE2ð Þ
þ sin WAE1ð Þ  sin WAA1ð Þ  sin WAE2ð Þ  sin WAA2ð Þ
ð3Þ
We finally applied continuous wavelet transformation on
the dT°-signal and quantified PRD as the average wavelet
coefficient corresponding to frequencies of ≤0.1 Hz [5].
PRD was dichotomized at the established cut-off value of
≥5.75 deg2.
Assessment of heart rate variability
Standard HRV parameters were calculated in time and
frequency domains according to the Task Force of the
European society of Cardiology [8]. For this study the
following standard HRV parameters were considered: mean
heart rate (MHR), standard-deviation of all normal-
to-normal intervals (SDNN), square root of the mean of
the sum of squared differences between adjacent normal-
to-normal intervals (RMSSD), heart rate variability index
(HRVi), spectral power in the low-frequency range (LF),
spectral power in the high-frequency range (HF) and the LF/
HF ratio. In addition to the standard HRV parameters we also
calculated heart rate turbulence (HRT) and deceleration
capacity of heart rate (DC) according to previously published
technologies [9,10]. Briefly, HRT refers to the biphasic
physiological response of heart rate following a spontaneous
ventricular premature contraction (VPC) and is composed of
an initial heart rate acceleration followed by a subsequent
heart rate deceleration. The two phases of HRT can be
quantified by two numerical parameters: turbulence onset
(TO) and turbulence slope (TS). Here, HRT was considered
abnormal if both TO and TS were abnormal (HRT category
2; TO ≥0% and TS ≤ 2.5 ms/RR interval [11]). If a patient
had no VPCs, HRT was defined as normal. DC is an integral
measure of all deceleration-related oscillations of heart rate,
related to tonic vagal activity. Calculation of DC is based on
the transformation of the sequence of RR intervals into a new
time series by phase-rectified signal averaging (PRSA). The
central deflection of the PRSA signal characterizes the average
capacity of the heart to decelerate and can be quantified by
Haar wavelet analysis using a scale of 2 (T = 1). DC≤2.5 ms
was considered abnormal [10]. All HRV parameters, with
exception of HRT, were evaluated during the nocturnal phase.
HRTwas assessed from the entire recording, as it is influenced
from the total number of VPCs, which are normally reduced
during the night hours.
Assessment of clinical markers
Patients were classified as being symptomatic if at least one
of the following findings were present: syncope; angina
pectoris (Canadian Cardiovascular Society [CCS] grading
≥ II) or heart failure (New York Heart Association [NYHA]
functional class ≥ II). All other patients were classified as
being asymptomatic. Glomerular filtration rate (GFR) wascalculated by means of the Cockroft-Gault formula. Renal
insufficiency was defined as GFR b 60 ml/min/1.73 m2. The
presence of chronic obstructive pulmonary disease (COPD)
was defined by long term use of bronchodilators or steroids for
lung disease. Extracardiac arteriopathywas considered present
if the patient suffered from claudication, carotid occlusion or
N50% stenosis, previous or planned intervention on the
abdominal aorta, limb arteries or carotids. Logistic euro-
SCORE was calculated as previously described [12].
Assessment of hemodynamic markers of aortic stenosis
In all patients, following hemodynamic variables were
assessed using echocardiography or invasive measurement:
LVEF, AVA, peak and mean aortic pressure gradient and
systolic pulmonary artery pressure (PAPsys). In patients
undergoing left and right heart catheterization, hemodynamic
variables were obtained invasively, as follows: LVEF was
obtained by the area-length method from a single- plane right
anterior oblique projection, PAPsys was obtained using a 7F
Swan-Ganz catheter and AVAwas calculated using the Gorlin
formula. In patients in whom no catheterization was
performed, hemodynamic variables were obtained by echo-
cardiography (iE33, Philips Medical Systems). In these
patients, LVEF was assessed by the modified Simpson rule
with images obtained from apical 4- and 2-chamber views.
AVA was estimated by the continuity equation using the
velocity–time integral of the aortic and left ventricular outflow
tract flows and PAPsys was estimated using the tricuspid
pressure gradient by adding mean right arterial pressure
derived from the inferior vena cava absolute diameter and
diameter change during inspiration.
Statistical analysis
Continuous variables are expressed as means with standard
deviations and are compared using the Wilcoxon rank sum test.
Categorical data are presented as percentages and are analyzed
using the chi-square test. Correlations between continuous
variables were assessed by Pearson's product-moment correla-
tion coefficient. To compare PRD between AS and MI we
performed propensity score matching analysis using the
Autonomic Regulation Trial [5] as matching population.
Propensity scores were generated by logistic regression analysis
and a nearest-neighbour matching techinque was applied [13].
The variables used to estimate the propensity scorewere age and
gender. Differences were considered statistically significant
when the two-sided p-value was b0.05. All statistical analyses
were performed using CRAN R 3.2.3.Results
As shown in Fig. 2, typical low-frequency oscillations of
cardiac repolarization could also be detected in patients with
moderate to severe AS (Fig. 2). In the patients studied, PRDwas
6.55 ± 3.96 deg2. Seventy three of the 139 patients (52.5%)
were classified as abnormal, based on PRD≥5.75 deg2. Using
propensity score matching analysis for age and gender we
selected 70 patients with AS (mean age = 71.4 ± 7.4 years; 32
females) and 70 post-MI patients from the Autonomic
Fig. 2. Typical dT° signal with characteristic low-frequency oscillations of repolarization obtained from a patient with moderate to severe aortic stenosis and
increased periodic repolarization dynamics (PRD) (7.87 deg2). For illustration purposes only 1000 heart beats are plotted.
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p = 0.737 for age and p = 0.494 for gender). PRD was
significantly higher in AS patients (6.04 ± 3.80 deg2)
compared to post-MI patients (5.06 ± 4.24 deg2; p = 0.019).
Table 1 depicts baseline and clinical characteristics as well as
hemodynamic parameters in patients with moderate to severe
AS stratified by PRD. Of particular note, there were no
significant differences in clinical and hemodynamic markers
between patients with normal and abnormal PRD.Table 1
Baseline, clinical characteristics and hemodynamic parameters.
All patients PRD b 5.75 deg2 PRD ≥ 5.75 deg2 p-value
Baseline and clinical characteristics
Number of patients, n (%) 139 66 (47.5) 73 (52.5)
Age, years (SD) 78.0 (8.8) 77.3 (8.7) 78.6 (8.9) 0.225
Females, n (%) 79 (56.8) 35 (53.0) 44 (60.3) 0.490
Severe AS, n (%) 105 (75.6) 49 (74.2) 56 (76.7) 0.888
Symptoms, n (%) 81 (58.3) 44 (66.7) 37 (50.1) 0.083
Hypertension, n (%) 111 (79.9) 51 (77.2) 60 (82.2) 0.610
Diabetes mellitus, n (%) 48 (34.5) 23 (34.8) 25 (34.2) 0.999
CAD, n (%) 84 (60.4) 43 (65.2) 41 (56.2) 0.364
Previous MI, n (%) 20 (14.4) 9 (13.6) 11 (15.1) 0.999
NYHA-Class ≥ III, n (%) 21 (15.1) 10 (15.2) 11 (15.1) 0.999
Renal insufficiency, n (%) 43 (30.9) 20 (30.3) 23 (31.5) 0.999
COPD, n (%) 9 (6.5) 5 (7.6) 4 (5.5) 0.876
Logistic euroScore, % (SD) 15.8 (13.8) 13.5 (9.7) 17.9 (16.4) 0.269
Hemodynamic parameters
AVA, cm2 (SD) 0.77 (0.27) 0.76 (0.28) 0.78 (0.24) 0.823
Mean gradient, mmHg (SD) 39.0 (20.1) 38.2 (17.7) 39.6 (22.1) 0.815
Peak gradient, mmHg (SD) 58.1 (31.8) 58.0 (28.8) 58.2 (34.4) 0.741
LVEF, % (SD) 51 (11) 51 (11) 52 (11) 0.772
PAPsys, mmHg (SD) 33 (15) 32 (13) 34 (16) 0.491
AS = aortic stenosis; AVA = aortic valve area; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; LVEF = left-ventricula
ejection fraction; NYHA = New York Heart Association; PAPsys = systolic pulmonary artery pressure; PRD = periodic repolarization dynamics.Table 2 shows the correlation between PRD and
parameters of HRV. Increased PRD was associated with
increased MHR (r = 0.36 [0.21–0.50]), decreased DC
(r = −0.42 [−0.55 to −0.27]) and increased LF (r = 0.31
[0.15–0.46]) and HF 0.30 [0.14–0.45]. Thirty-three of the 73
(45.2%) patients with increased PRD also suffered from
decreased DC ≤2.5 ms. The mean nocturnal heart rate
among patients was significantly higher in patients with
increased PRD (71 ± 11 bpm) compared to patients withr
Table 2
Correlation between PRD and markers of heart rate variability.
Mean (SD) Correlation coefficient
with PRD (95% CI)
p-value
Mean heart rate, bpm 68 (11) 0.36 (0.21–0.50) b0.001
SDNN, ms 78 (35) 0.13 (−0.04–0.29) 0.142
RMSSD, ms 25 (15) 0.13 (−0.04–0.29) 0.133
HRVi, U 32 (14) 0.05 (−0.12–0.22) 0.542
DC, ms 2.66 (6.28) −0.42 (−0.55 to −0.27) b0.001
LF, ms2 678 (928) 0.31 (0.15–0.46) b0.001
HF, ms2 218 (245) 0.30 (0.14–0.45) b0.001
LF/HF ratio 3.6 (3.5) 0.02 (−0.14–0.19) 0.792
DC = deceleration capacity of heart rate; bpm = beats per minute; HRVi =
heart rate variability index; HF = spectral power in the high-frequency range;
LF = spectral power in the low-frequency range; RMSSD = square root of the
mean of the sum of squared differences between adjacent normal-to-normal
intervals; SDNN = standard-deviation of all normal-to-normal intervals.
806 K.D. Rizas et al. / Journal of Electrocardiology 50 (2017) 802–807normal PRD (65 ± 10 bpm; p = 0.005). PRD was evenly
distributed among patients with normal (6.69 ± 4.05 deg2)
and abnormal HRT (5.89 ± 3.47 deg2; p = 0.465).Discussion
The findings of our study indicate that increased
sympathetic activity quantified by means of PRD was a
common finding among patients with AS. Its prevalence
(52.5%) is substantially higher compared with other patient
populations, e.g. post-MI patients where the prevalence of
increased PRD was estimated at 25% [5]. Interestingly, the
group of patients identified by increased PRD could not be
detected by conventional clinical and hemodynamic
markers, with almost half of the patients with increased
PRD being asymptomatic.
The exact mechanisms underlying PRD need further
investigation. However, there is a body of evidence that PRD
reflects the effect of sympathetic activity on ventricular
myocardium. First, PRD mimics the characteristic low-
frequency pattern of efferent sympathetic activity [14,15],
which can be also found in many other biosignals, including
heart rate, blood pressure, and microneurographic measuru-
ments of muscle sympathetic nervous system activity
(MSNA). Second, physiological and pharmacological stud-
ies showed that provocations such a tilt test or exercise led to
an increase of PRD in healthy individuals, while pharmaco-
logical blockade of the sympathetic nervous system by
beta-blockers resulted to a significant suppression of PRD
[5]. Third, Hanson et al. could demonstrate an oscillatory
behavior of ventricular action potential duration (APD) in the
same low-frequency range in patients with heart failure [16].
Using a modeling study the same group could show that
these low-frequency oscillations were enhanced by phasic
beta-adrenergic stimulation and phasic mechanical stretch. In
the presence of calcium overload and reduced repolarization
reserve, both characteristics of heart failure, these oscilla-
tions predisposed to early afterdepolarizations and arrhyth-
mic events [17]. The presence of sympathetic overactivity in
patients with severe AS has been already demonstrated using
invasive MSNA measurements [4]. Although the prognostic
value of increased SNS activity in patients with AS needsfurther investigation it is reasonable to suppose that it is a
sign of progression of the disease, which leads to a
counterbalancing SNS activation. More importantly this
sympathetic overactivity can be effectively reversed after
TAVR [4].
PRD, as a marker of increased sympathetic activity was
associated with increased nocturnal heart rate in this study.
The correlation between PRD and DC indicates that there is a
group of patients with AS suffering from both, sympathetic
and vagal autonomic dysfunction. In post-MI patients,
combined vagal and sympathetic dysfunction is associated
with poor outcome. We performed a post-hoc analysis in the
Autonomic Regulation Trial [5] and found that post-MI
patients with PRD ≥5.75 deg2 and DC ≤2.5 ms (10.7% of
the patients) had a 5-year mortality rate of 30.1%, compared
to a 2.9% 5-year mortality rate among patients with normal
PRD and DC (65.6% of the patients). In the population of
patients with AS we could identify 33 patients (23.7%) with
abnormal PRD and DC, which is substantially higher
compared to the post-MI population.
Zuern et al. [18] report a six fold increased risk of 2-year
mortality in patients with severe AS and combined
abnormalities of DC and HRT, so-called “severe autonomic
failure” (SAF). In this study, there was no significant
difference in the level of PRD between patients with normal
and abnormal HRT, which implies that increased PRD might
detect a different population than abnormal HRT. Although
both HRT and PRD are influenced by increased SNS
activity, this regulation takes place at different levels. While
HRT quantifies the baroreflex-mediated SNS activation to
the transient fall of arterial pressure caused by a VPC [9],
PRD detects the response of the ventricular myocardium to
phasic sympathetic activation.
Assessment of PRD requires a three-dimensional,
high-quality ECG recording. The algorithm of PRD is very
sensitive in detecting small changes in the amplitude,
direction or duration of repolarization, which cannot be
identified by conventional repolarization markers. Low-
frequency oscillations of repolarization can be also detected
from single–lead recordings by applying the PRD algorithm
on the QT-interval. Although this method might be much
simpler in nature, a post-hoc analysis in the Autonomic
Regulation trial [5] has shown that it is associated with a
lower predictive power for predicting mortality (area under
the curve [AUC] 0.67 [95% CI 0.60–0.73], p b 0.001 vs.
0.73 [95% CI 0.66–0.79], p b 0.001) for PRD and
cardiovascular mortality (AUC 0.66 [95% CI 0.57–0.75],
p = 0.001 vs. 0.72 [95% CI 0.62–0.81], p b 0.001 for
PRD).
The limitations of our study require mention. First, we
assessed PRD from Holter ECGs during the night hours,
while in the seminal study PRD was assessed from 30-min
recordings in standardized conditions. Second, patients with
atrial fibrillation were not included in this study, as is
presently unknown whether PRD can also be applied to
patients with atrial fibrillation. Third, the proposed cut-off
value of PRD originates from a post-MI population.
Additional studies are needed to test whether this cut-off
value also applies to patients with AS.
807K.D. Rizas et al. / Journal of Electrocardiology 50 (2017) 802–807In conclusion, the results of our study indicate that
calculation of PRD is feasible among patients with moderate
to severe AS and can identify a group of patients with
increased SNS activity who cannot be detected by conven-
tional clinical and hemodynamic markers. Future studies are
needed to evaluate the prognostic value of PRD inAS patients.
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Trial DesignImplantable cardiac monitors in high-risk
post-infarction patients with cardiac
autonomic dysfunction and moderately
reduced left ventricular ejection fraction:
Design and rationale of the SMART-MI trial
Wolfgang Hamm, MD, Konstantinos D. Rizas, MD, Lukas von Stülpnagel, MSc, Nikolay Vdovin, MD,
Steffen Massberg, MD, Stefan Kääb, MD, and Axel Bauer, MD Munich, GermanyBackground Most deaths after myocardial infarction (MI) occur in patients with left ventricular ejection fraction (LVEF)
N35%, for whom no specific prophylactic strategies exist. Deceleration capacity (DC) of heart rate and periodic repolarization
dynamics (PRD) are noninvasive electrophysiological markers depending on the vagal and sympathetic tone. The combination
of abnormal DC and/or PRD identifies a new high-risk group among postinfarction patients with LVEF 36%-50%. This new
high-risk group has similar characteristics with respect to prognosis and patient numbers to those of the established high-risk
group identified by LVEF ≤ 35%.
Study design The SMART-MI trial is an investigator-initiated randomized prospective multicenter trial that tests the
efficacy of implantable cardiac monitors (ICM) in this new high-risk group. The study will enroll approximately 1,600 survivors
of acute MI with sinus rhythm and an LVEF of 35%-50% in 17 centers in Germany who will be tested for presence of cardiac
autonomic dysfunction. Four hundred patients with either abnormal DC (≤2.5 ms) and/or PRD (≥5.75 deg2) will be
randomized in a 1:1 fashion to intensive follow-up via telemonitoring using an ICM device (experimental arm) or conventional
follow-up (control arm). For the ICM arm, specific treatment paths have been developed according to current guidelines.
Outcomes The primary end point is time to detection of predefined serious arrhythmic events during follow-up, including
atrial fibrillation ≥6 minutes, nonsustained ventricular tachycardia (cycle length ≤320 ms; ≥40 beats), atrioventricular block
≥IIb, and sustained ventricular tachycardia/ventricular fibrillation. The median follow-up period is 18 months with a minimum
follow-up of 6 months. The effect of remote monitoring on clinical outcomes will be tested as secondary outcome measure
(ClinicalTrials.gov NCT02594488). (Am Heart J 2017;190:34-9.)Background and rationale
Sudden cardiac death (SCD) is the leading single cause of
death in the industrialized world.1 Survivors of an acute
myocardial infarction (MI) are at increased risk for SCD.
Randomized controlled trials demonstrated that in high-risk
patients after MI mortality can be reduced by prophylactic
interventions including implanted cardioverter/defibriIlator
implantation.2,3 In these trials, the criterion of a reducedFrom the Medizinische Klinik und Poliklinik I, University Hospital Munich, Ludwig
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Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany.
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http://dx.doi.org/10.1016/j.ahj.2017.05.006left ventricular ejection fraction (LVEF ≤ 35%) was used to
identify high-risk post-MI patients.4 Accordingly, current
guidelines consider post-MI patients with LVEF ≤ 35% for
prophylactic ICD implantation, disregarding the fact that
most patients who die after MI have LVEF N 35%. Indeed in
a recent prospective cohort study including 2,343 post-MI
patients, only 57 (31%) of 181 deaths during a 5-year
follow-up occurred in patients with LVEF ≤ 35%.5
Although overall cardiovascular mortality is declining,
the incidence of SCD over the last decades remained
unchanged.6 These and other data stress the importance of
alternative approaches to identify high-risk post-MI pa-
tients, especially among those with LVEF N 35%, for
guidance of prophylactic therapies. (See Fig).
Experimental and clinical studies indicated that impor-
tant prognostic information after MI can be derived from
the functional status of the cardiac autonomic nervous
system.7 Both increased sympathetic and depressed vagal
Figure
Flowchart of the SMART-MI study.
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Volume 190activity after MI have been associated with an increased
susceptibility to malignant bradyarrhythmia and tachyar-
rhythmia eventually culminating in SCD.8
Deceleration capacity (DC) of heart rate and periodic
repolarization dynamics (PRD) are clinically validated
electrocardiogram (ECG)-based autonomic risk markers
that provide strong and independent prognostic informa-
tion in post-MI patients with LVEF N 35%.9,10 Decelera-
tion capacity and PRD reflect different facets of
autonomic function and can therefore be used in
combination to predict risk. Deceleration capacity is an
integral measure of autonomic, predominantly vagally
mediated regulations of heart rate.9 Periodic repolariza-
t ion dynamics captures previously unknown
low-frequency (b0.1 Hz) oscillations of cardiac repolari-
zation related to sympathetic activation.10 In a previous
study, combined assessment of PRD and DC identified a
new high-risk group among post-MI patients with
moderately reduced LVEF (36%-50%).11 This new
high-risk group has similar characteristics with respect
to prognosis and patient numbers to those of the
established high-risk group identified by LVEF ≤ 35%.
Although the poor prognosis of post-MI patients withautonomic dysfunction is well established, the exact
mode of death in these patients is still unknown.
Particularly, a better understanding of the association
with serious arrhythmic events is of crucial importance to
initiate specific preventive strategies in this high-risk
group.
As known from studies with implantable cardiac
monitors (ICMs) in post-MI patients with LVEF ≤ 40%,
eventual death is often preceded by primarily asymptom-
atic arrhythmic events, including new-onset atrial fibril-
lation, nonsustained ventricular tachyarrhythmias, and
higher-degree atrioventricular (AV) block.12 This sug-
gests a potential time frame for preemptive interventions
in case of early detection of arrhythmic events, which
could improve outcome.
The “Implantable cardiac monitors in high-risk
post-infarction patients with cardiac autonomic dysfunc-
tion and moderately reduced left ventricular ejection
fraction (SMART-MI)” study will assess the efficacy of
ICMs in detecting serious arrhythmic events in the
high-risk group of post-MI patients with moderately
reduced LVEF (36%-50%) and autonomic dysfunction.
The effect of home monitoring on clinical outcomes will
be tested as a secondary end point. This article presents
the rationale and design of the SMART-MI trial.Methods
Study design
The SMART-MI study (ClinicalTrials.org NCT02594488)
is a multicenter, randomized, open-labeled clinical trial.
Survivors of acute MI b40 days with LVEF 36%-50% and in
sinus rhythm undergo risk stratification by means of DC
and PRD assessed from a 20-minute resting ECG. High-risk
patients will be 1:1 randomized. The experimental arm
consists of intensified surveillance and follow-up by
means of an ICM (Reveal LINQ; Medtronic, Ireland)
with home-monitoring capability. The control arm of the
study consists of conventional follow-up as recommend-
ed by current guidelines.13 In all study patients, a blood
sample for bio-banking is obtained. Low-risk patients will
enter a registry. Figure summarizes the study flow of
patients within the trial. The primary end point is time to
detection of serious arrhythmic events during follow-up
as defined below. End points will be adjudicated by an
event adjudication committee blinded to the patients'
allocation. Seventeen centers in Germany, among them
15 university centers, will participate in this trial. The
inclusion and exclusion criteria are outlined in Table I.
The following baseline procedures will be performed
before randomization: targeted medical history and
physical examination, including pulse, blood pressure,
height, and weight (body mass index); 12-lead ECG;
echocardiography (N48 hours after index MI or when
CK-MB has normalized) for assessment of LVEF; screening
laboratory tests: white blood cell count, hemoglobin,
Table I. Inclusion and exclusion criteria
Inclusion criteria
Acute MI b40 d: STEMI and NSTEMI according
to definition by current ESC guidelines with
evidence of coronary lesion on coronary
angiogram requiring PCI
LVEF 36%-50% as assessed by echo,
LV angiogram, or MRI; N48 h after index
MI or when CK-MB has normalized
Evidence of cardiac autonomic dysfunction:
abnormal heart rate DC b2.5 ms and/or abnormal
PRD ≥5.75 deg2 N48 h after index MI or when
CK-MB has normalized
Age 18-80 y
Sinus rhythm
Optimal medical therapy
Written informed consent
Exclusion criteria
Indication for ICD or pacemaker
Known paroxysmal or persistent atrial fibrillation
Life expectancy b12 mo
Inability to comply with follow-up
Pregnancy
Participation in another trial that may interfere
Abbreviations: STEMI, ST-segment elevation MI; NSTEMI, non–ST-segment elevation
MI; ESC, European Society of Cardiology; PCI, percutaneous coronary intervention;
LV, left ventricular.
Table II. Primary and secondary end points
rimary end point: composite of predefined arrhythmias
Atrial fibrillation ≥6 min
Higher-degree AV block ≥IIb
Ventricular tachycardia with a cycle length ≤320 ms lasting for ≥12 s
(corresponding to 40 beats)
Sustained VT and VF
econdary end points
Composite of all-cause mortality, stroke, systemic arterial
thromboembolism, and unplanned hospitalizations for decompensated
heart failure
All-cause mortality
Cardiovascular mortality
Unplanned hospitalizations for decompensated heart failure
Sinus arrest N6 s
Nonsustained VT ≥16 beats
Bradycardias as defined above
Ventricular arrhythmias as defined above
Quality of life
Device-related complications including infections and major bleedings
(BARC ≥2)
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August 2017hematocrit, platelet count, serum creatinine, electrolytes,
activated partial thromboplastin time, international nor-
malized ratio, CK and its MB fraction, and troponin-T or
troponin-I; and 20-minute resting ECG for assessment of
cardiac autonomic markers (N48 hours after index MI or
when CK-MB has normalized).
Study outcomes
The primary end point is time to detection of the
following predefined serious arrhythmic events (Table II),
including atrial fibrillation ≥6 minutes, higher-degree AV
block (≥IIb, ie, second-degree AV block type 2 and
third-degree AV block), nonsustained ventricular tachycar-
dia (VT) with a cycle length ≤320 ms lasting for
≥12 seconds (corresponding to 40 beats),14 and sustained
VT/ventricular fibrillation (VF).
All of the predefined arrhythmias have been associated
with adverse clinical events in previous studies or
indicate a proven criterion for delivering ATPs in patients
with implanted ICDs.12,14,15
Secondary outcomes include the following: the com-
posite of all-cause mortality, stroke, systemic arterial
thromboembolism, and unplanned hospitalizations for
decompensated heart failure; all-cause mortality; cardio-
vascular mortality; unplanned hospitalizations for decom-
pensated heart failure; sinus arrest N6 seconds;
nonsustained VT ≥16 beats; bradycardias as defined
above; ventricular arrhythmias as defined above; quality
of life; and device-related complications includingP
S
infections and major bleedings (bleeding Academic
Research Consortium [BARC] ≥2) (Table II).
Assessment of cardiac autonomic markers and risk
stratification
A 20-minute resting ECG for assessment of DC and PRD
will be performed N48 hours after index infarction or
when CK-MB has normalized. Electrocardiogram raw
signals are digitally transferred to an ECG core laboratory
(LMU Munich) for standardized computation of DC and
PRD.9,10 Patients with either abnormal DC (≤2.5 ms) or
abnormal PRD (≥5.75 deg2) will be classified as high-risk
patients.
Implantable cardiac monitors
In patients randomized to the ICM arm, a commercially
available, CE-marked ICM (Medtronic Reveal LINQ) will
be subcutaneously implanted using local anesthesia
according to local standard operating procedures. The
ICM is capable of automatic detection of predefined
arrhythmias, which will be telemetrically transferred to
an ICM core laboratory (LMU Munich) on a daily basis.
Arrhythmia detection parameters of the ICMs are set as
recommended in the operating manual with “AF man-
agement” chosen as reason for monitoring. All detected
arrhythmias are immediately checked by an experienced
physician in the core laboratory. True-positive findings
meeting the predefined criteria of the primary end point
(see above) are reported to the local study centers within
48 hours. Treatment paths for different kind of arrhyth-
mias have been developed in line with current guidelines.
However, final treatment decisions are left to the local
treating physician.
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After all inclusion criteria have been confirmed,
patients will be randomized (according to a predefined
block randomization list with random block sizes
between 4 and 8) between ICM and conventional
follow-up with a randomization sequence of 1:1. Alloca-
tion to treatment will be made by means of a Web-based
computer-generated sequence with stratification accord-
ing to study center, age, and LVEF. The 2 treatment
groups will be studied concurrently. Time zero is defined
as the time of randomization. Patients will be considered
enrolled in the study and eligible for the final intention to
treat analysis at time of randomization.
Outpatient study visits are scheduled every 6 months. A
12-lead ECGwill be recorded and patients will be evaluated
for the occurrence of following events: MI, stroke, systemic
thromboembolism, unplanned hospitalization, bleeding,
infection, and arrhythmic events. In patientswith ICMs, the
device will be interrogated. At 12 and 24 months, a
20-minute resting ECG will be performed for reevaluation
of cardiac autonomic function.
The enrollment period is planned for 24 months with a
minimum follow-up of 6 months and a medium follow-up
of 18 months.
Safety monitoring
Events relevant for safety will be assessed by the site
principal investigator and will be confirmed by 2
members of the Event Adjudication Committee blinded
to the patient's allocation. Device-related complications
and major bleeding (BARC ≥2) will be used as trial safety
parameters. Events will be reported to the Safety
Monitoring Board.
Ethical conduct
The SMART-MI trial will be conducted in accordance
with the provisions of the Declaration of Helsinki, the
International Conference on Harmonization “Good Clin-
ical Practices,” and the respective national regulations.
Participating centers have to provide written approval of
the institutional medical ethics committee. Implantable
cardiac monitors used in this trial have a CE mark, are
approved by the Food and Drug Administration, and are
market released.
Statistical analysis
A total sample size of 400 patients is expected to
achieve 90% power to detect a statistically significant
difference (P ≤ .05) in time to first arrhythmic event.
Calculation of sample size is based on an annual event
rate of 5% in the control arm and 13% in the ICM arm.12
With these event rates, a total of 46 events are required in
both arms combined. The sample size calculation further
considers a dropout rate of 15% (including deaths as well
as patients refusing to continue follow-up).The main analyses will test superiority of the ICM arm
with respect to early detection of serious arrhythmic
events based on a time-to-event analysis. The intergroup
difference for the primary end point will be assessed by a
proportional hazards model. Because death may be
related to the events that determine the primary end
point, an independent censoring is not reasonable if
death takes place. Therefore, death will be introduced as
competing risk. The analysis will be based on the
cause-specific hazard approach. A proportional
cause-specific hazards model is used to assess the
difference in event detection speed between both trial
arms. Aalen-Johansen estimators are used to represent the
cause-specific cumulative event probabilities in both
treatment groups. CIs for the hazard ratio will be
calculated. The analysis allows for stratification with
respect to age (b70 years/≥70 years) and LVEF
(b45%/≥45%). Centers will be represented by a
random effect (frailty). We will present continuous
data by mean ± SD or median and interquartile range,
as appropriate. Categorical data will be presented as
rate and percentage. Depending on the normality of
distribution, we will compare continuous variables
by the Student t test or the Wilcoxon test, as
appropriate. Categorical data will be compared
using the χ2 test. Missing values in baseline variables
will be imputed following the MAR approach. The
analysis of secondary end points will use standard
proportional hazards models for the mortality as well
as the composite event end point. Cause-specific
hazard models will be used to analyze secondary end
points where appropriate.
Timelines
The first SMART-MI patient was enrolled May 2016. At
the time of submission of this manuscript, 43 patients
have been randomized (20 patients in the ICM arm, 23
patients in the control arm). Completion of recruitment is
expected by May 2018, and the last patient visit by
November 2018. First results of the main analysis should
be available by February 2019.
The study is predominantly funded by the Deutsches
Zentrum für Herz-Kreislauf-Forschung (DZHK). Medtro-
nic covers expenses for the ICM devices including
remote monitoring capabilities as well as staff expenses.
Medtronic has no role in the study design, data
collection, data analysis, data interpretation, or writing
of reports.
Discussion
SMART-MI is a phase III/IV early clinical trial that tests
the efficacy of ICMs in detection of serious arrhythmic
events in a new high-risk group of postinfarction patients
with LVEF 35%-50% and presence of cardiac autonomic
dysfunction.
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for different indications, either to reveal the underlying
cause of unexplained syncope,16 to assess the burden of
atrial fibrillation after ablation,17 or to screen patients
with cryptogenic stroke for presence of atrial fibrillation.
18 Assessment of arrhythmic risk after MI is presently not
considered a typical indication for ICM implantation. In
fact, there are only 2 studies in which ICMs have been
implanted for this specific indication. The nonrando-
mized CARISMA study included 297 survivors of acute MI
with reduced LVEF (≤40%) who underwent ICM
implantation.12 During a 2-year follow-up, predefined
bradyarrhythmia and tachyarrhythmia were detected in
46% of the patients (n = 137). The investigators of
CARISMA documented a 28% incidence of new-onset
atrial fibrillation (≥16 beats; frequency ≥ 125 beats/
min), a 13% incidence of nonsustained VT, a 10%
incidence of high-degree AV block, a 7% incidence of
sinus bradycardia, a 5% incidence of sinus arrest, a 3%
incidence of sustained VT, and a 3% incidence of VF,
respectively. Most arrhythmias (86%) were asymptomatic
but had important prognostic and therapeutic implica-
tions. Among the different kinds of arrhythmias,
high-degree AV block was the most significant predictor
of subsequent death. New-onset atrial fibrillation oc-
curred with a 4-fold higher incidence than expected and
was associated with an increased risk of developing
ventricular bradyarrhythmia and tachyarrhythmia.19 In-
terestingly, presence of cardiac autonomic dysfunction at
baseline predicted both new-onset atrial fibrillation20 and
higher-degree AV block21 with a hazard ratio of up to 7.0
and 6.0, respectively. In the nonrandomized ARREST
study,22 50 patients after acute MI with an LVEF ≥40%
underwent ICM implantation. New-onset atrial fibrillation
(≥2 minutes) could be detected in 29 patients, with 27
being asymptomatic. In contrast, asystoles and VTs could
only be detected in 4 and 3 patients, respectively. It
should be noted, however, that in both the CARISMA and
ARREST studies, the criteria for detection of atrial
fibrillation were very sensitive.
SMART-MI now uses ICMs to address a new high-risk
group of postinfarction patients that is not considered by
current guidelines. Although approximately 70% of
deaths after MI occur in postinfarction patients with
LVEF N 35%, no specific preventive strategies exist for
this large patient group. Autonomic risk stratification by
DC and PRD is capable of separating a high-risk group of
postinfarction patients with LVEF 35%-50% that equals
the established high-risk group with LVEF ≤ 35% with
respect to sample size and prognosis. Both markers can
be obtained from 20-minute high-resolution resting ECGs
recorded in the orthogonal Frank leads configuration.
The underlying algorithms could be easily implemented
in existing ECG systems. We estimate that in our study, 4
postinfarction patients with LVEF 35%-50% need to be
tested to identify 1 patient with abnormal DC and/orPRD. Although the strong prognostic value of DC and
PRD is not restricted to patients with LVEF ≤ 50%, we
used the upper threshold of LVEF to reduce the screening
effort.
The primary end point of SMART-MI is a diagnostic end
point, which also determines the sample size calculation.
Predefined arrhythmias include 4 different types of
arrhythmias that all have been associated with adverse
events in large clinical studies or represent indications for
ATPs in patients with implanted ICDs. In the ASSERT
study, atrial fibrillation N6 minutes has been associated
with a 2.5-fold risk of stroke or systemic thromboembo-
lism.15 Detection of asymptomatic atrial fibrillation
challenges the question of oral anticoagulation in many
patients. Although a recent post hoc analysis of the
ASSERT study indicated increased risk of stroke only in
patients with episodes of asymptomatic atrial fibrillation
lasting longer than 24 hours,23 ongoing large-scale
randomized trials including the ARTESIA trial
(NCT01938248) and the NOAH-AFNET 6 trial
(NCT02618577) test the efficacy of oral anticoagulation
in patients with episodes N6 minutes. In patients after
acute MI, new-onset atrial fibrillation might have addi-
tional implications as it might reflect beginning cardiac
deterioration.12 In CARISMA, higher-degree AV block was
associated with a 6.6-fold risk of death12 and might not
only indicate pacemaker implantation but also a careful
diagnostic workup for underlying problems. A VT with a
cycle length ≤320 ms lasting for 12 seconds or more is a
proven criterion for ATPs in patients with implanted
ICDs.14 Sustained VT/VF indicates a further invasive
approach by electrophysiological testing, coronary angi-
ography, or ICD implantation.
However, SMART-MI also evaluates the impact of
telemonitoring on clinical end points including death,
stroke, and unplanned hospitalizations. For this purpose,
arrhythmic events are transmitted on a daily base to an
ICM core laboratory. Treatment paths have been
developed in line with current guidelines for different
kinds of arrhythmias and include diagnostic workup as
well as therapeutic interventions. Such interventions may
include optimization of medical therapy, initiation of oral
anticoagulation, revascularization, ablation, and device
implantation.
There are several limitations of the SMART-MI study
that should be recognized. First, the maximum age of
patients included is 80 years. Therefore, the results will
not allow extrapolation to older post-MI patients. Second,
the study is restricted to patients in sinus rhythm. Third,
data on stability of DC and PRD measurements are
lacking. To address this issue, we will reevaluate DC and
PRD after 12 and 24 months. Fourth, the primary end
point is a diagnostic end point. Although clinical
outcomes are included in the secondary end point, the
study is not powered for these analyses. Finally, treatment
recommendations are based on current guidelines.
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atrial fibrillation or nonsustained VT, no clear guideline
recommendations exist.
In conclusion, SMART-MI seeks to evaluate the useful-
ness of ICMs for detection of serious arrhythmic events in
high-risk postinfarction patients with LVEF 35%-50% and
evidence of cardiac autonomic dysfunction. SMART-MI
will provide information about the prognostic relevance
of detected arrhythmias and their temporal relationships
to clinical events. Thus, the findings of SMART-MI will
provide the basis for developing preventive strategies in
this important patient group.Conflict of interest
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With drug-eluting stent (DES) platforms representing the concept of combined mechanical stenosis repair and 
localized drug delivery, percutaneous coronary intervention 
became a pharmacomechanical therapy option for coronary 
artery disease. The concept of drug coating of metallic scaf-
folds is ≈20 years old and started with the aim to increase 
the hemocompatibility of metallic scaffolds.1 In the era when 
plain balloon angioplasty was the default percutaneous coro-
nary intervention option and the incidence of acute ischemic 
events was at double-digit levels, heparin-coated stents have 
been shown effective in reducing stent thrombosis without any 
measurable effect on neointimal formation.1,2 Development of 
heparin-coated stent platforms revealed the difficulties of pro-
ducing a stable system able to deliver the needed amount of 
the active drug without compromising its chemical sequence. 
Different from physical adsorption and ionic binding tech-
niques, copolymerization of heparin with a variety of poly-
mers provided stable heparin binding on the stent surface.3 
This experience, among others, explained later in this review, 
served as a prerequisite for development of various DES plat-
forms, which have revolutionized the percutaneous coronary 
intervention field.
Advantages With Nonbiodegradable Polymers
Success of DES platforms in reduction of neointimal hyper-
plasia depends on the amount and kinetics of drug released. 
The experience with various formulations of polymer-free 
paclitaxel-eluting stents4,5 or polymer-free sirolimus-eluting 
stents (SESs)6 loaded with different increasing drug amounts 
demonstrated the importance of the drug amount for effec-
tive inhibition of neointima proliferation at an acceptable 
safety profile. The amount of drug loading through direct drug 
adsorption on the metallic surface is limited. Furthermore, 
most of the drugs are not able to adhere appropriately on the 
stent surface to insure controlled release. Therefore, polymer 
coating has become a key component of different DES plat-
forms. Various permanent (biostable) and biodegradable poly-
mers (BPs) have been used on DES platforms (Table 1).7–12 
Polymers selected to be used as a drug carrier should share 
following features: be biocompatible; do not interact with the 
active drug; provide a platform for appropriate drug-eluting 
kinetics; behave biologically inert after the drug has been 
completely eluted, and be mechanically stable at long-term in 
the dynamics of coronary circulation milieu.
Poly-(n)-butyl methacrylate, an inert synthetic polymer, 
has been used as a drug carrier on the first-generation SES, 
Cypher stent (Cordis, Johnson & Johnson, Miami Lakes, 
FL). The complex drug–polymer matrix on the Cypher stent 
(Table 2) allows a slow sirolimus release resulting in elution 
of 80% of drug within the first 30 days after DES implan-
tation.3 In contrast to this, the drug–polymer system of the 
paclitaxel-eluting stent, Taxus stent (Boston Scientific Corp, 
Natick, MA), based on a single layer of Translute (Table 1) 
polymer allows the release of <10% of the paclitaxel within 
10 days after DES implantation, whereas the remaining drug 
persists within the polymer lifelong.3 There is a large body 
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Stent Polymers
Do They Make a Difference?
Konstantinos D. Rizas, MD; Julinda Mehilli, MD
Advances in Interventional Cardiology
Abstract—The necessity of polymers on drug-eluting stent (DES) platforms is dictated by the need of an adequate amount 
and optimal release kinetic of the antiproliferative drugs for achieving ideal DES performance. However, the chronic 
vessel wall inflammation related to permanent polymer persistence after the drug has been eluted might trigger late 
restenosis and stent thrombosis. Biodegradable polymers have the potential to avoid these adverse events. A variety 
of biodegradable polymer DES platforms have been clinically tested, showing equal outcomes with the standard-
bearer permanent polymer DES within the first year of implantation. At longer-term follow-up, promising lower rates 
of stent thrombosis have been observed with the early generation biodegradable polymer DES platforms compared 
to first-generation DES. Whether this safety benefit still persists with newer biodegradable polymer DES generations 
against second-generation permanent polymer DES needs to be explored.  (Circ Cardiovasc Interv. 2016;9:e002943. 
DOI: 10.1161/CIRCINTERVENTIONS.115.002943.)
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Table 1. Characteristics of Polymers Used for Coronary Stent Coating
Polymer Structure Special Features Suitability for Stent Coating
Nonbiodegradable polymers
  Parylene C Highly crystalline material deriving from poly-para-
xylylene monomer after substitution of a chlorine atom for 
one of the aromatic hydrogens
Vapor-phase deposition 
forming a structural 
continuous film as thin as 
0.0001 inch, providing true 
pinhole-free conformal 
insulation, which makes it the 
material of choice for first-
layer device coating
Excellent barrier properties 
attributable to lower permeability to 
moisture and corrosive gases, such 
as nitrogen, oxygen, and carbon 
dioxide while retaining excellent 
electric properties
  PBMA7 Transparent liquid with high hydrophobicity and durability 
at molecular weight (200 000–320 000 Daltons)
Biocompatible with slow drug-
release kinetics
Coating entirely made off PBMA 
develops cracks in the presence of 
significant concentrations of drug. 
Therefore, PBMA and PEVA polymers 
are used as a mixture for stent 
coating
  PEVA7 PEVA copolymer consistency depends on the % of 
vinyl acetate with increasingly high durability at higher 
percentages
Rapid drug-release kinetics 
(50% within 24 h)
Coatings entirely made off PEVA are 
less durable but flexible and release 
drugs relatively rapidly. Therefore, 
PBMA and PEVA polymers are used as 
a mixture for stent coating
  SIBS8 The triblock SIBS polymer is a self-assembled physically 
cross-linked polyisobutylene. It is a thermoplastic 
elastomer with physical properties that overlap silicone 
rubber and polyurethane, susceptible to stress cracking 
in the presence of organic solvents with poor creep 
properties
Soluble in various nonpolar 
solvents, thus can be spray 
coated. Poor gas permeability 
which renders it more 
cumbersome to sterilize with 
ethylene oxide and not γ-ray 
sterilizable
Oxidatively, hydrolytically, and 
enzymatically stable over its lifespan 
in the body with a relatively low 
foreign-body reaction
  PC9 Thermoset, water-swellable methacrylate polymer 
comprised of 4 monomers: (1) 2-methacryloyloxyethyl 
PC monomer; (2) lauryl methacrylate; and (3) 
2-hydroxypropyl-methycrylate both attenuate 
hydrophilicity; whereas (4) trimethoxysilylpropyl 
methacrylate is a silane crosslinker, which determines the 
mechanical proprieties of PC polymer
The zwitterionic PC group in 
the 2-methacryloyloxyethyl 
PC monomer provides the 
hydrophilic and biomimetic 
surface similar to the PC head 
group in the cell membrane of 
erythrocytes
Lower thrombogenecity
  PVDF-HFP9 Semicrystalline fluorinated copolymer of vinylidene 
fluoride and hexafluoropropylene monomers. Its backbone 
is composed entirely of saturated carbon–carbon single 
bonds, which are >50% fluorinated resulting in polymer 
hydrophobicity
High elasticity and fatigue 
resistance attributable to low 
glass transition temperature of 
−29°C and semicrystallinity
Resistant to hydrolytic, oxidative, or 
enzymatic cleavage because of the 
lack of any reactive or enzymatic 
sensitive groups
  BioLinks10 Mixture of 3 polymers: the C10 polymer is comprised of 
hydrophobic n-butyl methacrylate, which binds the drug 
and a small amount of vinyl acetate. The C19 polymer 
is synthesized from a mixture of hydrophobic n-hexyl 
methacrylate and hydrophilic N-vinyl pyrrolidone and vinyl 
acetate monomers to provide enhanced biocompatibility. 
Polyvinyl pyrrolidone is a medical grade hydrophilic 
polymer
Polymers self-orientation 
resulting in a surface 
substantially hydrophilic, 
whereas the core remains 
substantially hydrophobic
Enhanced biocompatibility
Biodegradable copolymers
  PDLLA11 PLA polymer exists in an optically active stereoregular 
form (semicrystalline L-PLA) and in an optically inactive 
racemic form, PDLLA
Fully biodegradable by bulk 
hydrolysis at uniform rate 
throughout the polymer 
matrix. During bioresorption, 
long chains are progressively 
shortened through cleavage 
of its backbone ester 
linkages. The PLA enters the 
tricarboxylic acid cycle and 
is eliminated from body as 
carbon dioxide and water
Homogeneous dispersion of the drug 
within the polymer matrix because of 
its amorphous structure
(Continued )
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of scientific evidence demonstrating the superiority of SES 
compared with paclitaxel-eluting stent on the antirestenotic 
efficacy and safety,13 thus identifying the limus-family drugs 
as the most appropriate and effective for DES coating.
The importance of the type of the polymer became evident 
during the development of newer DES platforms. Coating with 
a polymer composed of methacryloyloxyethyl lauryl meth-
acrylate and a synthetic form of phosphorylcholine has been 
used in the first version of the zotarolimus-eluting stent (ZES). 
Phosphorylcholine is the major component of the outer layer 
of the cell membrane, and coating on metallic scaffolds has 
been shown to increase their biocompatibility and hemocom-
patibility.14 Two DES platforms based on the phosphorylcho-
line polymer coating have been clinically tested: Endeavor 
ZES (Medtronic Cardio Vascular Inc, Santa Rosa, CA) and 
ZoMaxx ZES (Abbott Vascular, Santa Clara, CA). The main 
difference between them consists on drug-release kinetics. 
After implantation of Endeavor ZES, 98% of zotarolimus is 
eluted within 14 days, whereas after implantation of ZoMaxx 
ZES, 90% of zotarolimus is released within 30 days.15 In large 
randomized trials, the fast drug-release formulation of ZES has 
been shown inferior to the first-generation SES on antireste-
notic efficacy.16,17 Therefore, the manufacturer modified the 
polymer carrier of Endeavor stent (BioLinx tripolymer; Table 
1) without changing the other components of the ZES plat-
form. Waseda et al15 investigated the effect of polymer formu-
lations on neointimal proliferation after ZES implantation. At 
follow-up, intravascular ultrasound-determined percent neo-
intimal obstruction was significantly lower in Resolute ZES 
(BioLinx polymer—slow drug-release kinetic), compared with 
Endeavor and ZoMaxx ZES (phosphorylcholine polymer—
fast and intermediate drug-release kinetic): 3.7±4.0, 17.5±10.1, 
and 14.6±8.1, respectively.15 Furthermore, we reported sig-
nificantly lower angiographic in-stent late lumen loss (LLL) 
with Resolute ZES (0.29±0.56 mm) compared with Endeavor 
ZES (0.58±0.55 mm).18 The intracoronary imaging and angio-
graphic data are supported by the clinical outcomes reported in 
a large meta-analysis of 12 randomized trials—Resolute ZES 
was associated with 60% reduction of ischemia-driven target 
lesion revascularization and ≈50% reduction of ischemia-
driven target vessel revascularization compared with Endeavor 
ZES.19 This experience highlights the key role of polymer on 
DES platforms as an essential element for drug-release control, 
determining the final clinical performance of DES.
Currently, the everolimus-eluting stent (EES), Xience stent 
(Abbott Vascular, Santa Clara, CA), is considered as the stan-
dard-bearer among the DES platforms. Different from the first-
generation DES, EES has a thin-strut cobalt-chromium backbone 
of 81 µm (instead of 130–140 µm) and has a novel polymeric 
drug carrier, the noninflammatory ultrapure fluorinated copo-
lymer.20 Large randomized trials and different network meta-
analyses demonstrated particularly increased safety with EES 
platform compared with both bare metal stent and other DES 
platforms.21–23 The most intriguing finding is the observed 80% 
reduction of early stent thrombosis with EES compared with 
bare metal stent.22 In ex vivo shunt models and animal studies, 
less platelet aggregation and less inflammatory cell attachment, 
as well as earlier endothelialization, have been observed with 
EES compared with other thick- or thin-strut DES or bare metal 
stents.24–26 Added to the clinical evidence of lower acute stent 
thrombosis with EES, the accumulated evidence strongly sug-
gests acute thromboresistance of EES platforms related to the 
presence of permanent fluorocopolymer coating.
Disadvantages With Non-BPs
The success of first-generation DES was shadowed by the 
observed increased risk of late stent thrombosis and late catch-
up restenosis.13,27 Alongside drug toxicity and hypersensitivity, 
the permanent persistence of the durable polymer was identi-
fied as trigger of impaired arterial healing.28 In animal studies, 
durable polymers on first-generation SES and paclitaxel-
eluting stent provoke chronic inflammation, which triggers 
impaired arterial healing.29,30 Furthermore, although consid-
ered biostable, a degradation of the poly-(n)-butyl methac-
rylate polymer from the stent surface at long-term has been 
reported.31 The released methacrylate acid induces vascular 
smooth muscle cell apoptosis, which might delay maturation 
and normalization of endothelium function, consequently 
  PLGA11 PGA is highly crystalline and less hydrophobic compared 
with PLA because of the lack of the methyl site. The 
type and ratio of the individual PLA and PGA monomers 
determine PLGA crystallinity
Fully biodegradable with 
PLA degradation through 
tricarboxylic acid cycle, 
whereas PGA is either 
excreted unchanged in the 
kidney or metabolized through 
tricarboxylic cycle
Adjustable mechanical strength 
and biodegradation rate because of 
distinct ability of polymer crystallinity 
modification
  PLEC12 PLEC is analiphatic semicrystalline polyester produced by 
ring-opening polymerization of a lactone
Particularly miscible with 
a variety of polymers. 
Progressive increase of 
cristallinity when molecular 
weight and annealing are 
decreased, which reduces 
polymer permeability
Low biodegradability by slow 
hydrolysis. Changeable drug-eluting 
process during biodegradation, at 
start, predominate drug dissolution 
and later, drug diffusion
PC indicates phosphorylcholine; PBMA, poly-n-butyl methacrylate; PDLLA, poly(D,L)-lactic acid; PEVA, polyethylene-co-vinyl acetate; PGA, polyglycolide acid; PLA, 
polylactide acid; PLEC, poly(L-lactide–co-ε-caprolactone); PLGA, poly(D,L-lactide-co-glycolide); PVDF-HFP, poly(vinylidene fluoride-co-hexafluoropropylene); and SIBS, 
poly(styrene-block-isobutylene-block-styrene).
Table 1. Continued
Polymer Structure Special Features Suitability for Stent Coating
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impairing the vascular healing process.31 Poor stent-strut cov-
erage related to delayed arterial healing has been identified as 
the pathological substrate of late and very late stent thrombo-
sis after the implantation of first-generation DES.28 Although a 
lower prevalence of uncovered stent struts with second-gener-
ation thin-strut DES compared with first-generation DES has 
been observed, the reported frequency of neoatherosclerosis 
remained similar with both DES generations.32,33
In-stent neoatheroslerosis has been observed after implan-
tation of intracoronary metallic scaffolds with or without 
drug coating. However, it occurs much earlier and more fre-
quently after DES implantation. Unstable neoatheroslero-
sis has been identified within 2 years after first-generation 
DES implantation and within 5 years after bare metal stent 
implantation.33,34 Its development has been speculated to be 
based on impaired endothelialization of the stented segment 
with polymer-induced chronic inflammation as one of the 
triggers of this process.33 Previous studies have demonstrated 
a chronic inflammatory reaction with an acute component 
and a persistent foreign-body response with different types 
of polymers, which are currently being used on DES plat-
forms.29,35 Although this has been demonstrated even for poly-
lactic-co-glycolic acid BPs, Lincoff et al35 demonstrated less 
inflammatory response after implantation of stents using a 
high-molecular weight form of poly-lactic-co-glycolic acid. 
Furthermore, BPs are only temporary on the stent surface 
having the potential of less or no chronic inflammation of the 
stented vessel wall after they completely erode.
BP-Based DESs
Development of BP-DES platforms is the obvious result of 
the accumulated evidence with earlier DES generations and 
increased knowledge about the histopathologic substrate 
behind adverse events after DES implantation. Several ran-
domized trials comparing BP-DES with permanent poly-
mer DES (PP-DES) platforms have been performed (Table 
3).36–56 In the Rapamycin-Eluting Stents With Different Poly-
mer Coating to Reduce Restenosis (ISAR-TEST 3) and 3 
Table 2. Characteristics of CE-Approved Polymer-Based DES Tested in Randomized Controlled Trials
Stent Bare-Stent Material Polymer
Polymer 
Degradation Drug Drug-Eluting Time
BioMatrix Flex 316S SS PDLLA 6–9 mo Biolimus A9, 15.6 µg/mm 40% at time of PCI; 
60% in 6–9 mo
Combo 316 L SS PDLLA and PLGA and coating 
with anti-CD34
Sirolimus
Cypher 316 L SS 1st coat: parylene C; 2nd and 
3rd top coat: PEVA and PBMA
No Sirolimus, 180 µg/cm2 80% in 1 mo
DESyne Nx Co-Cr PBMA No Novolimus, 5 μg/mm 4–6 wk
Endeavor Co-Cr PC with base coat No Zotarolimus, 10 µg/mm 98% in 0.5 mo
Firehawk Co-Cr with abluminal 
grooves
PLA 6–9 mo Sirolimus, 3 μg/mm 75% in 1 mo
MiStent Co-Cr PLGA 3 mo Crystalline sirolimus, 2.44 
µg/mm2
9 mo
Nobori 316S SS PDLLA 12 mo Biolimus A9, 15.6 µg/mm 40% at time of PCI; 
60% in 6–9 mo
Orsiro Co-Cr covered with an 
amorphous silicon-carbide 
layer
PLLA 14 mo Sirolimus, 1.4 µg/mm2 12 mo
Promus element Pl-Cr PBMA and PVDF-HFP No Everolimus, 100 µg/cm2 80% in 1 mo
Resolute Co-Cr BioLinks No Zotarolimus, 10 µg/mm 85% in 2 mo; 15% in 
6 mo
Synergy Pl-Cr PDLLA 4 mo Everolimus, 100 µg/cm2 3 mo
Yukon choice PC 316 L SS microporous stent PDLLA 2–3 mo Sirolimus, 4.8 µg/mm2 95% in 1 mo
Ultimaster Co-Cr PDLLA and PLEC 4 mo Sirolimus, 3.9 μg/mm 30% at the time of PCI; 
the rest released to 
polymer bioabsorption
TAXUS Express 326 L SS SIBS No Paclitaxel 10% in 0.5 mo; 90% is 
in polymer forever
Xience Co-Cr PBMA and PVDF-HFP No Everolimus, 100 µg/cm2 80% in 1 mo
CE indicates Conformité Europeenne; CoCr, cobalt-chromium; DES, drug-eluting stent; PC, phosphorylcholine; PCI, percutaneous coronary intervention; PBMA, poly-
n-butyl methacrylate; PDLLA, poly(D,L)-lactic acid; PEVA, polyethylene-co-vinyl acetate; PGA, polyglycolide acid; PlCr, platinum-chromium; PLA, polylactide acid; PLEC, 
poly(L-lactide–co-ε-caprolactone); PLGA, poly(D,L-lactide-co-glycolide); PLLA, poly-L lactic acid; PVDF-HFP, poly(vinylidene fluoride-co-hexafluoropropylene); SIBS, 
poly(styrene-block-isobutylene-block-styrene); and SS, stainless steel.
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Table 3. Randomized Trials Comparing BP-DES vs PP-Limus-Eluting Stent
Study
Patients’ 
Number
BP-DES 
Type
PP-DES 
Type Population Primary End Point
BASKET- 
PROVE II36*
1530 BP-BES PP-EES De novo native artery lesions; vessel size ≥3 mm, without left main lesions, 
without cardiogenic shock or planned surgery <1 y, and without increased 
bleeding risk
Composite of cardiac death, 
nonfatal MI, or clinically driven 
non-MI–related TVR within 2 y
BIFLOW II37 452 BP-SES PP-EES Stable or unstable CAD, silent ischemia, or clinical evidence of myocardial 
ischemia; de novo native coronary artery lesions <26 mm in length; vessel size 
2.25–4.0 mm; without MI <72 h; without left main artery or 3-vessel disease; 
with LVEF >30%
In-stent LLL at 9-mo repeat 
angiogram
BIOSCIENCE38 2119 BP-SES PP-EES Stable CAD or ACS, with both de novo or restenotic lesions in native coronary 
arteries or bypass grafts
TLF at 1 y
CENTURY II39 1816 BP-SES PP-EES Stable or unstable CAD; de novo native artery lesion; vessel size 2.5–4.0 mm; 
without MI <48 h; without PCI <30 d; without bifurcation or left main lesions or 
>2 vessels to be treated
Freedom from TLF at 9 mo
COMPARE II40,41 2707 BP-BES PP-EES De novo native coronary artery lesions; vessel size 2.0–4.0 mm; life expectancy 
≥5 y; without planed major surgery ≤30 d; without cardiogenic shock or previous 
DES implantation ≤1 y
Composite of cardiac death, 
nonfatal MI, and clinically driven 
TVR within 12 mo
DESSOLVE II42,43 184 BP-SES PP-ZES Stable angina pectoris; single de novo type A/B1/B2 lesions; vessel size, 2.5–3.5 
mm; stenosis length <30 mm
In-stent LLL at 9-mo repeat 
angiogram
EVOLVE44 291 BP-EES PP-EES Stable or unstable CAD, silent ischemia, or clinical evidence of myocardial 
ischemia; de novo native coronary artery lesion ≤28 mm; vessel size, 2.5–3.5 
mm; coronary TIMI flow >1; without recent MI; without bifurcation lesions
TLF at 30 d
EVOLVE II45 1684 BP-EES PP-EES Stable or unstable CAD, silent ischemia, or clinical evidence of myocardial 
ischemia; ≤3 de novo native coronary artery lesion ≤34 mm in length; vessel size, 
2.25–4.0 mm; without recent ST-segment–elevation MI; without left main disease 
or chronic total occlusions.
TLF at 1 y
ISAR-TEST 346* 404 BP-SES PP-SES Ischemic symptoms or evidence of myocardial ischemia with at least 1 de novo 
stenosis in native coronary vessels
In-stent LLL at 6–8 mo repeat 
angiogram
ISAR-TEST 447,48 2603 BP-SES PP-EES; 
PP-SES
Ischemic symptoms or evidence of myocardial ischemia with at least 1 de novo 
stenosis native coronary vessels
TLF at 1 y
LEADERS49,50 1707 BP-BES PP-SES Stable CAD or ACS with at least 1 lesion suitable for coronary stent implantation; 
vessel size, 2.25–3.5 mm
Composite of cardiac death, 
MI, and clinically indicated TVR 
at 9 mo
NEXT51,52 3241 BP-BES PP-EES Patient eligible for PCI with DES willing to comply with follow-up for ≤3 y TLR at 1 y; death or MI within 3 y
Nobori Japan53 335 BP-BES PP-SES Stable or unstable ischemic heart disease; de novo lesions in ≤2 native coronary 
vessel disease; vessel size, 2.5–3.5 mm; ≤30 mm in length; with LVEF >30%; 
without MI <72 h; without planed surgery or PCI after index PCI; without bifurcation, 
left main, or ostial lesions; without thrombotic lesions
Freedom from cardiac death, MI, 
and TVR at 9 mo
SORT OUT V54 2464 BP-BES PP-SES Chronic stable CAD or ACS; at least 1 de novo lesion in native coronary arteries 
eligible for PCI
Composite of cardiac death, MI 
definite ST, and clinically driven 
TVR at 9 mo
SORT OUT VI55 2999 BP-BES PP-ZES Stable CAD or ACS, including MI with or without ST-segment–elevation; at least 1 
coronary lesion eligible for PCI; vessel size, 2.25–4.0 mm
Composite of cardiac death, 
MI not clearly attributable to a 
nontarget lesion, clinically indicated 
TLR at 1 y
TARGET I56 458 BP-SES PP-EES Stable CAD with single de novo coronary lesion; vessel size, 2.5–4.0 mm; length, 
<24 mm; without bifurcation, left main or chronic occlusion lesions
In-stent LLL at 9 mo repeat 
angiogram
ACS indicates acute coronary syndromes; BASKET-PROVE II, Safety and Efficacy Study Comparing 3 New Types of Coronary Stents; BIOFLOW II, Study of the Orsiro Drug 
Eluting Stent System; BIOSCIENCE, Sirolimus-Eluting Stents With Biodegradable Polymer Versus an Everolimus-Eluting Stents; BP-BES, biodegradable polymer biolimus-
eluting stent; BP-EES, biodegradable polymer everolimus-eluting stent; BP-SES, biodegradable polymer sirolimus-eluting stent; CAD, coronary artery disease; CENTURY 
II, Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients With Coronary Artery Disease; COMPARE II, Comparison of the 
Everolimus Eluting With the Biolimus A9 Eluting Stent; DES, drug-eluting stents; DESSOLVE II, Clinical Investigation of the MiStent DES in Coronary Artery Disease; EVOLVE 
II, Assess the Synergy Stent System for the Treatment of Atherosclerotic Lesion(s); ISAR-TEST 3, Rapamycin-Eluting Stents With Different Polymer Coating to Reduce 
Restenosis; ISAR-TEST 4, 3 Limus Agent Eluting Stents With Different Polymer Coating; LEADERS, Limus Eluted From a Durable Versus Erodable Stent Coating; LLL, late 
lumen loss; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NEXT, Nobori Biolimus-Eluting Versus Xience/Promus Everolimus-Eluting Stent Trial; PCI, 
percutaneous coronary intervention; PP-DES, permanent polymer drug-eluting stents; PP-EES, permanent polymer everolimus-eluting stent; PP-SES, permanent polymer 
sirolimus-eluting stent; PP-ZES, permanent polymer zotarolimus-eluting stent; SORT-OUT V, Randomised Clinical Comparative Study of the Nobori and the Cypher Stent; 
SORT OUT VI, Randomized Clinical Comparison of Biomatrix Flex and Resolute Integrity; ST, stent thrombosis; TARGET I, Randomized MicroPort's Firehawk DES Versus 
Xience V; TIMI, Thrombolysis in Myocardial Infarction; TLF, target lesion failure; TLR, target lesion revascularization; and TVR, target vessel revascularization.
*Only patients receiving polymer-based drug-eluting stents.
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Study
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C
D
Figure 1 Continued. One-year death (A), 1-year definite/probable stent thrombosis (B), 1-year myocardial infarction (C), and 1-year target 
lesion revascularization (D). BASKET-PROVE II indicates Safety and Efficacy Study Comparing 3 New Types of Coronary Stents; BIO-
FLOW II, Study of the Orsiro Drug Eluting Stent System; BIOSCIENCE, Sirolimus-Eluting Stents With Biodegradable Polymer (Continued  ) 
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Limus Agent Eluting Stents With Different Polymer Coating 
(ISAR-TEST 4), we compared sirolimus-eluting BP-DES to 
standard-bearer permanent polymer–based SES and EES. In-
stent LLL at 6 to 8 months of angiography was 0.17±0.45 
mm with BP-SES and comparable to PP-SES (0.23±0.46 
mm).46,47 Lack of difference in the 5-year rates of target lesion 
revascularization observed with BP-SES (13.9%), PP-EES 
(12.6%), and PP-SES (15.6%) confirmed the early angio-
graphic findings.48
The Limus Eluted From a Durable Versus Erodable Stent 
Coating (LEADERS) investigators who randomly compared 
BP-BES (Biomatrix, Biosensors) with PP-SES (Cypher) 
reported similar rates of the composite end point of cardiac 
death, myocardial infarction, and clinically indicated target 
vessel revascularization within 9 months of DES implanta-
tion (9.2% with BP-BES versus 10.5% with PP-SES; rela-
tive risk, 0.88; 95% confidence interval [CI], 0.64–1.19; 
P
noninferiority
=0.003).49 While at 5-year follow-up the cumulative 
Figure 2. Longer-term death (A), longer-term definite/probable stent thrombosis (B), longer-term myocardial infarction (C), and longer-term 
target lesion revascularization (D). (Continued )  
A
B
Figure 1 Continued. Versus an Everolimus-Eluting Stents; BP-DES, biodegradable polymer drug-eluting stent; CENTURY II, Clinical 
Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients With Coronary Artery Disease; CI, confidence 
interval; COMPARE II, Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent; DESSOLVE II, Clinical Investigation of 
the MiStent DES in Coronary Artery Disease; EVOLVE II, Assess the Synergy Stent System for the Treatment of Atherosclerotic Lesion(s); 
ISAR-TEST 3, Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis; ISAR-TEST 4, 3 Limus Agent Eluting 
Stents With Different Polymer Coating; LEADERS, Limus Eluted From a Durable Versus Erodable Stent Coating; M-H, Mantel-Haenszel; 
NEXT, Nobori Biolimus-Eluting Versus Xience/Promus Everolimus-Eluting Stent Trial; PP-DES, permanent polymer drug-eluting stent; 
SORT-OUT V, Randomised Clinical Comparative Study of the Nobori and the Cypher Stent; SORT OUT VI, Randomized Clinical Compari-
son of Biomatrix Flex and Resolute Integrity; and TARGET I, Randomized MicroPort's Firehawk DES Versus Xience V.
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incidence of primary end point was numerically lower with 
BP-BES (22.3%) compared with PP-SES, 26.1%, relative risk 
0.83, 95% CI, 0.68 to 1.02; P
noninferiority
<0.001.50
A limitation of both first-generation PP-DES and BP-BES 
(Biomatrix/Nobori) is their thick-strut stainless steel metal-
lic backbone, which by itself is associated with higher risk of 
restenosis and might serve as a substrate for increased throm-
bogenicity.25,57 However, in a porcine coronary model, thick-
strut BP-BES revealed less inflammation and foreign-body 
immunoreaction than thin-strut PP-EES.58 In the Test Safety of 
Biodegradable and Permanent Limus-Eluting Stents Assessed 
by Optical Coherence Tomography (TEST-6-OCT) trial, thick-
strut BP-BES stent showed similar stent coverage and vascular 
healing response with thin-strut PP-EES ≤9 months after 
implantation.59 The results of the Comparison of the Everolimus 
Eluting With the Biolimus A9 Eluting Stent (COMPARE II) 
trial, in which patients randomly received thick-strut BP-BES 
or thin-strut fluoropolymer-based EES, the current standard-
bearer among DESs, support the animal and intracoronary 
imaging data. At 12-month follow-up, the primary end point—
composite of cardiac death, nonfatal myocardial infarction, and 
clinically indicated target vessel revascularization—occurred in 
5.2% of BP-BES and in 4.8% of PP-EES patients (relative risk, 
1.07; 95% CI, 0.75 to 1.52; P
noninferiority
<0.0001).40 Despite these 
findings, in comprehensive network meta-analyses, thin-strut 
PP-EES and PP-ZES are identified as currently the safest stent 
C
D
Figure 2 Continued. *Data available for BASKET-PROVE II36 trial are cardiac death, nonfatal myocardial infarction, and target vessel 
revascularization. #ISAR-TEST 447,48 the comparator permanent polymer drug-eluting stent (PP-DES) is everolimus-eluting stent, Xience 
stent. §Data available for DESOLVE trials42,43 were clinically driven target lesion revascularization. BASKET-PROVE II indicates Safety and 
Efficacy Study Comparing 3 New Types of Coronary Stents; BP-DES, biodegradable polymer drug-eluting stent; CI, confidence interval; 
COMPARE II, Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent; DESSOLVE II, Clinical Investigation of the MiStent 
DES in Coronary Artery Disease; ISAR-TEST 4, 3 Limus Agent Eluting Stents With Different Polymer Coating; LEADERS, Limus Eluted 
From a Durable Versus Erodable Stent Coating; M-H, Mantel-Haenszel; NEXT, Nobori Biolimus-Eluting Versus Xience/Promus Everolimus-
Eluting Stent Trial; and PP-DES, permanent polymer drug-eluting stent.
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platforms even in comparison with thick-strut BP-BES.23,60 This 
highlights the fact that performance of DES depends on the 
optimal combination of all 3 DES components—drug, metallic 
scaffold design, and polymer.
Similar to PP-DES platforms, the BP-DES technology has 
evolved toward thinner metallic backbones. Five new thin-
strut BP-DES platforms received recently the Conformité 
Europeenne approval. The BP-SES, Ultimaster (Terumo 
Corporation, Tokyo, Japan) stent consists of a cobalt-chro-
mium thin-strut (80 μm) platform coated with sirolimus in a 
matrix with bioresorbable poly(D,L-lactide-co-caprolactone) 
polymer at a unique gradient coating design intended to reduce 
polymer cracking and delamination on the hinges of the stent. 
Findings from the optical coherence tomography substudy of 
the Clinical Evaluation of New Terumo Drug-Eluting Coronary 
Stent System in the Treatment of Patients With Coronary Artery 
Disease (CENTURY II) trial revealed comparable tissue cov-
erage with both BP-SES and PP-EES stents (mean neointimal 
thickness at 9 months, 110±10 versus 93±9 µm; P=0.22 and 
% of uncovered stent struts, 1.02 versus 2.26; P=0.35, respec-
tively).61 In the CENTURY II trial, patients enrolled in 58 cen-
ters from Europe, Japan, and Korea were randomly assigned to 
treatment with either thin-strut BP-SES or thin-strut PP-EES. 
Primary end point survival free of target vessel failure (cardiac 
death, target vessel myocardial infarction, and clinically indi-
cated target lesion revascularization) at 9 months was 95.6% 
with BP-SES and 95.1% with PP-EES (P
noninferiority
<0.0001).39
In the Sirolimus-Eluting Stents With Biodegradable 
Polymer Versus an Everolimus-Eluting Stents (BIOSCIENCE) 
trial, 2119 patients were randomly assigned to treatment with 
BP-SES or PP-EES.38 The BP-SES (Orsiro, Biotronik AG, 
Bülach, Switzerland) is a novel DES platform consisting of an 
ultrathin (60–80 µm) cobalt-chromium L605 backbone cov-
ered with amorphous silicon-carbide layer and biodegradable 
poly-L-lactic acid polymer. Primary end point 12-month tar-
get lesion failure was with both BP-SES and PP-EES (6.7%). 
target lesion revascularization rates were 4.0% with BP-SES 
and 3.1% with PP-EES (rate ratio, 1.30; 95% CI, 0.82–2.06; 
P=0.27), whereas the incidence of definite/probable stent 
thrombosis was numerically lower with BP-SES (2.8%) com-
pared with P-EES (3.4%; rate ratio, 0.83; 95% CI, 0.50–1.35; 
P=0.45).38 To highlight is the very low in-stent LLL observed 
with the ultrathin Orsiro stent (0.1 mm), which is also identi-
cal to the in-stent LLL observed with the BP-EES (Synergy 
stent; Boston Scientific Corp).37,44 The Synergy stent consists 
of thin-strut platinum-chromium backbone (74–81 μm), a bio-
degradable poly(D,L-lactide-co-glycolide) and the everolimus 
drug. In the Assess the Synergy Stent System for the Treatment 
of Atherosclerotic Lesion(s) (EVOLVE II) trial, target lesion 
failure at 1 year was virtually identical with both BP-EES and 
PP-EES (Promus Element stents; Boston Scientific Corp)—
6.7% versus 6.4% respectively (P
noninferiority
=0.0003).45 In the 
Randomized MicroPort's Firehawk DES Versus Xience V 
(TARGET I) trial, the Firehawk stent (86-μm cobalt-chro-
mium with abluminal grooves filled with polylactide acid 
and sirolimus; Microport Medical, Shangai, China) was 
noninferior to PP-ESS on the primary end point 9-month in-
stent LLL (0.13±0.24 versus 0.13±0.18 mm, respectively; 
P
noninferiority
<0.001).56
Another concept is tested in the design of BP-SES 
(MiStent platform; Micell Technologies, Durham, NS). The 
special feature of this stent is the absorbable polymer matrix 
containing a crystalline form of sirolimus. In the DESOLVE II 
randomized trial, MiStent performed superior to the Endeavor 
stent on the primary end point (in-stent LLL, 0.27±0.46 mm 
with MiStent versus 0.58±0.41 mm with Endeavor stent).42
We pooled the data from 16 randomized controlled trials in 
which thick- or thin-strut BP-based DES were compared with 
PP-based limus-eluting stents to assess differences in efficacy 
and safety parameters between these platforms (Table 3). As 
expected and observed in previous meta-analyses,62,63 no addi-
tional benefit with BP-DES compared with PP-DES was iden-
tified on the efficacy and safety end points ≤1-year follow-up 
(Figure 1A–1D). However, advantages of BP-DES platforms 
would be expected to emerge later in time when polymer 
has been degraded. For only 6 of these trials, follow-up data 
between 2 and 5 years were available.36,41,43,48,50,52 At longer-
term follow-up, a significantly lower risk of stent thrombosis 
was observed with BP-DES compared with PP-DES (odds 
ratio, 0.43; 95% CI, 0.25–0.73; Figure 2A–2D). Although 
promising, this finding should be interpreted with caution. 
First, the outcomes derive mostly from 4 large trials in which 
the comparator was more frequently thick-strut first-genera-
tion SES. Second, the number of patients considered might 
be still not large enough for evaluation of such rare events. 
Comprehensive network meta-analyses, including larger 
cohorts of patients, considering randomized and nonrandom-
ized trials, and performing mixed treatment comparisons, 
have yielded contradictory results in this regard.23,60 Finally, in 
everyday practice, thick-strut BP-DESs are being substituted 
by the newer thin- or ultrathin BP-DES platforms. Long-term 
data with the latest ones are still lacking.
Summary
The necessity of polymers on DES platforms is dictated by the 
need of an adequate amount and optimal release kinetic of the 
antiproliferative drugs for achieving ideal DES performance. 
With the use of BPs to control drug release, the polymer-
induced vessel inflammation, which partially triggers develop-
ment of neoatheroslerosis with its clinical consequences very 
late stent thrombosis and restenosis, is limited in time. Indeed, 
the current data demonstrate increased long-term safety with 
the early generation BP-DES platforms compared with first-
generation PP-DES. The newer BP-DES generations perform 
noninferior to second-generation PP-DES within the first year 
after implantation. Whether this transforms in safety benefit at 
long-term needs to be investigated.
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